 
 
Official Title of Study: 
A Phase 3 Randomized, Double-Blind Study of Nivolumab Monothera py or Nivolumab  
Combined with Ipilimumab vs Placebo in Participants with Locali zed Renal Cell Carcinoma  
Who Underwent Radical or Partial Nephrectomy and Who Are at Hig h Risk of Relapse 
CheckMate 914: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 914 
 
Protocol: CA209-914 
 
Study ID: [REMOVED]  
 
Document Date (Date in which doc ument was last revised): 08-Dec-2022 
Page: 1
Protocol Number: CA209914
IND Number: 122,840
EUDRACT Number 2016-004502-34
Date 14-Feb-2017
Revised Date 08-Dec-2022
CLINICAL PROTOCOL CA209914
A Phase 3 Rando mized, D ouble-Blind Study of Nivolumab Monotherapy or Nivolumab 
Combined with Ipilimumab vs Placebo in Participants with Locali zed Renal Cell Carcinoma 
Who Underwent Radical or Partial Nephrectomy and Who Are at Hig h Risk of Relapse
CheckMate 914: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 914
Protocol Amendment 06
Medical Monitoring Contact Information
Senior Clinical Trial Physician
Bristol Myers Squibb Company
100 Binney Street Cambridge, MA 02142
Phone: 
email: Senior Clinical Scientist
Bristol Myers Squibb Company
86 Morris Avenue Summit, NJ 07901
Phone 
email: 
Clinical Scientist
Bristol Myers Squibb Company
3401 Princeton Pike, Lawrenceville,
NJ 08648
Phone 
email: 
24-hr Emergency Telephone Number
USA: 
International: 
Bristol-Myers Squibb Company
3401 Princeton Pike
Lawrenceville, NJ 08648
This document is the confidential and proprietary information o f Bristol-Myers Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS sponsored 
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Protocol Amendment No.: 06
Date: 08-Dec-2022 2study. Any permitted disclosures will be made only on a confide ntial "need to know" basis 
within your organization or  to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly 
authorized in writing by BMS. Any supplemental information (e.g., amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents of this document.  Any person who receives 
this document without due authorization from BMS is requested t o return it to BMS or 
promptly destroy it. All other rights reserved. References to B MS in this protocol may apply 
to partners to which BMS has t ransferred obligations, e.g., a C ontract Research 
Organization (CRO). 
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Protocol Amendment No.: 06
Date: 08-Dec-2022 3DOCUMENT HISTORY
Document Date of Issue Summary of Changes
Protocol 
Amendment 0608-Dec-2022The purpose of Protocol Amendment 06 is to address the timing of interim 
and final disease-free survival (DFS) analyses in Part B, which were initially planned to occur at least 8 months of each other. Howe ver, the 
earlier versions of the protocol did not capture the scenario to proceed directly to the final DFS analysis in Part B in the event that the interim 
analysis and final analysis are projected in a shorter time inte rval 
(approximately within 6 months). With this amendment, the scenar io with 
DFS final analysis only is explicitly stated. Also, the redundan t OS interim 
analysis scenario in Part B is now omitted.
Protocol 
Amendment 0513-Feb-2022The purpose of Protocol Amendment 05 is to address the timing of interim 
and final disease-free survival (DFS) analyses in Part A, which  were 
initially planned to occur within 6 months of each other. Howev er, the 
earlier versions of the protocol did not capture the scenario t o proceed 
directly to the final DFS analysis in Part A in the event that Par t B 
enrollment is ongoing when the required number of events needed  for 
interim analysis of DFS in Part A is achieved. With this amendmen t, the
scenario with DFS final an alysis only is  pre-sp ecified.
Administrative 
Letter 1019-Feb-2021Corrected language in Section 9.2.5, Pregnancy to ensure proper  
alignment throughout all sections of the protocol.
Administrative 
Letter 0904-Jan-2021â€¢Updated Study Personnel
â€¢Clarifications to Synopsis and to Section 5.1, Overall Design
â€¢Corrected typographical errors in Section 10.3.4, Interim Analy ses and 
Hierarchical Testing
Revised Protocol 
0427-Oct-2020The purpose of Revised Protocol 04 is to remove Interim Analysi s 1 for 
disease-free survival (DFS), from both Part A and Part B, to delay Interim 
Analysis 2 for DFS in Part A, and for both Part A and Part B Ove rall 
Survival (OS) to be hierarchically analyzed at the same time as th e interim 
or final analysis for DFS in the same group of subjects. This r evision also 
incorporates several changes to provide additional information and/or clarification to sections indicated. Some updates include clari fications and 
updates to contraception requirements, the clarification of tim ing for 
follow up visits and patient-reported outcomes collection, the addition of 
SARS-CoV-2 serology collection with a corresponding exploratory  
objective and endpoint, the addition of Appendix 9 regarding TN M 
staging and Fuhrman grading correlations, the incorporation of additional 
biomarker sample collections to better align with tumor assessments,collection of tumor necrosis status which will allow for SSIGN score assessments, and an extension of the required length of time to  collect 
adverse events (AEs) (serious adverse events [SAEs] or non-seriou s AEs)
considered related to the study therapy. This revision also inc orporates 
Administrative Letter 08.
Administrative 
Letter 0805-Feb-2020Advises sites of inadvertent omission to Revised Protocol 03 of  changes 
made to protocol in Administrative Letters 05 and 07. Although changes 
were omitted, they were still effective.
Revised Protocol 
0301-Nov-2019The purpose of Revised Protocol 3 is to add Part B to the study  for 
evaluation of nivolumab monotherapy. 
Also incorporates Administrative Letter 06
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Protocol Amendment No.: 06
Date: 08-Dec-2022 4Administrative 
Letter 0705-Feb-2019 Update Appendix 4
Administrative 
Letter 0616-Nov-2018 Study Personnel Updates
Administrative 
Letter 0501-Aug-2018Correct typographical errors in Sections 6.1 and 7.2, and corre sponding 
sections of the synopsis.
Revised Protocol 
0206-Apr-2018The purpose of this revised protocol is to reduce frequency of patient 
questionnaires, update exclusion criterion for serum creatinine, remove 42-day screening window, provide more flexibility in scheduling  scans, 
update background data, and provide additional information and/ or 
clarification to sections indicated.
Administrative 
Letter 0328-Mar-2018The main purpose of this letter is to update the information related to a change in the Medical Monitor for this study.
Administrative 
Letter 0216-Nov-2017The main purpose of this letter is to update the information related to a change in the Medical Monitor for this study.
Administrative 
Letter 0128-Jun-2017The main purpose of this letter is to correct a typographical e rror in 
Exclusion Criteria 2b and 4a in Revised Protocol 01, dated 22-M ar-2017.
Revised Protocol 
0122-Mar-2017 Incorporates Amendment 01
Amendment 01 22-Mar-2017â€¢Consider the placebo products as investigational products
â€¢Remove the bioequivalence language
Original Protocol 14-Feb-2017 Not Applicable
7.0 Approved 930108721 7.0v Approved 1.0 v
C l i n i c a l  P r o t o c o l C A 2 0 9 9 1 4 
BM S - 9 3 6 5 5 8 n i v o l um a b 
O V E R A L L  R A T IO N A L E  FO R  P RO TO CO L  AM E N DM E N T  0 6 : 
T h e  p u r p o s e  o f  P r o t o c o l  Am e n dm e n t  0 6  i s  t o  a d d r e s s  t h e  t im i n g  o f  i n t e r im  a n d  f i n a l  d i s e a s e - f r e e  
s u r v i v a l  ( D F S )  a n a l y s e s  i n  P a r t  B ,  w h i c h  w e r e  i n i t i a l l y  p l a n n e d  t o  o c c u r  a t  l e a s t  8  m o n t h s  a p a r t  
f r om  e a c h  o t h e r .  H o w e v e r ,  t h e  e a r l i e r  v e r s i o n s  o f  t h e  p r o t o c o l  d i d  n o t  c a p t u r e  t h e  s c e n a r i o  w h e r e  
t h e  i n t e r im  a n d  f i n a l  a n a l y s e s  o f  D F S  i n  P a r t  B  a r e  p r o j e c t e d  t o  o c c u r  i n  a  s h o r t e r  t im e  i n t e r v a l  
( a p p r o x im a t e l y  w i t h i n  6  m o n t h s ) . 
T h e r e f o r e ,  t h i s  am e n dm e n t  f o r  P a r t  B  i s  b e i n g  i s s u e d  t o  a l l o w  t h e  p o s s i b i l i t y  o f  c o n d u c t i n g  o n l y  
t h e  f i n a l  D F S  a n a l y s i s  w i t h o u t  t h e  i n t e r im  D F S  a n a l y s i s  i n  t h e  e v e n t  t h e s e  t w o  a n a l y s e s  i n  P a r t  B  
w o u l d  o c c u r  w i t h i n  6  m o n t h s  o f  e a c h  o t h e r .  T a b l e  1 0 . 1 . 2 2p r o v i d e s  d e t a i l s  o n  t h e  a l p h a ,  c r i t i c a l  
h a z a r d  r a t i o ,  a n d  t a r g e t  n um b e r  o f  e v e n t s  f o r  t h i s  s c e n a r i o .  A  6 - m o n t h  p e r i o d  w a s  d e t e rm i n e d  a s  
t h e   t h r e s h o l d   b a s e d   o n   t h e   o p e r a t i o n a l   c o n s i d e r a t i o n s   o f   t h i s   3 - a rm   s t u d y   p a r t .   O v e r a l l ,   t h i s  
am e n dm e n t  f o r  P a r t  B  i s  s im i l a r  t o  P r o t o c o l  Am e n dm e n t  0 5 ,  w h i c h  a d d e d  a  s im i l a r  s c e n a r i o  f o r  
P a r t  A . 
A d d i t i o n a l l y ,  w o r d i n g  c l a r i f i c a t i o n s  h a v e  b e e n  m a d e  f o r  t h e  i n t e r im  o v e r a l l  s u r v i v a l  ( O S )  a n a l y s e s  
i n   P a r t   B .  I f   t h e   f i r s t   i n t e r im   O S   a n a l y s i s   w e r e   t o   r e a c h   t h e   s t a t i s t i c a l   s i g n i f i c a n c e   w i t h  
a p p r o x im a t e l y   1 0 2   e v e n t s ,   t h e n   t h e   s t u d y   w o u l d  s t o p   f o r   e a r l y   s u p e r i o r i t y   f o r   t h e   f o rm a l   O S  
c om p a r i s o n ,   a n d   s e c o n d   i n t e r im   O S   a n a l y s i s   w i t h   a p p r o x im a t e l y   1 2 7   e v e n t s   w o u l d   n o t   b e  
p e r f o rm e d .  D u e  t o  t h i s  r e a s o n ,  t h e  s c e n a r i o  w i t h  1 2 7  O S  e v e n t s  i s  r e d u n d a n t ,  a n d  i t  i s  n o w  om i t t e d  
f r om  t h e  p r o t o c o l  t o  s im p l i f y  t h e  i n t e r im  O S  a n a l y s e s  p l a n  i n  P a r t  B .  W i t h  t h i s  u p d a t e ,  i t  i s  n o w  
c l e a r l y  s t a t e d  t h a t  t h e   i n t e r im  O S  a n a l y s e s   i n  P a r t  B  a r e  t o  b e  b a s e d  o n  1 0 2  a n d  1 4 6  e v e n t s ,  a s  
i n i t i a l l y  p l a n n e d . 
S UMM A R Y  O F  K E Y  C H A NG E S  FO R  P RO TO CO L  AM E N DM E N T  0 6 
S e c t i o n  N um b e r  &  T i t l e  D e s c r i p t i o n  o f  C h a n g e B r i e f  R a t i o n a l e 
S e c t i o n  1 0 . 1 . 1 P a r t  A :  C om b i n a t i o n  
C om p a r i s o n  o f  D F S T y p o g r a p h i c a l   e r r o r   h a s   b e e n  
u p d a t e d  w i t h i n  t h e  s e c t i o n  t o  a l i g n  
w i t h   v a l u e s   p r e s e n t e d   i n  T a b l e  
1 0 . 1 . 1 - 1 .T y p o g r a p h i c a l   e r r o r   h a s   b e e n  
c o r r e c t e d . 
S e c t i o n   1 0 . 1 . 2 :   P a r t   B :  
M o n o t h e r a p y  C om p a r i s o n  o f  D F S 
T a b l e  1 0 . 1 . 2 - 2 :  P a r t  B  S umm a r y  o f  
S am p l e   S i z e   P a r am e t e r s   a n d  
S c h e d u l e  o f  M o n o t h e r a p y  ( w i t h o u t  
a n  I n t e r im  A n a l y s i s ) 
S e c t i o n   1 0 . 3 . 4 :   I n t e r im   A n a l y s e s  
a n d  H i e r a r c h i c a l  T e s t i n g P a r am e t e r s  a n d  s c h e d u l e  o f  a n a l y s i s  
f o r  f i n a l  D F S  a n a l y s i s  a l o n e  i n  P a r t  
B  w e r e   a d d e d .   A l s o ,   s umm a r y  
T a b l e  1 0 . 1 . 2 - 2  w a s  a d d e d . I n  t h e  e v e n t  t h a t  t h e  t a r g e t  n um b e r  o f  
e v e n t s  n e e d e d  f o r  t h e  f i n a l  a n a l y s i s  i s  
p r o j e c t e d   i n   a   s h o r t e r   t im e   i n t e r v a l  
( a p p r o x im a t e l y  w i t h i n  6  m o n t h s ) ,  t h e  
i n t e r im   a n a l y s i s   o f   D F S   w i l l   n o t   b e  
p e r f o rm e d  a n d  o n l y  o n e  f i n a l  a n a l y s i s  
o f  D F S  w i l l  b e  c o n d u c t e d  i n  P a r t  B . 
P r o t o c o l  Am e n dm e n t  N o . :  0 6 
D a t e :  0 8 - D e c - 2 0 2 2 5
7 . 0 A p p r o v e d  9 3 0 1 0 8 7 2 1 7 . 0 v A p p r o v e d  1 . 0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 06
Section Number & Title Description of Change Brief Rationale
Section 10.3.4 : Interim Analyses 
and Hierarchical TestingLanguage of the Part B OS interim
analyses is clarified and one of the scenarios for the second interim OS 
analysis in Part B is omitted.The Part B OS interim analyses 
language is updated to clearly state the plan for the pre-specified interim 
analyses. Also, OS interim analysis 
with approximately 127 events is aredundant scenario, and it is now omitted.
Section 10.3.1: Efficacy Analyses Stratum(s) with small number of 
participants.In the event that there are fewer subjects randomized to a stratum, the 
participants in the stratum will be 
combined into another stratum.
Protocol Amendment No.: 06
Date: 08-Dec-2022 6
7.0 Approved 930108721 7.0v Approved 1.0 v
TABLE OF CONTENTS 
  
TITLE PAGE ................................................................................................................  
DOCUMENT HISTORY .............................................. ................................................  
OVERALL RATIONALE FOR PROTOCOL AMENDMENT 06: ............................  
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 06 ................  
TABLE OF CONTENTS ..............................................................................................  
1 SYNOPSIS .................................................... .............................................................  
2 SCHEDULE OF ACTIVITIES..................................................................................  
3 INTRODUCTION ................................................ .....................................................  
3.1 Study Rationale .................................................................................................  
3.1.1 Research Hypothesis ................................................................................  
3.2 Background ................................................ .......................................................  
3.2.1 Indication Background .............................................................................  
3.2.1.1 Nivolumab Monotherapy in RCC ...................................................  
3.2.1.2 Ipilimumab in Renal Cell Carcinoma .............................................  
3.2.1.3 Nivolumab Plus Ipilimumab in RCC...............................................  
3.2.2 Nivolumab Mechanism of Action .............................................................  
3.2.3 Ipilimumab Mechanism of Action ............................................................  
3.3 Benefit/Risk Assessment ................................... ...............................................  
4 OBJECTIVES AND ENDPOINTS .................................... .......................................  
5 STUDY DESIGN.......................................................................................................  
5.1 Overall Design ............................................ ......................................................  
5.1.1 Data Monitoring Committee and Other External Committees ................  
5.1.1.1 Data Monitoring Committee ...........................................................  
5.1.1.2 Blinded Independent Central Review ..............................................  
5.2 Number of Participants .....................................................................................  
5.3 End of Study Definition ................................... .................................................  
5.4 Scientific Rationale for Study Design...................... .........................................  
5.4.1 Rationale for Selection of Partici pants at Moderate to High Risk of 
Relapse ........................................................................................................  
5.4.2 Rationale for 6 Month Treatment Duration .............................................  
5.4.3 Rationale for 30 min Infusion Duration for Nivolumab and Ipilimumab   
5.4.4 Rationale for Nivolumab Monotherapy ...................................................  
5.5 Justification for Dose .................................... ....................................................  
5.5.1 Justification for Dosage in Combination Treatment of Nivolumab and 
Ipilimumab ..................................................................................................  
5.5.2 Justification for Dose of Nivolum ab Monotherapy Treatment in Part B.  
6 STUDY POPULATION ............................................................................................  
6.1 Inclusion Criteria ..............................................................................................  
6.2 Exclusion Criteria ........................................ .....................................................  
6.3 Lifestyle Restrictions ........................................................................................  
6.4 Screen Failures ........................................... .......................................................  
6.4.1 Retesting During Screening or Lead-In Period .......................................  
7 TREATMENT ................................................... ........................................................  
7.1 Treatments Administered ................................... ...............................................  


































Clinical Protocol
BMS-936558CA209914
nivolumab
Protocol Amendment No.: 06Date: 08-Dec-2022 7
7.0 Approved 930108721 7.0v Approved 1.0 v
7.1.1 Administration .........................................................................................  
7.1.1.1 Nivolumab .......................................................................................  
7.1.1.2 Ipilimumab ......................................................................................  
7.2 Method of Treatment Assignment ....................................................................  
7.3 Blinding.............................................................................................................  
7.3.1 Unblinding at the Time of Disease Recurrence .......................................  
7.4 Dosage Modification ....................................... ..................................................  
7.4.1 Dose Delay Criteria for Study Treatment ................................................  
7.4.2 Criteria to Resume Treatment ..................................................................  
7.4.3 Treatment of Study Treatment-related Infusion Reactions ......................  
7.5 Preparation/Handling/Storage/Accountability ............... ...................................  
7.5.1 Retained Samples for Bioavailability / Bioequivalence ...........................  
7.6 Treatment Compliance ...................................... ................................................  
7.7 Concomitant Therapy........................................ ................................................  
7.7.1 Prohibited and/or Restricted Treatments.................................................  
7.7.2 Other Restrictions and Precautions .........................................................  
7.7.3 Permitted Therapy ...................................................................................  
7.8 Treatment After the End of the Study ...................... .........................................  
8 DISCONTINUATION CRITERIA .................................... .......................................  
8.1 Discontinuation from Study Treatment ............................................................  
8.1.1 Study Treatment Discontinuation Criteria ...............................................  
8.1.2 Post Study Treatment Study Follow-up....................................................  
8.2 Discontinuation from the Study ............................ ............................................  
8.3 Lost to Follow-Up ......................................... ....................................................  
9 STUDY ASSESSMENTS AND PROCEDURES ............................ .........................  
9.1 Efficacy Assessments ........................................................................................  
9.1.1 Definitions of Recurrence ........................................................................  
9.1.2 Methods of Measurements .......................................................................  
9.1.3 Imaging and Clinical Assessment ............................................................  
9.1.3.1 Assessment of Baseline Disease-free Status ...................................  
9.1.3.2 Investigator Assessment of Recurrence ..........................................  
9.1.3.3 BICR Assessment of Recurrence .....................................................  
9.1.3.4 Date of Recurrence .........................................................................  
9.1.4 Imaging Restriction and Precautions ......................................................  
9.1.5 Outcomes Research Assessments .............................................................  
9.2 Adverse Events .................................................................................................  
9.2.1 Time Period and Frequency for Collecting AE and SAE Information ....  
9.2.2 Method of Detecting AEs and SAEs .........................................................  
9.2.3 Follow-up of AEs and SAEs .....................................................................  
9.2.4 Regulatory Reporting Requirements for SAEs .........................................  
9.2.5 Pregnancy ................................................................................................  
9.2.6 Laboratory Test Result Abnormalities .....................................................  
9.2.7 Potential Drug Induced Liver Injury (DILI) ............................................  
9.2.8 Other Safety Considerations ....................................................................  
9.2.9 Management Algorithms ..........................................................................  
9.3 Overdose .................................................. .........................................................  




































Clinical Protocol
BMS-936558CA209914
nivolumab
Protocol Amendment No.: 06Date: 08-Dec-2022 8
7.0 Approved 930108721 7.0v Approved 1.0 v
9.4 Safety ................................................................................................................  
9.4.1 Clinical Safety Laboratory Assessments ..................................................  
9.4.2 Imaging Safety Assessment ......................................................................  
9.5 Pharmacokinetics ..............................................................................................  
9.6 Pharmacodynamics .......................................... .................................................  
9.7 Pharmacogenomics ...........................................................................................  
9.8 Biomarkers ................................................ ........................................................  
9.8.1 Additional Research Collection ...............................................................  
9.8.2 Tissue Specimens .....................................................................................  
9.8.3 Exploratory Serum Biomarkers ...............................................................  
9.8.4 Peripheral Blood RNA .............................................................................  
9.8.5 Myeloid-Derived Suppressor Cells ..........................................................  
9.8.6 Peripheral Blood DNA Mutation Research .............................................  
9.8.7 Whole Blood for Genotyping ...................................................................  
9.8.8 Immunogenicity Assessments ...................................................................  
9.8.9 Other Assessments ...................................................................................  
9.9 Health Economics OR Medical Resource Utilization and Health  Economics .  
10 STATISTICAL CONSIDERATIONS ................................. ...................................  
10.1 Sample Size Determination ................................ .............................................  
10.1.1 Part A: Combination Comparison of DFS ............................................  
10.1.2 Part B: Monotherapy Comparison of DFS ............................................  
10.1.3 Contribution of Components Analysis of DFS: .....................................  
10.2 Populations for Analyses ................................. ...............................................  
10.3 Statistical Analyses .........................................................................................  
10.3.1 Efficacy Analyses ...................................................................................  
10.3.2 Safety Analyses.......................................................................................  
10.3.3 Other Analyses .......................................................................................  
10.3.3.1 Pharmacokinetic Analyses ............................................................  
10.3.3.2 Biomarker Analyses ......................................................................  
10.3.3.3 Outcomes Research Analyses .......................................................  
10.3.4 Interim Analyses and Hierarchical Testing ...........................................  
11 REFERENCES ................................................. .......................................................  
12 APPENDICES ................................................. ........................................................  
APPENDIX 1 ABBREVIATIONS AND TRADEMARKS ....................... .................  
APPENDIX 2 STUDY GOVERANCE CONSIDERATIONS ..................... ...............  
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, 
FOLLOW UP AND REPORTING ....................................... ..................................  
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION .....................................................................  
APPENDIX 5 ECOG PERFORMANCE STATUS .....................................................  
APPENDIX 6 MANAGEMENT ALGORITHMS FOR STUDIES UNDER CTCAE 
VERSION 4.0 .........................................................................................................  
APPENDIX 7 COUNTRY-SPECIFIC REQUIREMENTS ...................... ...................  
APPENDIX 8 PROTOCOL AMENDMENT SUMMARY OF CHANGE HISTORY
.................................................................................................................................  
































Clinical Protocol
BMS-936558CA209914
nivolumab
Protocol Amendment No.: 06Date: 08-Dec-2022 9
7.0 Approved 930108721 7.0v Approved 1.0 v
APPENDIX 9 CORRELATIONS OF CLASSIFICATIONS IN CANCER STAGING 
SYSTEMS........................................................ .......................................................  
 Clinical Protocol
BMS-936558CA209914
nivolumab
Protocol Amendment No.: 06Date: 08-Dec-2022 10
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
1 SYNOPSIS
Protocol Title: A Phase 3 Randomized, Double-Blind S tudy of Nivolumab Monothera py or 
Nivolumab Combined with Ipilimumab vs Placebo in Participants w ith Localized Renal Cell 
Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of 
Relapse 
Short Title : CheckMate 914: CHECKpoint pathway and nivoluMAb clinical Tria l Evaluation 
914
Study Phase: 3
Rationale:
The current standard treatment for early stage (I-III) renal ce ll cancer (RCC) is surgery. While the 
prognosis of stage I tumors is excellent, stage II and particul arly stage III have a hi gh risk of relapse 
and represent a high unmet medical need.
The clinical activity of nivolumab and nivolumab plus ipilimuma b observed to date in advanced 
RCC include 1 positive Ph ase 3 study demonstrating prolonged s urvival with nivolumab 
monotherapy compared to everolimus in metastatic RCC and signifi cant improvement in OS with 
nivolumab plus ipilimumab compared with sunitinib in the Checkm ate 214 study. Based on the 
Checkmate 214 study results, the combination of nivolumab and i pilimumab is approved by the 
US Food and Drug Administr ation (FDA) for the tr eatment of interme diate- and poor-risk, 
previously untreated patients with advanced RCC, and it is inco rporated into the European 
Association of Urology guidelines. These results suggests the po tential for improved clinical 
outcomes also in the adjuvant setting. In 2015, nivolumab was a pproved in the United States for 
the treatment of metastatic RCC in patients who previously rece ived anti-angiogenic therapy. 
The study CA209914 aims to explore the role of the nivolumab and ipilimumab combination 
compared to placebo and the role of nivolumab monotherapy compa red to placebo post-surgery in 
added efficacy and safety in preventing disease recurrence and the impact on survival.
If the safety profile is acceptable and nivolumab monotherapy o r nivolumab combined with 
ipilimumab is shown to improve DFS, this study would support the approval of nivolumab or 
nivolumab combined with ipilimumab in treatment-naive advanced RCC patients post-surgery. 
Study Population:
Participants with predominately clear cell RCC who have had a n ephrectomy will be included. 
Key Inclusion Criteria:
a) Kidney tumor has been completel y resected with negative surgi cal margins obtained. The 
randomization must occ ur greater than 4 weeks and less than (or equal to) 12 weeks fr om 
the date of nephrectomy. Partial nephrectomy is allowed provide d all inclusion criteria are 
met.
b) Post-nephrectomy tumor shows RCC with a predominately clear c ell histology, including 
participants with sarcomatoid features. 
Protocol Amendment No.: 06
Date: 08-Dec-2022 11
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
c) Pathological TNM staging per AJCC staging version 2010 (refer to Appendix 9 for 
correlations of classifications  in cancer staging systems): 
â€¢pT2a, G3 or G4, N0M0
â€¢pT2b, G any, N0M0
â€¢pT3 (a, b, c), G any, N0M0
â€¢pT4, G a ny, N0M0
â€¢pT any, G any, N1M0
d) Participants must have no clinical or radiological evidence o f macroscopic residual disease 
or distant metastases (M0) after nephrectomy
i) Baseline tumor assessment, p erformed 4 to approximately 12 we eks after nephrectomy, 
shows no metastasis or residual tumor lesions per local review and as confirmed by 
Blinded Independent Central R eview (BICR). Results of BICR of t he baseline tumor 
assessment confirming absence of metastasis or residual tumor l esions must be received 
before rando mization. 
Note: participants with one or more regional lymph nodes identi fied with short axis 
â‰¥15 mm on the baseline (post-operative) tumor assessments are co nsidered to have 
gross residual disease and are therefore ineligible.
e) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1 (Appendix 5).
f) Either a formalin-fixed, paraffin-embedded (FFPE) tissue bloc k or unstained tumor tissue 
sections, obtained within 3 months prior to enrollment, prefera bly from nephrectomy, with 
an associated pathology report, must be submitted to the centra l laboratory prior to 
randomization. FFPE block or 20 unstained slides is ideal, but a minimum of 10 unstained 
slides will be acceptable if tumor tissue is limited. Biopsy sh ould be excisional, incisional, 
or core needle. Fine needle aspiration is unacceptable for subm ission.
Key Exclusion Criteria
a) Any severe or serious, acute or chronic med ical or psychiatric condition or laboratory 
abnormality that may increase the risk associated with study participation or study drug 
administration including ongoing or active infection requiring parental antibiotics
b) Participants with a conditi on requiring systemic treatment wi th either corticosteroids 
(> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 
14 days prior to the first dose of study drug. Topical, ocular, intra-articular, intranasal, 
inhaled steroids, and adrenal replacement steroid doses > 10 mg  daily prednisone or the 
equivalent are permitted in the absence of active immune diseas e. 
c) Uncontrolled adrenal insufficiencyd) Participants with an active known or suspected autoimmune dis ease. Participants with type 
I diabetes mellitus, hypothyroidism only requiring hormone repl acement, skin disorders 
(such as vitiligo, psoriasis, or alopecia) not requiring system ic treatment, or conditions not 
expected to recur in the absence of an external trigger are permitted to enroll. 
Protocol Amendment No.: 06
Date: 08-Dec-2022 12
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Objectives and Endpoints:
Objective Endpoint
Primary
â€¢Part A: To compare disease-free survival (DFS) 
per Blinded Independent Central Review (BICR) of nivolumab combined with ipilimumab versus placebo infusions in participants with localized RCC, with a predominantly clear cell histology who have undergone a nephrectomy. 
â€¢Part B: To compare disease-free survival (DFS) per Blinded Independent Central Review 
(BICR) of nivolumab versus placebo infusions 
in participants with localized renal cell carcinoma, with a predominantly clear cell histology who have undergone nephrectomy.The primary endpoint is DFS. The primary endpoint of 
DFS will be programmatically determined based on the disease recurrence date provided by the BICR. DFS is 
defined as the time from randomization to development 
of local disease recurrence (ie, recurrence of primary tumor in situ or occurrence of a secondary RCC primary cancer), distance metastasis, or death, 
whichever came first.
Secondary
â€¢Part A: To compare OS, including the 5-year 
OS rates, of nivolumab combined with 
ipilimumab versus placebo infusions in 
participants with localized RCC with a predominantly clear cell histology who have undergone a nephrectomy.
â€¢Part B: To compare overall survival (OS), including the 5-year OS rates, of nivolumab versus placebo infusions in participants with localized renal cell carcinoma with a predominantly clear cell histology who have undergone a nephrectomy.
â€¢Part B: To evaluate differences in disease-free survival (DFS) per Blinded Independent Central Review (BICR) and overall survival (OS) of contemporaneously randomized nivolumab combined with ipilimumab participants versus nivolumab participants with localized renal cell carcinoma, with a predominantly clear cell histology, who have undergone a nephrectomy.â€¢OS, defined as the time between the date of randomization and the date of death. For participants 
without documentation of death, OS will be censored 
on the last date the participants was known to be alive. 
â€¢DFS and OS in contemporaneously randomized 
combination and monotherapy participants.
â€¢To describe the safety and tolerability of 
nivolumab combined with ipilimumab and nivolumab monotherapy up to 30 and 100 days of last dose of study therapy.â€¢Safety and tolerability endpoint: type, incidence, 
severity (graded by the National Cancer Institute 
[NCI] Common Terminology Criteria for Adverse Events [CTCAE, Version 4.0], timing, seriousness, and relatedness, and labor atory abnorma lities up to 
30 and 100 days of last dose  of study therapy in all 
treated participants
Protocol Amendment No.: 06
Date: 08-Dec-2022 13
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Overall Design:
The original study design (Par t A) is a double- blind, randomize d trial of the nivolumab and 
ipilimumab combination therapy versus placebo infusions in part icipants with early stage localized 
RCC with a predo minantly clear cell histology who underwent rad ical or partial nephrectomy. 
Approximately 1000 participants will be screened, and approximately 800 participants will be 
randomized. 
At the implementation of Revised Protocol 03, Part A of the stu dy remains identical to the original 
protocol design. The addition of P art B to the protocol include s a monotherapy nivolumab arm. A 
target of approximately 800 participants are planned to be rand omized between 3 arms in a 
1:1:2 ratio in Part B, with the primary endpoint of DFS and seco ndary endpoints of OS, and safety 
and tolerability.  
Approximately 1600 participants in total are expected to be ran domized in this study. 
TNM staging will be stratified according to the following chara cteristics:
â€¢pT2a, G3 or G4, N0, M0 and pT2b, G any, N0, M0
â€¢pT3, G any, N0, M0
â€¢pT4, G any, N0, M0 and pT any, G any, N1, M0
Randomization must occur greater than 4 weeks and less than (or equal to) 12 weeks from the date 
of nephrectomy.
Tumor tissue obtained within 3 months prior to enrollment, pref erably at the time of the 
nephrectomy, must be provided for biomarker analyses. 
Screening/baseline imaging should be performed at least 4 weeks  post-nephrectomy- and 
submitted to the radiology vendor for BICR confirmation of disea se-free status. Pre-nephrectomy 
images are also requested, if available. Participant eligibilit y must be confirmed by BICR prior to 
randomization and will be based only on the review of the basel ine scans (and pre-nephrectomy 
scans if available). As a result, pre-nephrectomy scans, if ava ilable, and baseline scans are 
encouraged to be submitted to BICR within 8 weeks of the nephrectomy to allow for timely return 
of the decision from the BICR. 
The Treatment Phase begins when the randomization call is made into the Interactive Response 
Technology (IRT). For Part A of the study:
â€¢Arm A: nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg ev ery 6 weeks (or every 
third nivolumab dose if dosing is delayed) 
â€¢Arm B: Placebo infusions at the same frequency o f nivolumab and ip ilimumab infusions
Protocol Amendment No.: 06
Date: 08-Dec-2022 14
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
For Part B:
â€¢Arm A: nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg ev ery 6 weeks (or every 
third nivolumab dose if dosing is delayed) 
â€¢Arm B: Placebo infusions at the same frequency of nivolumab and  ipilimumab infusions
â€¢Arm C: Nivolumab 240 mg every 2 weeks and ipilimumab placebo eve ry 6 weeks (or every 
third nivolumab dose if dosing is delayed) 
Treatment must be completed within 36 weeks after the first dos e; any cycles not received within 
36 weeks after the first dose will be omitted, and the participa nt will enter the Follow-up Phase. 
Tumor assessments will occur in accordance with the Schedule of  Activities or until recurrence 
has been identified by the investigator and is confirmed by BIC R. Sites should submit all scans to 
the third-party vendor on a rolli ng basis, preferably within 7 business days of scan acquisition, and 
submit any pertinent cytology/pathology re port for central review. PK and immunogenicity 
samples, biomarker assessments, and NCCN Functional Assessment of Cancer Therapy - Kidney 
Symptom Index (FKSI-19) and EuroQoLâ€™s EQ-5D-3L will be collecte d according to the Schedule 
of Activities . Adverse event (AE) assessments should be documented at each cli nic visit. 
The Follow-up Phase begins at the completion of  12 cycles, when  the decision to discontinue a 
participant from study therapy is made (no further treatment with study therapy), or at Week 36, 
whichever comes first. Participants will have 2 follow-up visits  (Follow-up 1 and Follow-up 2) for 
safety within 30 ( Â±7 days) and 100 days ( Â±7 days), respectively, from the last dose of study 
therapy. If the date of discontinuation is greater than 30 days aft er last dose, the Follow-up visit 1
can coincide with the date of discontinuation ( Â±7 days). Any ongoing tr eatment related- AEs will 
be followed until the toxicities resolve, return to baseline, o r are deemed irreversible. After the 
Follow-up 2 Visit, all participants will be followed for overall survival status every 12 weeks 
(Â±1 week) until death, withdrawal of consent, lost to follow-up, o r end of study.
Protocol Amendment No.: 06
Date: 08-Dec-2022 15
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Figure 1: CA209914 Study Design Schematic for Part A 
Protocol Amendment No.: 06
Date: 08-Dec-2022 16
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Figure 2: CA209914 Part B Study Design Schematic
Number of Participants: 
Approximately 1600 participants will be randomized in this stud y, 800 participants in Part A and 
800 participants in Part B. 
Treatment Arms and Duration:
For Part A of the study:
â€¢Arm A: Nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg ev ery 6 weeks (or 
every third nivolumab dose if dosing is delayed) 
â€¢Arm B: Placebo infusions at the same frequency of nivolumab and  ipilimumab infusions
For Part B of the study:
â€¢Arm A: Nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg ev ery 6 weeks (or 
every third nivolumab dose if dosing is delayed) 
â€¢Arm B: Placebo infusions at the same frequency of nivolumab and  ipilimumab infusions
â€¢Arm C: Nivolumab 240 mg every 2 weeks and ipilimumab Pl acebo every 6 weeks (or every 
third nivolumab dose if dosing is delayed) 
Each cycle will be 2 weeks (14 days). Participants will receive  study drug until the end of 12 cycles 
(12 nivolumab doses and 4 ipilimumab doses), recurrence, unaccep table toxicity, 36 weeks after 
Protocol Amendment No.: 06
Date: 08-Dec-2022 17
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
first dose, or withdrawal of cons ent, whichever occurs first. T he first cycle will be a combination 
dose.
Study Treatment: 
Study Drug for CA209914
Medication Potency IP/Non-IP
Nivolumab Solution for Injection100 mg (10 mg/mL) or 
40 mg (10 mg/mL)IP
Ipilimumab 200 mg (5 mg/mL) IP
0.9% Sodium Chloride for Injection NA IP
5% Dextrose for Injection NA IP
Data Monitoring Committee:
A Data Monitoring Committee (DMC) w ill be established to provide oversight of safety and 
efficacy considerations in protocol CA209914. Additionally, the  DMC will provide advice to the 
sponsor regarding actions the committee deems necessary for the  continuing protection of 
participants. The DMC will be charged with assessing such actions in light o f an acceptable 
benefit/risk profile for nivolumab and ipilimumab. The DMC will  act in an advisory cap acity to 
BMS and will monitor participant safety and evaluate the availa ble efficacy data for the study. The 
oncology therapeutic area of BMS has primary responsibility for  design and conduct of the study.
Blinded Independent Review Committee:The BICR will review tumor images  and pertinent clinical data ( cytology/pathology report) in all 
randomized participants to determine eligibility and response f or the DFS analyses. Details of the 
BICR responsibilities, procedures, composition, and process will  be specified in the BICR charter.
Protocol Amendment No.: 06
Date: 08-Dec-2022 18
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
|2 SCHEDULE OF ACTIVITIES
Table 2-1: Screening Procedural Outline (CA209914) All Participan ts
ProcedureScreening Visita
Notes
Eligibility Assessments
Informed Consent X Register in Interactive Response Technology (I RT) system to obtain participant number.
Inclusion/Exclusion Criteria X Must be confirmed prior to randomiz ation.
Medical History X All medical history relevant to the disease und er study.
Safety Assessments
Full Physical Examination, 
Measurements, Vital Signs, and 
Performance StatusXIncludes height, weight, ECOG Performance Status ( Appendix 5), BP, HR, and 
temperature within 14 days prior to randomization. 
Assessment of Signs and Symptoms X Within 14 days prior to randomiz ation.
Review of Concomitant Medications XWithin 14 days prior to randomization. Document vaccine use wit hin 30 days prior to first 
dose of study treatment. See  Section 6.2 and Section 7.7 for additional details.
Serious Adverse Events (SAE)
AssessmentX (see Notes)Collect Serious Adverse Events from time of consent.
In addition, collect all AEs (SAEs and non-serious AEs) associat ed with suspected or 
confirmed SARS-CoV-2 infection from time of consent.
Laboratory Tests
Laboratory Test XMust be performed within 14 days prior to randomization:
â€¢CBC w/differential
â€¢Chemistry panel including: AST, ALT, ALP, T.Bili, BUN or serum urea level, 
creatinine, phosphate, Ca, Na, Mg, K, Cl, LDH, glucose, and albumin
â€¢Thyroid panel including TSH, Free T4, Free T3
â€¢Hep B/C (HBVsAg, HCV antibody or HCV RNA) 
â€¢(sites in countries or locals where HIV testing is required, se e Appendix 7)
Protocol Amendment No.: 06
Date: 08-Dec-2022 19
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
|Table 2-1: Screening Procedural Outline (CA209914) All Participan ts
ProcedureScreening Visita
Notes
Pregnancy Test XWOCBP only. Serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent 
units of HCG) to be done at screening visit and within 24 hours prior to first dose of study 
therapy. 
Efficacy Assessments
Baseline Tumor Assessments XCT/MRI of the chest, abdomen, and pelvis. See  Section 9.1.3.1 . Baseline assessments should 
be taken no less than 4 weeks after the nephrectomy, and sites are strongly enc ouraged to 
submit scans to the Blinded Independent Central Review (BICR) p referably within 8 weeks 
after the nephrectomy to allow for return of the results from t he BICR. Pre-nephrectomy 
images are also requested, if available, and should be submitted to the BICR within 8 weeks 
post-nephrectomy. BICR c onfirmation of disease-free status is r equired prior to 
randomization.
Tumor Tissue Samples XSubmission of sufficient tumor tissue, preferably obtained from the nephrectomy, with 
associated pathology report will be required. Formalin-fixed, paraffin-embedded (FFPE) 
block or 20 unstained slides, a minimum of 10 slides will be ac ceptable if tumor tissue is 
limited (see Section 9.8.2 ).
AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BICR, Blinded Independent Central Review; BP, 
blood pressure; BUN, blood urea nitrogen; Ca, calcium; CBC, complete blood count; Cl, chloride; ECOG, Eastern Cooperative Onco logy Group; FFPE, formalin-
fixed paraffin-embedded; HBVsA g, hepatitis B surface antigen; H CG, human chorionic gonadotropin; HCV, hepatitis C virus; HIV, human immunodeficiency 
virus; HR, heart rate; IRT, Interactive Response Technology; LD H, lactate dehydrogenase; K, potassium; Mg, magnesium, NA, sodi um; SAE, serious adverse 
event; T.Bili, total bilirubin; WOCBP, women of childbearing pot ential. 
aSome of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used as s afety monitoring by the treating 
physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or local regulations.
Protocol Amendment No.: 06
Date: 08-Dec-2022 20
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 2-2: On-treatment Procedural Outline (CA209914) Part A and  Part B
ProcedureCycle 1 Day 1
(Nivolumab + 
Ipilimumab )Cycles 2, 3, 5, 6, 8, 
9, 11, & 12
Day 1a,b
Each Cycle = 
2 weeks
(Nivolumab 
alone)Cycles 4, 7, & 
10
Day 1,
(Nivolumab + 
Ipilimumab)Notes
Safety Assessments
Targeted Physical 
Examination, Vital Signs, 
and Performance StatusXX XWeight, BP, HR, temperature, and ECOG Performance Status 
(Appendix 5) to be performed within 72 hours prior to dosing
Assessment of Signs and 
SymptomsXX X
Adverse Event
(AE)Assessment and 
Serious Adverse Event 
(SAE) AssessmentContinuously (see Notes)Participants will be followed for drug-related toxicities until  these 
toxicities resolve, return to baseline, or are deemed irreversible. All 
adverse events (SAEs and non-serious AEs), including those associated with suspected or confirmed SARS-CoV-2 infection, wil l 
be collected continuously during the treatment period and documented for a minimum of 100 days after last dose ( Appendix 3).
Review of Concomitant 
MedicationsX X X Record at each visit.
Laboratory Tests X X XLaboratory tests do not need to be repeated at C1D1 if performe d 
within 14 days prior to first dose. 
After C1D1, within 72 hours prior to dosing and results should b e 
reviewed prior to administration of each dose of study drug:
â€¢CBC w/differential.
â€¢Chemistry panel including AST, ALT, ALP, T. Bili, BUN or 
serum urea level, creatinine, phosphate, Ca, Mg, Na, K, Cl, LDH, glucose, and albumin.
â€¢TSH (with reflexive Free T4 and Free T3).
Protocol Amendment No.: 06
Date: 08-Dec-2022 21
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 2-2: On-treatment Procedural Outline (CA209914) Part A and  Part B
ProcedureCycle 1 Day 1
(Nivolumab + 
Ipilimumab )Cycles 2, 3, 5, 6, 8, 
9, 11, & 12
Day 1a,b
Each Cycle = 
2 weeks
(Nivolumab 
alone)Cycles 4, 7, & 
10
Day 1,
(Nivolumab + 
Ipilimumab)Notes
Pregnancy Test X X XWithin 24 hours prior to the initial administration o f study drug, then
every 4 weeks, regardless of dose delay. Serum or Urine. WOCBP only.
Pharmacokinetic 
Samples
PK Samples X X See Table 9.5-1 . At Cycles 1, 2, 5, 8, & 11.
Immunogenicity blood 
sample X X See Table 9.5-1 . At Cycles 1, 2, 5, 8, & 11. 
Exploratory Biomarker 
Assessments
Whole Blood (DNA) X Only at baseline. 
Serum X XPrior to dosing.
At Cycle 1, 4, and 7, and upon occurrence of â‰¥ Grade 3 non-laboratory 
drug-related AE and/or lab abnormalities regarded a s a drug-related
SAE, to be collected when clinically safe and feasible.
ctDNA XX (C2D1, C5D1, 
C9D1 only)Samples should be collected prior to dosing. Subsequent sample 
collections will be aligned with tumor assessments performed on  
Weeks 23, 36, and 52 ( Â±1 week window). If a tumor assessment is 
not performed, ctDNA sampling is not required.
Peripheral Blood RNA XPrior to dosing at Cycle 1 and upon â‰¥ Grade 3 non-laboratory 
drug-related AE and/or laboratory abnormalities regarded as a
drug-related SAE, to be collected when clinically safe and feasible.
Myeloid Derived 
Suppressor Cells XXCytochex Tube. Prior to dosing.
At Cycle 1 and 7.
Protocol Amendment No.: 06
Date: 08-Dec-2022 22
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 2-2: On-treatment Procedural Outline (CA209914) Part A and  Part B
ProcedureCycle 1 Day 1
(Nivolumab + 
Ipilimumab )Cycles 2, 3, 5, 6, 8, 
9, 11, & 12
Day 1a,b
Each Cycle = 
2 weeks
(Nivolumab 
alone)Cycles 4, 7, & 
10
Day 1,
(Nivolumab + 
Ipilimumab)Notes
SARS-CoV-2 Serology X X (C12D1 only)Samples should be collected prior to dosing. Serum will be colle cted 
at C1D1 and C12D1 for all participants, and approximately 4 weeks after a suspected or confirmed SARS-CoV-2 infection to be used forpotential future measurements of anti-SARS-CoV-2 serology (anti-SARS-CoV-2 total or immunoglobulin G (IgG) [see Section 9.8.9 ]). If 
a suspected or confirmed SARS-CoV-2 infection occurs within 4 
weeks of the C1D1 or C12D1 time point, a single serum sample wil l 
be collected to satisfy the requirements for both the C1D1 or C1 2D1
and approximately 4 week after infection time points.
Efficacy Assessments
Tumor Assessments See Notes. CT/MRI of the chest, abdomen, and pelvis. Assessment should be 
performed at Weeks 23, 36, and 52 (Â± 1 week) regardless of any dose 
delays. Use same imaging method as was used at screening/baseli ne. 
See Section 9.1.3 for additional details. 
Patient-Reported 
Outcomes
EQ-5D-3L XCycles 3, 6, 9, and 
12Completed on Day 1 of Cycles 1, 3, 6, 9, and 12 prior to any 
study-related procedures.
FKSI-19 Xc Cycles 3, 6, 9 and 
12Completed on Day 1 of Cycles 1, 3, 6, 9, and 12 prior to any 
study-related procedures.
Protocol Amendment No.: 06
Date: 08-Dec-2022 23
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 2-2: On-treatment Procedural Outline (CA209914) Part A and  Part B
ProcedureCycle 1 Day 1
(Nivolumab + 
Ipilimumab )Cycles 2, 3, 5, 6, 8, 
9, 11, & 12
Day 1a,b
Each Cycle = 
2 weeks
(Nivolumab 
alone)Cycles 4, 7, & 
10
Day 1,
(Nivolumab + 
Ipilimumab)Notes
Drug Administration
Randomize X Begins with call to Interactive Response Technology.
Administer nivolumab or 
placeboXX XParticipants must begin study treatment within 3 calendar days of randomization. 
Administer ipilimumab or 
placeboXXParticipants must begin study treatment within 3 calendar days of randomization.
AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressu re; BUN, blood urea nitrogen; 
C1D1, Cycle 1 Day 1; Ca, calcium; CBC, complete blood count; Cl , chloride; ECOG, Eastern Cooperative Oncology Group; FKSI-19, Functional Assessment of 
Cancer Therapy - Kidney Symptom Index; HR, heart rate; LDH, lact ate dehydrogenase; K, potassium; Mg, magnesium, NA, sodium; SAE, serious adverse event; 
SARS CoV-2, severe acute respiratory syndrome coronavirus 2; T. Bili, total bilirubin; TSH, thyroid stimulating hormone; WOCBP,  women of childbearing 
potential. 
aIf a dose is delayed, the procedures scheduled for that same time point should also be delayed to coincide with when that time  pointâ€™s dosing actually occurs.
bIf all cycles are not given within 36 weeks after the first dose , the participant will discontinue treatment and move to Post-t reatment Follow-up.
cNote: at baseline visit (C1D1) only, Question GP5 on FKSI-19 can be left blank as participant has not yet received treatment.
Protocol Amendment No.: 06
Date: 08-Dec-2022 24
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 2-3: Post-treatment Follow-up (CA209914) Part A and Part B
ProcedureFollow-Up 
Visit 1 and 2a Survival Follow-Upb Notes
Safety Assessments
Targeted Physical 
Examination, Vital 
Signs, and Performance 
StatusXWeight, BP, HR, temperature, and ECOG Performance Status
(Appendix 5). 
Assessment of Signs 
and SymptomsX
Adverse Event (AE)
Assessment and Serious 
Adverse Event (SAE)
AssessmentX See NotesParticipants will be follo wed for drug-related toxicities until these 
toxicities resolve, return to baseline, or are deemed irreversible. All 
AEs will be documented for a minimum of 100 days after last dos e 
(Appendix 3).
Participants will be followed for all SAEs, non-serious AEs of special 
interest (as defined in Section 9.2 ), and all AEs (SAEs and 
non-serious AEs) associated with suspected or confirmed 
SARS-CoV-2 infection and study treatment-related AEs (SAEs and 
non-serious AEs) until resolution, the condition stabilizes, the  event is 
otherwise explained, the event is deemed irreversible, the participant is lost to follow-up (as defined in Section 8.3), or for suspected cases 
of SARS-CoV-2, until SARS-CoV-2 infection is ruled out.
Also, all non-serious AEs considered related to the study treat ment
should be collected t hrough survival follow-up visits until 
approximately 1 year following discontinuation of study treatmen t
(see Section 9.2.1 and Section 9.2.3 for additional details). 
Review of Concomitant 
MedicationsXXDuring survival follow-up any new anti-tumor therapy initiated f or 
either disease recurrence or a secondary malignancy at any time  
during this period will be captured in the CRF
Protocol Amendment No.: 06
Date: 08-Dec-2022 25
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 2-3: Post-treatment Follow-up (CA209914) Part A and Part B
ProcedureFollow-Up 
Visit 1 and 2a Survival Follow-Upb Notes
Laboratory Tests XCBC w/differential, AST, ALT, AL P, T. Bili, BUN or serum urea
level, creatinine, phosphate, Ca, Mg, Na, K, Cl, LDH, glucose, and 
TSH (with reflexive Free T4 and Free T3).
Pregnancy Test X Serum or Urine. WOCBP only.
Pharmacokinetic 
Samples
PK Samples X
Immunogenicity blood 
sampleX
Exploratory 
Biomarker 
Assessments
Serum See NotesUpon disease recurrence or occ urrence of  â‰¥ Grade 3 non-laboratory 
drug-related AE and/or lab abnormalities regarded a s a drug-related
SAE, to be collected when clinically safe and feasible
Peripheral Blood RNA See NotesUpon disease recurrence or occurrence of â‰¥ Grade 3 non-laboratory
drug-related AE and/or lab abnormalities regarded a s a drug-related
SAE, to be collected when clinically safe and feasible.
ctDNASee NotesSample collection is aligned with the tumor assessments on
Weeks 23, 36, and 52 ( Â±1 week window). If a tumor assessment is 
not performed, ctDNA sampling is not required.
SARS-CoV-2 Serology See NotesSerum will be collected at Follow-up visit 2 only for all partic ipants, 
and approximately 4 weeks after  a suspected or confirmed 
SARS-CoV-2 infection to be used for potential future measurements 
of anti-SARS-CoV-2 serology (ant i-SARS-CoV-2 total or IgG [see 
Section 9.8.9 ]). If a suspected or confirmed SARS-CoV-2 infection 
occurs within 4 weeks of the follow-up visit 2 time point, a single 
serum sample will be collected to satisfy the requirements for both the follow-up visit 2 and approximately 4 week after infection time points.
Protocol Amendment No.: 06
Date: 08-Dec-2022 26
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 2-3: Post-treatment Follow-up (CA209914) Part A and Part B
ProcedureFollow-Up 
Visit 1 and 2a Survival Follow-Upb Notes
Tumor Biopsy See NotesTumor biopsy collection at the time of recurrence is optional b ut 
highly encouraged.
Efficacy Assessments
Tumor Assessments See Notesâ€¢Timing for scans should be based on date of first treatment, whi ch 
is considered Week 1. Weeks 23, 36, and 52 (Â± 1 week window at 
each time point).
â€¢After Week 52 (first year), tumor assessments should occur ever y 
6m o n t h s  ( Â±2 week window) until Year 6. 
â€¢Annually for Year 6 to Year 10 ( Â±2 week window).
â€¢Additional imaging of potential disease sites should be performed 
whenever disease recurrence or occurrence of a secondary malignancy is suspected. 
â€¢Tumor assessments can be discontinued when recurrence has been confirmed by BICR.  
â€¢Brain CT or MRI with contras t or bone imagi ng (confirmatory 
imaging in addition to bone imaging may be required) if clinically indicated.
â€¢See Section 9.1.3 for additional details. 
Patient-Reported 
Outcomes
EQ-5D-3L Xc(see Notes) See Notesc Perform at Follow-up 1 and 2 , the first Survival Visit and at every 
other survival Follow-Up visit thereafter (Survival Follow-up v isit 3, 
5, 7, etc).c
All patient-reported outcomes should be completed prior to study-related procedures, if possible.FKSI-19 Xc(see Notes) See Notesc
AE, Adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressu re; BUN, blood urea nitrogen; 
Ca, calcium; CBC, complete blood c ount; Cl, chloride; ctDNA, circulating tumor DNA; ECOG, Eastern Co operative Oncol ogy Group; FKSI-19, Functional 
Assessment of Cancer Therapy - Kidney Symptom Index; HR, heart r ate; LDH, lactate dehydrogenase; K, potassium; Mg, magnesium, NA, sodium; SAE, serious 
Protocol Amendment No.: 06
Date: 08-Dec-2022 27
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
adverse event; SARS CoV-2, severe acute respiratory syndrome co ronavirus 2; T.Bili, total bilirubin; TSH, thyroid stimulating hormone; WOCBP, women of 
childbearing potential. 
aParticipants must be followed for at least 100 days after last dose of study treatment. Follow-up visit 1 (Follow-up 1) = 30 d ays from the last dose Â±7 days or 
coincide with the date of discontinuation ( Â±7 days) if date of discontinuation is greater than 30 days after last dose.  Follow-up visit 2 (Follow-up 2) = 100 days 
(Â±7 days) from the last dose of study medication.
bFrom Follow-up 2, all participants will be followed for overall survival status every 12 weeks ( Â±7 days) un til the time for the final analysis. Survival status can 
be ascertained by telephone contact if the participant is unable to return to the site. If new anti-tumor therapy is initiated f or either disease recurrence or a 
secondary malignancy at any time during this period, this and all other pertinent data obtained should be recorded on the appr opriate Case Report Form (CRF).
cIf participant is unable to perform the patient-reported outcom e assessment in person, the EQ-5D-3L and FKSI-19 can be performe d via telephone. The same 
window ( Â±7 days) applies for telephone contacts.
Protocol Amendment No.: 06
Date: 08-Dec-2022 28
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
3 INTRODUCTION
Renal cell carcinoma (RCC) is the eighth most common cancer in the world with an increasing 
incidence.1In the United States, there were approximately 63,000 new cases  in 2015 and almost 
14,000 deaths.2There were approximately 84,000 cases of RCC and 35,000 deaths due to kidney 
cancer in 2012 in the European Union.3,4Despite the earlier detection of smaller kidney tumors, 
the rate of RCC-related mortalit y has increased,5,6suggesting that recurrence and advanced disease 
are responsible for mor tality. In this context, optimizing the management of early-stage RCC, as 
well as advanced RCC, are key priorities in the oncological cli nical practice. 
When RCC is localized early in the course of the disease, it is well established that radical surgical 
resection is curative for a proportion of patients however, it i s estimated that 20- 30% of patients 
will experience relapse.16Most relapses occur within 3 years after surgery, with a median  time of 
1-2 years however; recurrences have been reported through 30 yea rs.16Prognostic factors that 
have been associated with an increased risk of recurrence inclu de anatomic extent of disease, 
histopathology, presence of tum or necrosis, and cer tain biomarkers.7Effective adjuvant therapy, 
in addition to surgi cal management, may offer an alternative approach to the standa rd of care for 
patients with high risk of recurrence. Investigational research is currently ongoing regarding 
prognostic factors, time and risk of recurrence, and use of adju vant therapy in the localized RCC 
setting.
Several trials have shown no benefit with adjuvant interferon- o r interleukin-2-based therapies or 
a CA-IX antibody. This is in contrast to a number of clinically  proven therapies for stage IV RCC. 
Additional trials are currently assessing the efficacy of the a pproved multi-targeted tyrosine kinase 
inhibitors, including sorafenib (SORCE) and axitinib (ATLAS) ( Table 3-1), in the adjuvant setting.
Protocol Amendment No.: 06
Date: 08-Dec-2022 29
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 3-1: Clinical Trials Database Listed Large, Multicenter, P lacebo-Controlled, Randomized, Double-
blind, Adjuvant Clinical Trials in RCC (Completed)
AcronymTrial 
No.Status InterventionFunding Body/
SponsorsDesignStart Date/
Est 
Complete 
DateStratificationEstimated 
EnrollmentOutcome 
Measures
ARISERNCT000
87022Completed Girentuximab Industry; WilexMC, DB, 
R, PC07/2004
10/2012High-risk patients 
based on TN stage or 
Fuhrman grade, 
ECOG PS = 0 or 1864Primary 
endpoint DFS, 
not met
ASSURENCT032
6898CompletedSorafenib or 
SunitinibNIH; NCI, 
ECOG, SWOG, 
Cancer and 
Leukemia 
Group B, NCICMC, DB, 
R, PC05/200604/2016At least intermediate 
high-risk UISS, 
ECOG PS = 0 or 1, 
clear or non-clear cell 
RCC1923Primary 
endpoint DFS 
not met
ATLASNCT015
99754Terminated AxitinibIndustry; SF J 
Pharma., PfizerMC, DB, 
R, PC04/201205/2019High-risk UISS, 
ECOG PS = 0 or 1, 
predominate clear 
cell histology592OS, DFS, 
toxicity
PROTECTNCT012
35962Completed Pazopanib Industry; GSKMC, DB, 
R, PC11/2010
04/2017Modified UISS, 
Karnofsky 
performance scale of 
at least 80, clear cell 
or predominate clear 
cell histology1500Primary 
endpoint DFS 
not met
SORCENCT004
92258Completed SorafenibMedical 
Research 
Council UKMC, DB, 
R, PC05/2007
2013Intermediate- and 
high-risk SSIGN, 
ECOG PS = 0 or 1, 
clear or non-clear cell 
RCC1656OS, DFS, 
toxicity, QoL
SWOG-S0931NCT011
20249Active, not 
recruitingEverolimusNIH, SWOG, 
NCIMC, DB, 
R, PC04/2011Pathological high or 
very high risk, no 
further details 
available, ECOG PS 
= 0 or 11218RFS, OS
toxicity
Protocol Amendment No.: 06
Date: 08-Dec-2022 30
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 3-1: Clinical Trials Database Listed Large, Multicenter, P lacebo-Controlled, Randomized, Double-
blind, Adjuvant Clinical Trials in RCC (Completed)
AcronymTrial 
No.Status InterventionFunding Body/
SponsorsDesignStart Date/
Est 
Complete 
DateStratificationEstimated 
EnrollmentOutcome 
Measures
S-TRACNCT003
75674Completed Sunitinib Industry, PfizerPC, DB, 
R, DB07/2007
06/2017High-risk UISS, 
ECOG PS = 0-2, 
predominate clear 
cell histology720Primary 
endpoint DFS 
met per IRC not 
met per 
investigator. OS 
(immature)
ARISER, Adjuvant Rencarex Immunotherapy Phase III trial to Stud y Efficacy in non-metastatic RCC8;ASSURE, Adjuvant Sorafenib or Sunitinib for Unfavorable 
Renal Carcinoma; ATLAS, Adjuvant Axitinib9Treatment of Renal Cancer: A Randomized Double-blind Phase 3 St udy of Adjuvant Axitinib v Placebo in Subjects 
at High Risk of Recurrent RCC; PROTECT, a Randomized, Double-bl ind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as 
Adjuvant Therapy for Subjects with Localized or Locally Advance d RCC Following Nephrectomy; SORCE , a Phase III Randomized, Dou ble-blind Study 
Comparing Sorafenib with Placebo in Patients with Resected Prim ary Renal Cell Carcinoma at High or Intermediate Risk of Recurrence; S-TRAC, Sunitinib 
Treatment of Renal Adjuvant Cancer: A Randomized Double-blind P hase 3 Study of Adjuvant Suntinib v Placebo in Subjects at High  Risk of Recurrent RCC 10; 
SWOG-S0931, EVEREST, EVErolimus for Renal Cancer Ensuring Surgi cal Therapy, a Phase III Study.
DB, Double-blind; ECOG, Eastern Cooperative Group; DFS, Disease- free survival; PS, performance score; MC, multicenter; NCI, Nat ional Cancer Institute; NIH, 
National  Institute of Health; OL, open-label; OS, overall survival; PC,  placebo-controlled; QoL, quality of life; SWOG, Southwest Oncology Group; R, randomized; 
TN, tumor, node; UISS, UCLA Integrated Staging System
Protocol Amendment No.: 06
Date: 08-Dec-2022 31
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
The first trial to report results, ECOG 2805 (ASSURE), revealed  no benefit in disease-free survival 
(DFS) after 1 year of adjuvant sunitinib or sorafenib versus pla cebo.11Median DFS was 5.8 years 
(IQR, 1.6âˆ’8.2) for sunitinib (hazard ratio [HR] 1.02, 97.5% CI 0 .85â€“1.23, P = 0.8038), 6.1 years 
(IQR, 1.7â€“not estimable [NE]) for sorafenib (HR 0.97, 97.5% CI 0.80â€“1.17, P=0.7184), and 
6.6 years (IQR, 1.5â€“NE) for placebo. The most common Grade 3 or worse AEs were hypertension 
(105 [17%] participants on sunitinib and 102 [16%] participants on sorafenib), hand-foot syndrome 
(94 [15%] participants on sunitini b and 208 [33%] participants on sorafenib), rash (15 [2%] 
participants on sunitinib and 95 [15%] par ticipants on sorafenib) , and fatigue (110 [18%] 
participants on sunitinib and 44 [7%] par ticipants on sorafenib). Reduced doses of sunitinib still 
resulted in high toxicity.
In the Phase III PROTECT trial, 1538 participants with completely resected RCC were randomly 
assigned to pazopanib or placebo for 1 year. The starting dose of pazopanib was  reduced from 800 
to 600 mg daily, after enrollment of 403 participants, due to h igh rates of treatment 
discontinuations due to excess risk of hepatotoxicity. After me dian follow-up of approximately 
60 months, DFS for those treated with 600 mg/day dosing was not statistically different between 
pazopanib and placebo (67 versus 64 percent three-year DFS, HR 0.94, 95% CI 0.77-1.14). 
However, DFS was improved for those assigned to 800 mg/day dosi ng (66 versus 56 percent, HR 
0.66, 95% CI 0.49-0.90). Overall survival, a secondary endpoint , was immature.12
In a Phase III rando mized, double-bli nd, placebo-controlled trial (ATLAS) conducted in 
724 participants with localized RCC status postnephrectomy, axiti nib 5 mg oral twice daily, failed 
to demonstrate a DFS advantage in the total s tudy population. T here was no significant difference 
in DFS per independent review committee assessment in the inten tion-to-treat population (HR 
0.870, 95% CI 0.660â€“1.147; p 0.3211) or per investigator assessment (HR 0.776, 95% CI 0.599â€“
1.005; P = 0.0536).Overall survival data were not mature. Grade 3 or greater toxicities were more 
frequent in the axitinib arm (61 versus 30 percent).13
Another large Phase III trial, ARISER, a double-blind, placebo-controlled study, evalu ated 
girentuximab (an antibody targeting carbonic anhydrase IX). Co- primary endpoints were DFS and 
OS assessed by independent radiologic review. No statist ically signif icant DFS (HR = 0.97; 95% 
CI 0.79â€“1.18) or OS (HR = 0.99; 95% CI 0.74â€“1.32) benefit was o bserved. 14
In SORCE, a Phase III study comparing sorafenib 400 mg twice da ily for 3 years, sorafenib 400 mg 
twice daily for  1 year follo wed by placebo f or 2 years, and placebo for 3 year s. Participants were
randomized in a 3:3:2 fashion. This study targ eted intermediate- or high-r isk disease by Leibovich 
score and allows both clear cell and non-clear cell histologies. The init ial sorafenib dose was 
400 mg twice per day orally, amended during trial recruitment to  a reduced starting dose of 400 mg 
daily. The primary  outcome was investigator-re ported DFS. There were no differences in DFS or 
OS for all ra ndomized participants, high-risk participants only, and particip ants with only clear 
cell RCC. Median DFS was not reached for three years of sorafen ib or for placebo (HR= 1.01, 
95% CI 0.82 - 1.23, P = 0.946). The mean DFS was 6.81 years for thr ee years of sorafenib and 6.82 
years for placebo, a difference of 0.01 (95% CI 0.49 â€“ 0.48, P = 0.99).15
Protocol Amendment No.: 06
Date: 08-Dec-2022 32
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Recently, the S-TRAC s tudy was reported to have met its primary endpoint of improved DFS by 
blinded independent central review (BICR) for sunitinib vs placeb o. The popul ation targeted in 
the study was predominantly clear cell and had a diagnosis of l ocoregional RCC (tumor stage 3 or 
higher, regional lymph-node metastasis or both) on the basis of  modified UISS criteria. The 
median DFS was 6.8 years (95% CI, 5.8 to NR) vs 5.6 years (95% C I, 3.8 to 6.6), (HR = 0.76, 
95% CI, 0.59-0.98, P = 0.03). Of note, investigator-assessed DF S did not show any statistical 
difference between suni tinib and placebo. Over all survival (OS) data were not mature at the time 
of data cutoff. Dose reductions because of AEs were more frequen t in the sunitinib group than in 
the placebo group (34.3% vs  2%), as were dose interruptions (46.4% vs 13.2%) and 
discontinuations (28.1% vs 5.6%). Grade 3 or 4 AEs were more fre quent in the sunitinib group 
(48.4% for Grade 3 events and 12.1% for Grade 4 events) than in  the placebo group (15.8% and 
3.6%, respectively). Ther e was a similar incidence of serious a dverse events (SAEs) in the 2 groups 
(21.9% for sunitinib vs 17.1% fo r placebo). No deaths were attributed to toxic effects. From a
quality of life prospective, participants in the sunitinib arm had lower scores (EQ-5D and 
QLC-C30) than the placebo group, reaching clinically significan t differences for diarrhea and loss 
of appetite.10
Based on the above resul ts, sunitinib (50 mg d aily 4 weeks on, 2 weeks off, for 1 year) was 
approved in the United States as adjuvant therapy following nep hrectomy for participants at high 
risk of relapse. Although improved DFS findings per BICR were n oted in the S-TRAC study, there 
was an absence of DFS improvement based on investigator assessm ent, immature OS finding, a 
need for frequent dose adjustments, and interruptions to manage  sunitinib-related toxicities, and 
an overall decrease in quality of life of participants on suniti nib. National Cancer Comprehensive 
Network (NCCN) guidelines have been updated and indicate for RCC clear cell histology and high 
risk; clinical trial (preferred) or surveillance or adjuvant su nitinib (category 2B).16
In conclusion, at this time, surgery for primary tumors remains the best chance to cure patients 
with localized RCC. However, s urvival rates in higher risk pati ents remain poor, and novel 
therapeutic approaches are needed to improve prognosis in these  patients.
3.1 Study Rationale
Encouraging results have been observed in both tr eatment-experie nced and treatment-naive 
advanced RCC participants who received either nivolumab monother apy or nivolumab plus 
ipilimumab ( Section 3.2.1). Therefore, it is rational to continue to evaluate these immu notherapies 
in the adjuvant setting versus the  current RCC sta ndard of care. 
With the implementation of this proposed amendment, Part A of the study remains ident ical to the 
original protocol design. The addition of Part B to the protoco l includes a monotherapy nivolumab 
arm. A target of approximately 1600 participants are planned (n= 800 Part A and n=800 Part B) to 
be randomized in study CA209914, with the primary endpoint of D FS and secondary endpoints of 
OS, and safety and tolerability. 
The study is designed to demonstrate superiority of the combina tion of nivolumab a nd ipilimumab 
over placebo, and to then demonstrate superiority of monotherapy nivolumab over placebo and to 
support registration of the combination and monotherapy in adju vant RCC. The contribution of 
Protocol Amendment No.: 06
Date: 08-Dec-2022 33
7.0 Approved 930108721 7.0v Approved 1.0 v
C l i n i c a l  P r o t o c o l C A 2 0 9 9 1 4 
BM S - 9 3 6 5 5 8 n i v o l um a b 
c om p o n e n t s   o f   t h e   c om b i n a t i o n   i s   p l a n n e d   t o   b e   a s s e s s e d   u s i n g   a   c o n t em p o r a n e o u s l y   e n r o l l e d  
c om b i n a t i o n  a n d  m o n o t h e r a p y  s u b g r o u p  w i t h i n  t h e  C A 2 0 9 9 1 4  s t u d y .  
T h e  o r i g i n a l  p r im a r y  e n d p o i n t ,  D F S  f o r  t h e  c om b i n a t i o n  t r e a tm e n t  c om p a r e d  t o  t h e  p l a c e b o  a rm  
i s  l a r g e l y  u n im p a c t e d  b y  R e v i s e d  P r o t o c o l  0 3 .  T h e  p r im a r y  t e s t  f o r  p a r t i c i p a n t s  r a n d om i z e d  1 : 1  t o  
r e c e i v e  n i v o l um a b  +  i p i l im um a b  v e r s u s  p l a c e b o  w i l l  o c c u r  a s  o r i g i n a l l y  p l a n n e d . 
T h e   a d d i t i o n a l   m o n o t h e r a p y   a rm   i n   P a r t   B ,   w i l l   a l l o w   t h e   e f f i c a c y   a s s e s sm e n t   b y   d i r e c t l y  
e v a l u a t i n g  t h e  d i f f e r e n c e  b e t w e e n  2 0 0  p a r t i c i p a n t s ,  c o n t em p o r a n e o u s l y  r a n d om i z e d  t o  n i v o l um a b  
+  i p i l im um a b  v e r s u s  4 0 0  p a r t i c i p a n t s  c o n t em p o r a n e o u s l y  r a n d om i z e d  t o  n i v o l um a b  m o n o t h e r a p y . 
E v a l u a t i n g  b o t h  n i v o l um a b  m o n o t h e r a p y  a n d  t h e  c om b i n a t i o n  o f  n i v o l um a b  a n d  i p i l im um a b  w i l l  
p r o v i d e  a  r i s k - b e n e f i t  a s s e s sm e n t  o f  b o t h  a d j u v a n t  c om b i n a t i o n  t h e r a p y  a n d  m o n o t h e r a p y .  
3 . 1 . 1  R e s e a r c h  H y p o t h e s i s 
T r e a tm e n t   w i t h   n i v o l um a b   c om b i n e d   w i t h   i p i l im um a b   c om p a r e d   w i t h p l a c e b o   i n f u s i o n s  a n d  
t r e a tm e n t  w i t h   n i v o l um a b   m o n o t h e r a p y  c om p a r e d  w i t h  p l a c e b o   i n f u s i o n s ,  w i l l   im p r o v e  D F S   i n  
p a r t i c i p a n t s  w i t h  l o c a l i z e d  R C C  w i t h  a  p r e d om i n a n t l y  c l e a r  c e l l  h i s t o l o g y  w h o  u n d e r w e n t  r a d i c a l  
o r  p a r t i a l  n e p h r e c t om y . 
3 . 2  B a c k g r o u n d 
A   d e t a i l e d   d e s c r i p t i o n   o f   t h e   c h em i s t r y ,   p h a rm a c o l o g y ,   e f f i c a c y ,   a n d   s a f e t y   o f   n i v o l um a b   a n d  
i p i l im um a b  i n  c om b i n a t i o n  i s  p r o v i d e d  i n  t h e  N i v o l um a b  I n v e s t i g a t o r â€™ s  B r o c h u r e  ( I B ) . 
3 . 2 . 1  I n d i c a t i o n  B a c k g r o u n d 
3 . 2 . 1 . 1  N i v o l um a b  M o n o t h e r a p y  i n  R C C 
H a r n e s s i n g  t h e  imm u n e  s y s t em  w o u l d  b e  a n  a t t r a c t i v e  o p p o r t u n i t y ,  t o g e t h e rw i t h e o r t s t o  ï¬ n d  c e l l 
s u r f a c e  m a r k e r s  t h a t  c a n  b e  u s e d  t o  t r a c e  a n d  t a r g e t  d o rm a n t  r e n a l - c e l l  c a r c i n om a  c e l l s .  N i v o l um a b  
m o n o t h e r a p y   h a s   b e e n   s t u d i e d   i n   p a r t i c i p a n t s   w i t h   a d v a n c e d   R C C  i n   s e v e r a l   BM S - s p o n s o r e d  
s t u d i e s  ( P h a s e  1  t h r o u g h  3 ) :  M D X 1 1 0 6 - 0 3 ,  C A 2 0 9 0 0 9 ,  C A 2 0 9 0 1 0 ,  a n d  C A 2 0 9 0 2 5 .  M D X 1 1 0 6 - 0 3 
w a s  a  P h a s e  I  r e f r a c t o r y  s o l i d  t um o r  t r i a l ,  w h i c h  i n c l u d e d  3 4  p a r t i c i p a n t s  w i t h  p r e v i o u s l y - t r e a t e d  
a d v a n c e d  R C C  w h o  r e c e i v e d  n i v o l um a b  a t  1  m g / k g  ( n  =  1 8 )  o r  1 0  m g / k g  ( n  =  1 6 )  g i v e n  e v e r y  
2  w e e k s . 1 7 ,1 8 ,1 9 I n   b o t h   t h e   1   m g / k g   a n d   1 0   m g / k g   c o h o r t s ,   a p p r o x im a t e l y   3 0%   o f  p a r t i c i p a n t s 
e x p e r i e n c e d  a n  o b j e c t i v e  r e s p o n s e  w i t h  m e d i a n  d u r a t i o n  o f  r e s p o n s e  o f  1 2 . 9  m o n t h s .  R e s p o n s e s  
w e r e  g e n e r a l l y  r a p i d  w i t h  a  m e d i a n  t im e  t o  r e s p o n s e  o f  1 6  w e e k s .  N o t a b l y ,  r e s p o n s e s  c o u l d  o c c u r  
a f t e r  t r e a tm e n t   c e s s a t i o n   a n d   p e r s i s t  o f f   t r e a tm e n t .   M e d i a n   p r o g r e s s i o n - f r e e   s u r v i v a l   ( P F S )   w a s  
7 . 3  m o n t h s .  M e d i a n  o v e r a l l  s u r v i v a l  (m O S )  w a s  2 2 . 4  m o n t h s .  T h e s e  r e s u l t s  w e r e  p r om i s i n g  g i v e n  
t h a t   m a n y   o f   t h e   p a r t i c i p a n t s  w e r e   h e a v i l y   p r e - t r e a t e d   w i t h   7 1%  h a v i n g   h a d   2  o r   m o r e   l i n e s   o f  
t h e r a p y .  T r e a tm e n t - r e l a t e d  A E s  o f  a n y  g r a d e  w e r e  o b s e r v e d  i n  8 5 %  o f  R C C  p a r t i c i p a n t s ;  t h e  m o s t  
c omm o n  w e r e  f a t i g u e  ( 4 1% ) ,  r a s h  ( 2 7% ) ,  d i a r r h e a  ( 1 8% ) ,  a n d  p r u r i t i s  ( 1 8% ) .  G r a d e  3 - 4  t r e a tm e n t - 
r e l a t e d  A E s  w e r e  o b s e r v e d  i n  1 8%  o f  R C C  p a r t i c i p a n t s .  T h e  s p e c t r um ,  f r e q u e n c y ,  a n d  s e v e r i t y  o f 
t r e a tm e n t - r e l a t e d   A E s   w e r e   s im i l a r   i n   t h e  R C C  p o p u l a t i o n   c om p a r e d   t o   t h e   o v e r a l l   s t u d y  
p o p u l a t i o n  a n d  w e r e  s im i l a r  a c r o s s  d o s e  l e v e l s .  
P r o t o c o l  Am e n dm e n t  N o . :  0 6 
D a t e :  0 8 - D e c - 2 0 2 2 3 4 
7 . 0 A p p r o v e d  9 3 0 1 0 8 7 2 1 7 . 0 v A p p r o v e d  1 . 0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
In order to identify a potential dose-response r elationship in RCC, a randomized Phase 2 st udy 
(CA209010) was conducted in 168 participants with advanced RCC previously treated with an 
antiangiogenic therapy who received nivolumab at 0.3 mg (n = 60 ), 2 mg/kg (n = 24) or 10 mg/kg 
(n=54) given every 3 weeks.18No dose response relationship was found as measured by PFS, with 
median PFS of 2.7, 4.0, and 4.2 months for the 0.3, 2, and 10 m g/kg groups, respectively (P = 0.9). 
Objective response rate (ORR) was 20%, 22%, and 20% in the 0.3, 2, and 10 mg/kg groups, 
respectively. Median time to achievement of an objective respon se was 2.8-3.0 months. The 
median durati on of res ponse was 22.3 months (4.8, NR) in the 10 mg/kg arm and not yet r eached 
in the 2 lower dose cohorts. Median OS was at 18.2 to 25.5 month s, with a minimum of follow-up 
of 24 months. Fatigue was the mos t frequent toxicity  (22- 35%). No new toxicities were identified 
with 11% experiencing Grade 3-4 treatment-related AEs, none of w hich were due to pneumonitis. 
Treatment-related AEs led to discontinuation of study drug in 7 % of participants. 
A parallel biomarker-focused trial, CA209009, using the same 3 nivolumab dose levels (0.3, 2, 
and 10 mg/kg every 3 weeks) was executed to explore predictors o f response and identify 
mechanisms of resistance.20This study included 67 participants with previously-treated, adv anced 
RCC who were randomized to one of the 3 nivolumab dose groups an d 24 participants with 
previously-untr eated RCC who received nivolumab at 10 mg/kg eve r y  3  w e e k s .  T h e  r e s u l t s  
mirrored the eff icacy and toxicity profile  of CA 209010, with an O RR of 18% in previously-tr eated 
participants, and 13% in previously untreated participants and d isease stabilization in another 32% 
of previously treated and untreated participants. At 24 weeks, 36% of participants were free from 
progression. Of 56 participants with  evaluable pretreatment tumor  samples, 18 (32%) had â‰¥5% 
PD-L1 tumor expression. ORR was 22% among those with â‰¥5% PD-L1 tum or expressio n versus 
8% among those with < 5% PD-L1 tumor expression. 
Based on the clinical activity o f nivoluma b observed in these Phase 1 and 2 studies, a large Phase 3 
trial (CA209025) was conducted in 821 participants with advanced RCC previously tr eated with 
1 or 2 antiangiogenic therapies who were randomized to receive n ivolumab 3 mg/kg every 2 weeks 
or everolimus 10 mg daily. A planned interim analysis, after a minimum of follow-up of 
14 months, demonstrated a statist ically signif icant and clinically meaningful improvement in OS 
of nivolumab monotherapy vs everolimus (median OS, 25.0 months vs 19.6 months, respectively; 
HR 0.73 [98.5% CI, 0.57 to 0.93] P = 0.002). ORR was 25% for nivol umab vs 5% for everolimus. 
Additional efficacy results are presented in Table 3.2.1.1-1. Among 756 participants with 
quantifiable PD-L1 tumor expression in pretreatment samples, 24 % had â‰¥1% PD-L1 e xpression. 
Among participants with â‰¥1% PD-L1 expression, median OS wa s 21.8 months in th e nivolumab  
group and 18.8 months in the evero limus group (HR, 0.79; 95% CI, 0.53 to 1.17). Among 
participants with < 1% PD-L1 expression, the median OS was 27.4 mo nths in the nivolumab group 
and 21.2 months in the everolimus group (HR, 0.77; 95% CI 0.60 t o 0.97). No new safety concerns 
were identified, and nivolumab monotherapy showed a favorable s afety profile as compared to 
everolimus, evidenced by the lower rates of drug-related AEs (a ll grades, 79% vs 88%; Grade 3-
4, 19% vs 37%, respectively) and drug -related AEs leading to di scontinuation (all grades , 8% vs 
13%, respectively) in the nivolumab group . These results were the basis for regulatory approval of 
nivolumab monotherapy in advanced RCC.
Protocol Amendment No.: 06
Date: 08-Dec-2022 35
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Single agent activity and tolerability of anti-PD1 in the first  line metastatic setting further supports 
the evaluation of  nivolumab monotherapy in the adjuvant s etting. In the phase 2, nonrandomized, 
noncomparative, KEYNOTE-42721study, pembrolizumab was studied as monotherapy in 110 
participants with advanced clear cell RCC who had not received p rior systemic therapy, including 
41 IMDC favorable-risk participants. The interim data showed si ngle-agent activity with an overall 
response rate of 38.2% including a CR rate of 2.7%. Responses lasting for 6 months or more were 
observed in 74.8% of participants. The median PFS was 8.7 month s (95% CI: 6.7-12.2 months) 
and the 6 month PFS rate was 60.2%. In an analysis based on PD- L1 status, participants whose 
tumors expressed PD-L1 (combin ed positive scor e [CPS] â‰¥ 1) (n = 46) had an ORR of 50.0% (95% 
CI: 34.9â€“65.1), with a CR rate  of 6.5%. In participants whose tu mors did not express PD-L1 (CPS
< 1) (n = 53), ORR was 26.4% (95% CI: 15.3â€“40.3) (all responses  were PRs).
TITAN-RCC provided support to the added value of ipilimumab in combination with nivolumab 
in advanced renal cell carcinoma. In the phase 2 TITAN-RCC22study (0216-ASG), open-label 
nivolumab was initiated as monotherapy and an â€œimmunotherapeuti c boostâ€ of nivolumab plus 
ipilimumab was given only to nonresponders. The study enrolled 207 previously untreated and 
pretreated (2nd line), advan ced or metastatic renal cell carcin oma (mRCC) subjects with 
intermediate and high risk disease according to IMDC.
Participants were treated first-line (n = 108) or second-line (a fter a TKI, n = 99) with nivolumab 
240â€¯mg given e very 2 weeks as induction therapy. Those with ear ly significant progressive disease 
by week 8 or either stable or progressive disease at week 16 re ceived 2 to 4 boost cycles of 
nivolumab plus ipilimumab. Those who did not respond to the boo sts were considered 
immunotherapy resistant. Par tial (PR) and comp lete res ponders (CR) to nivolumab m onotherapy 
continued with nivolumab maintenance therapy, with combination therapy added only if they 
began to progress.Confirmed ORR with first-line nivolumab monotherapy at 16 weeks  was 28.7% (95% confidence 
interval 20â€“38). Boosting improved ORR to 37% (95% confidence i nterval 28â€“47). In the 
second-line setting it was 18.2%. Boosting improved ORR to 28.3 % (95% confidence interval 
20-8). In the first-line setting, improvement in BOR with the addition  of boost therapy was  29.8%. In the 
second-line setting it was 38.6%. Discontinuation due grade 3 or 4 adverse events was 14% in the f irst-line and 20% in the second-
line setting.
Protocol Amendment No.: 06
Date: 08-Dec-2022 36
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 3.2.1.1-1: Summar y of Efficacy Results - All Randomized Sub jects -
CA209025
Efficacy Parameters Nivolumab (N = 410) Everolimus (N = 411)
Primary Endpoint
Overall Survival
Events, n (%) 183/410 (44.6) 215/411 (52.3)
Stratified log-rank test P valuea,b0.0018
HR (98.52% CI)c0.73 (0.57, 0.93)
Median OS (95% CI), monthsd25.00 (21.75, NR) 19.55 (17.64, 23.06)
OS Rate at 6 months (95% CI), %d89.2 (85.7, 91.8) 81.2 (77.0, 84.7)
OS Rate at 12 months (95% CI), %d76.0 (71.5, 79.9) 66.7 (61.8, 71.0)
Secondary Endpoints
Objective Response Rate per 
Investigator (CR + PR)e
N (%) 103 (25.1) 22 (5.4)
95% CIf(21.0, 29.6) (3.4, 8.0)
Odds ratio estimate (95% CI)g,h5.98 (3.68, 9.72)
P Valuei< 0.0001
Duration of responsee
Ongoing responders, n/N (%) 49/103 (47.6) 10/22 (45.5)
Median (95% CI), monthsd11.99 (7.85, 23.03) 11.99 (6.44, NR)
Min, Maxj0.0, 27.6+ 0.0+, 22.2+
Progression-free survival
Events, n (%) 318 (77.6) 322 (78.3)
Stratified log-rank test p valuea0.1135
HR (95% CI)c0.88 (0.75, 1.03)
Median 95% CI) 4.60 (3.71, 5.39) 4.44 (3.71, 5.52)
aLog-rank test stratified by the MSKCC risk group (poor vs inter mediate vs favorable), the number of prior 
antiangiogenic therapies in the advanced/metastatic setting (1 vs 2), and the region (W. Europe, US/Canada vs Rest 
of the World) as entered into the IVRS.
bBased on the 398 observed d eaths and Oâ€™Br ien-Fleming alpha spending function, the boundary for statistical 
significance requires the P value to be less than 0.0148.
cStratified Cox proportional hazard model. Hazard ratio is nivolumab over everolimus. 
dBased on Kaplan-Meier Estimates. 
Protocol Amendment No.: 06
Date: 08-Dec-2022 37
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
eThe confirmed ORR was 88/410 (21.5%) in the nivol umab group and  16/411 (3.9%) in the everolimus gr oup 
(stratified CMH test P value < 0.0001), with a median DOR of 23 .03 months in the nivolumab gr oup and 
13.73 months in the  everolimus group.
fCR+PR, confidence interval based on the Clopper and Pearson met hod.
gCochran-Mantel-Haenzel test stratified by the MSKCC risk group (poor vs intermediate vs favorable), the number 
of prior anti-angiogenic therapies in the advanced/metastatic setting (X vs 2) and the regio n (Western Europe vs 
US/Canada vs Rest of the World) as entered into the IVRS.
hRatio of nivolumab over everolimus
iTwo-sided p value from CMH test for the comparison of the odds ratio of nivolumab over everolimus.
jSymbol + indicated a censored value. 
3.2.1.2 Ipilimumab in Renal Cell Carcinoma
Ipilimumab monotherapy for the treatment of m RCC was studied in the Phase 2 clinical trial 
MDX010-11.23Two sequential c ohorts were studied, each with a loading dose of 3 mg/kg 
followed by 3 doses of either 1 mg/kg (group 3-1; n = 21) or 3 mg/kg (group 3-3; n = 40). 
Participants with stable disease or partial or complete response were allowed additional treatment. 
In Group 3-1 (n = 21), 1 participant (5%) had a PR.24In Group 3- 3 (n = 40), 5 participants (12.5%) 
had a PR. Among 14 treatment-naiv e participants in G roup 3-3, 3 (21%) had a PR.
In the ipilimumab monotherapy Phase 2 clinical trial MDX010-11,  the major toxicities were colitis 
(all Grade 3/ 4; 14% in G roup 3-1, 33% in Group 3-3) a nd hypophysitis (1 Grade 3/4, 1 Grade 1/2 
in Group 3-3;  none in Group 3-1). Most reported AEs were Grade 1/2 (57% in G roup 3-1, 35% in 
Group 3-3) or Grade 3 (38% in Group 3-1, 48 % in Group 3-3).25The most common 
treatment-r elated AEs in Group 3-1 (total 81%) and Group 3- 3 (total  93%) were diarrhea (38% and 
40%, respectively) and fatigue (33% and 38%, resp ectively). Mos t AEs were manageable with 
appropriate treatment, including high -dose corticosteroids and hormone replacement. 
3.2.1.3 Nivolumab Plus Ipilimumab in RCCPromising safety and efficacy results were also observed with th e combination of nivolumab and 
ipilimumab in the advanced RCC population in s tudy CA209016,
26a Phase 1 dose-escalation 
study of nivolumab in combination with VEGFR-TKIs or ipilimumab  in participants with 
metastatic RCC. Treatment-experienced and -naive participants w ith metastatic RCC were 
randomized to receive nivolumab 3 mg/kg + ipilimumab 1 mg/kg (a rm N3 + I1) or nivolumab 
1 mg/kg + ipilimumab 3 mg/kg (arm N 1 + I3) IV Q3W for 4 doses foll owed by nivolumab 3 mg/kg 
IV Q2W until progression/toxicity. In Arm N1+I3, 25 out of 47 p articipants (53%) were 
treatment-naive. A pproximately 62% were characterized as Interme diate Risk by the Memorial 
Sloan Kettering Cancer Center (MSKCC) categories, and 4.3% were categorized a s Poor Ris k. In 
Arm N3 + I3, 21 of 47 participants (45%) were treatment-naive. Sixty-six percent (66.0%) were 
classified as Intermediate Risk, and 6.4% were categorized as P oor Risk. The pr imary objective 
was to assess safety/tolerability; the secondary objective was to assess antitumor activity. 
Protocol Amendment No.: 06
Date: 08-Dec-2022 38
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
After a minimum of 22 months, the  level of clinical activity, a s measured by confirmed ORR, for 
the combination of nivolumab and ipilimumab in CA209016 was subs tantially greater than that 
observed in studies of either nivolumab ( Section 3.2.1.1 ) or ipilimumab monotherapy 
(Section 3.2.1.2 ) in metastatic RCC, including in the treatment-naive subpopula tion (see Table 
3.2.1.3-1). The  dosing regimen including nivolumab 3 mg/kg combin ed with ipilimumab 1 mg/kg 
(N3 + I1) was chosen for further clinical evaluation because it  exhibited similar clinical activity to 
nivolumab 1 mg/kg combined with ipilimumab 3 mg/kg (N1 + I3) but  had a more favorable safety 
profile.
Table 3.2.1.3-1: Antitu mor Activity in All Participants (CA20901 6)
N3 + I1 (n = 22)
Previously TreatedN3 + I1 (n = 25)
Treatment-NaiveN1 + I3 (n = 26)
Previously TreatedN1 + I 3 (n = 21)
Treatment-naive
Confirmed ORR, 
n (%) (95% CI)10 ( 45.5)9 (36.0)
(18.0, 57.5)10 ( 38.5)9 (42.9) 
(21.8, 66.0)
Median duration 
of response, 
weeks (range)60.1 (9.29, NA)88.7 (30.00, 
105.00)74.4 (12.29, 108.29) NR (23.57, NA)
Ongoing 
responses, 
% (n/N)4 ( 40.0) 4 ( 44.4) 2 ( 20.0) 5 ( 55.6)
Best objective 
response, n (%)
Complete 
response3 ( 13.6) 2 (8.0) 0 0
Partial response 7 ( 31.8) 7 (28.0) 10 ( 38.5) 9 (42.9)
Stable disease 6 ( 27.3) 13 (52.0) 11 ( 42.3) 6 (28.8)
Progressive 
disease6 ( 27.3) 6 (27.3) 3 ( 11.5) 5 (23.8)
Unable to 
determine0 0 2 (  7.7) 1 (4.8)
PFS
Median months 
(CI)6.6 ( 1.41, 16.39) 8.3 ( 3.55, 19.29) 10.1 ( 5.42, 20.76) 8.5 ( 2.00, NA)
6-month PFS
Median months 
(CI)54.5 ( 32.1,  72.4) 8.3 ( 3.55, 19.29) 65.4 ( 44.0,  80.3) 61.9 ( 38.1,  78.8)
Median OS NR ( 10.02, NA) NR (26.68, NA) 30.9 ( 25.99, NA) NR ( 17. 45, NA)
NA, not applicable; N,R not reached.
Among the 91 participants treated with the nivolumab + ipilimumab combination in CA209016 
who provided evaluable baselin e tumor samples, 37.4% had â‰¥1% PD-L1 tumor expression, and 
16.5% had â‰¥5% PD-L1 tumor expression. ORR was 47.1% among participants with  â‰¥1% PD-L1 
Protocol Amendment No.: 06
Date: 08-Dec-2022 39
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
expression and 36.8% among parti cipants with < 1% PD-L1 expressi on. Among participants with 
â‰¥5% PD-L1 expression, ORR was 40.0%. 
Among all treated participants in the Arms N3 + I1 and N1 + I3, A Es were seen in 43/47 (91.5%)
participants in the N3 + I1 arm and 45/47 (95.7%) participants in the N1 + I3 arm. In the N3 + 
I1 arm, the most frequently reported drug-related AEs were fatig ue (51.1%); rash, and pruritus 
(each 31.9%); nausea (27.7%); arthralgia (25.5%).28In the N1 + I3 arm, the most frequently 
reported drug-related AEs were fatigue (68.1%); dia rrhea, and nau sea (each 44.7%); pruritus 
(36.2%); lipase increased (34%); AST increased (31.9%); ALT inc reased, and decreased appetite 
(29.8%); hypothyroidism (27.7%); and rash (25.5%).28
In the N3 + I1 arm, the most frequently reported, Grade 3-4 drug-related AE was lipase increased 
(14.9%). In the N1 + I3 arm, the  most frequently reported Grade 3-4 drug related AEs were lipase 
increased (27.7%); ALT increased (21.3%); diarrhea, and colitis  (14.9%); AST increased 
(12.8%).28
Treatment-related AEs (in cluding Grade 3-4), tr eatment-related AEs leading to discontinuation, 
and treatment-related SAEs all occ urred more commonly in participants in the N1 + I3 arm than 
in the N3 + I1 arm (Table 3.2.1.3-2).
Table 3.2.1.3-2: Summar y of Safety Results in Study CA209016 - All  Treated 
Subjects
Arm I-1
IPI1 + NIV3
N = 47Arm I-3
IP13 + NIV1
N = 47
Death, n (%) 16 ( 34.0) 18 ( 38.3)
Within 30 Days of Last Dose 0 1 (  2.1)
Within 100 Days of Last Dose 3 (  6.4) 4 (  8.5)
Due to Study Drug Toxicity 00
Any Grade Grade 3-4 Any Grade Grade 3-4
All-causality SAEs, n (%) 29 ( 61.7) 20 ( 42.6) 30 ( 63.8) 24 ( 51.0)
Drug-related SAEs, n (%) 11 ( 23.4) 9 ( 19.1) 16 ( 34.0) 16 ( 34.0)
All-causality AEs Leading to 
Discontinuation, n (%)5 ( 10.6) 3 (  6.4) 15 (31.9) 11 ( 23.4)
Drug-related AEs Leading to Discontinuation, n (%)5 ( 10.6) 3 (  6.4) 13 ( 27.7) 9 ( 19.1)
All-causality AEs, n (%) 47 (100.0) 33 ( 70.2) 47 (100.0) 34 ( 72.3)
Drug-related AEs, n (%) 43 ( 91.5) 18 ( 38.3) 45 ( 95.7) 29 ( 61.7)
All-causality Select AEs, within 30 
Days of Last Dose, by Category, n 
(%)Any Grade Grade 3-4 Any Grade Grade 3-4
Endocrine 14 ( 29.8) 3 ( 6.4) 19 (40.4) 0
Gastrointestinal 16 ( 34.0) 3 ( 6.4) 25 (53.2) 12 ( 25.5)
Hepatic 11 ( 23.4) 3 ( 6.4) 15 (31.9) 8 ( 17.0)
Pulmonary 3 (  6.4) 0 5 (10.6) 0
Renal 11 ( 23.4) 2 (  4.3) 10 (21.3) 2 (  4.3)
Skin 29 ( 61.7) 1 (  2.1) 33 ( 70.2) 1 (  2.1)
Protocol Amendment No.: 06
Date: 08-Dec-2022 40
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 3.2.1.3-2: Summar y of Safety Results in Study CA209016 - All  Treated 
Subjects
Arm I-1
IPI1 + NIV3
N = 47Arm I-3
IP13 + NIV1
N = 47
Hypersensitivity/Infusion Reactions 5 ( 10.6) 0 3 (  6.4) 0
Drug-related Select AEs, within 30 
Days of Last Dose, by Category, n 
(%)Any Grade Grade 3-4 Any Grade Grade 3-4
Endocrine 13 ( 27.7) 2 ( 4.3) 19  (40.4) 0
Gastrointestinal 12 ( 25.5) 2 ( 4.3) 21 ( 44.7) 11 ( 23.4)
Hepatic 9 ( 19.1) 3 ( 6.4) 13 ( 27.7) 8 ( 17.0)
Pulmonary 3 ( 6.4) 0 5 ( 10.6) 0
Renal 9 ( 19.1) 2 ( 4.3) 6 ( 12.8) 1 ( 2.1)
Skin 23 ( 48.9) 0 28 ( 59.6) 1 ( 2.1)
Hypersensitivity/Infusion Reactions 5 ( 10.6) 0 3 (  6.4) 0
All-causality Immune-mediated AEs, 
by Category
Immune-mediated AEs Treated with Immune-modulating medicationAny Grade Grade 3-4 Any Grade Grade 3-4
Diarrhea/Colitis 3 ( 6.4) 2 ( 4.3) 12 ( 25.5) 10 ( 21.3)
Hepatitis 5 ( 10.6) 2 ( 4.3) 11 ( 23.4) 8 ( 17.0)
Pneumonitis 1 ( 2.1) 0 5 ( 10.6) 0
Nephritis and Renal Dysfunction 2 ( 4.3) 1 ( 2.1) 1 ( 2.1) 0
Rash 8 ( 17.0) 1 ( 2.1) 9 ( 19.1) 1 ( 2.1)
Hypersensitivity 00 0 0
Immune-Mediated Endocrine AEs 
Treated with or without Immune-
Modulating MedicationsAny Grade Grade 3-4 Any Grade Grade 3-4
Adrenal Insufficiency 3 ( 6.4) 1 ( 2.1) 6 ( 12.8) 0
Hypophysitis 1 ( 2.1) 1 ( 2.1) 2 ( 4.3) 0
Hypothyroidism/Thyroiditis 10 ( 21.3) 0 14 ( 29.8) 0
Hyperthyroidism 4 ( 8.5) 1 ( 2.1) 8 ( 17.0) 0
Diabetes Mellitus 00 0 0
MedDRA version 18.1; CTC version 4.0. All events are within 100 days of the last dose of study drug, unless otherwise 
indicated. 
Sources: Table S.6.2A (deaths), Table S.6.3A (all -causality SAEs), Table S.6.3B (drug-related SAEs), Table S.6.4B 
(all-causality AEs leading to discontinuation), Table S.6.4D (d rug-related AEs leading to discontinuation), Table S.6.2 
(all-causality AEs), Table S.6.3.1 (drug-r elated AEs), Table S. 6.101 (all-caus ality select AEs), Tab le S.6.105 (all-
causality endocrine select AEs), Table S.6.103 (drug-related se lect AEs), Table S.6.107 (drug-related endocrine select 
AEs), Table S.6.202 (all-causality IMAEs with exception of endocrine), and Tab le S.6.204 (all-causality endocrine 
IMAEs).
Based on the results from CA 209016, a large Phase 3 trial was initiated comparing nivolumab  
3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for  4 doses followed by 
nivolumab 3 mg/kg IV every 2 week s vs sunitinib 50 mg orally dai ly for 4 weeks on, 2 weeks off, 
in participants with previously untreated advanced or metastati c RCC (CA 209214). The co-
Protocol Amendment No.: 06
Date: 08-Dec-2022 41
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
primary endpoints were ORR, PFS, and OS in International M etastatic Renal Cell Carcinoma 
Database Consortium (IMDC) intermediate and poor-risk participan ts. Overall, alpha of 0.05 was 
split among the co-primary e ndpoints (0.001 for ORR, 0.009 for PFS, and 0.04 fo r OS). ORR, 
PFS, and OS in all randomized participants (including all IMDC risk groups) we re secondary 
endpoints.
There were 550 participants randomized to nivolumab + ipilimuma b (including 425 participants 
with intermediate/poor risk) and 546 participants randomized to  sunitinib (including 422 
participants with intermediate/poor risk). The st udy was stopped early based on the independent 
data monitoring committee recommendation after reviewing the re sults of the planned interim 
analysis of OS (at a median follow-up of 25.2 months), which de monstrated a 37% reduction in 
the risk of death for intermediate/poor risk participants in th e nivolumab +  ipilimu mab group 
compared to those in the sunitinib group. The combination of niv olumab with ipilimumab also met 
the co-primary endpoint of ORR in intermediate/poor risk partic ipants, yielding an ORR of 42% 
vs 27% in the sunitinib arm. A  clinically meaningful improvemen t in PFS was also demonstrated 
with the nivolumab + ipilimumab combination vs sunitinib. Detai led information is presented in 
Table 3.2.1.3-3.
Table 3.2.1.3-3: CA209- 214 Overall Survival, Objective Response, Best Overall, and 
Duration of Response (Intermediate/Poor Risk)
Nivo + Ipi  (N = 425) Sunitinib  (N = 422)
Overall survival (OS)
  Months (95% CI)NR (28.2 -NE) 26.0 (22.1 -NE)
Hazard ratio (99.8% CI), 0.63 (0.44 â€“0.89)  P < 0.0001
Confirmed objective response rate (ORR)a
  % (95% CI)42 (37-47) 27 (22-31)
P <0.0001
Confirmed best overall response (BOR)a, %
Complete response 9 1
Partial response 32 25
Stable disease 31 45
Progressive disease 20 17
Unable to determine / not reported 8 12
Duration of response (DOR)  Months (95% CI)NR (21.8 -NE) 18.2 (14.8 - NE)
NE, not estimable; NR, not reached.
Source: ESMO Congress 2017
aImmune-related Response Criteria (irRC)-assessed ORR and BOR by  RECIST v1.1
Among all treated participants, treatment-related AEs were seen  in 93% (46% Grade 3/4) 
participants in the nivolumab + ipilimumab arm and 97% (63% Gra de 3/4) participants in the 
sunitinib arm. In the nivolumab + ipilimumab arm, the most freq uently reported treatment-
Protocol Amendment No.: 06
Date: 08-Dec-2022 42
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
related AEs were fatigue (37%), pruritus (28%), and diarrhea (2 7%). In the sunitinib arm, the 
most frequently reported treatment-related AEs were diarrhea (5 2%); fatigue (49%); 
hypertension (40%); hand-foot syndrome (43%); nausea (38%); and  stomatitis and mucosal 
inflammation (each 28%).24,25
For all treated participants, treatment-related AEs leading to discontinuation occurred in 22% and 
12%, and treatment-related deaths o ccurred in 7 and 4 subjects for the nivolumab + ipilimumab 
combination and sunitinib arm s, respectively . Detailed  informat ion is presented in Table 3.2.1.3-
4.
Table 3.2.1.3-4: CA209-214 Treatment-Related Adverse Events: All  Treated 
Participants
NIVO + IPI
N = 547SUN
N = 535
Treatment-related event % Any grade Grade 3-4 Any grade Grade 3-4a
AEs in â‰¥ 25% of participants 93 46 97 63
Fatigue 37 4 49 9
Pruritus 28 < 1 9 0
Diarrhea 27 4 52 5
Nausea 20 2 38 1
Hypothyroidism 16 < 1 25 < 1
Decreased appetite 14 1 25 1
Dysgeusia 6 0 33 < 1
Stomatitis 4 0 28 3
Hypertension 2 < 1 40 16
Mucosal inflammation 2 0 28 3
Hand-foot syndrome 1 0 43 9
AEs leading to discontinuation, % 22 12
Deaths n = 7bn =4c
Source: ESMO Congress 2017
aTwo participants had grade 5 cardiac arrest.
bPneumonitis, immune-mediated bronchitis, lower GI hemorrhage, h emophagocytic syndrome, sudden death, liver 
toxicity, lung infection.
cCardiac arrest (n = 2), heart failure, multiple organ failure.
CA209214 demonstrated that the combination of nivolumab + ipili mumab yielded significant 
improvements in ORR and OS in intermediate/poor-risk treatment- naive advanced RCC compared 
to sunitinib. The safety profile of nivolumab + ipilimumab was manageable and consistent with 
previous studies, supporting the use of the combination as a ne w standard of care option in this 
Protocol Amendment No.: 06
Date: 08-Dec-2022 43
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
population.24,25, 27A recent pub lication also reports the finding of nivolumab plus  ipilimumab 
leading to fewer symptoms and better HRQoL than sunitinib in pa rticipants at intermediate or poor 
risk with advanced renal cell carcinoma.
3.2.2 Nivolumab Mechanism of Action
Cancer immunotherapy rests on the  premise that tumors can be re cognized as foreign rather than 
as self and can be effectively attacked by an activated immune system. An effective immune 
response in this setting is thought to rely on immune surveilla nce of tumor antigens expressed on 
cancer cells that ultimately results in an adaptive immune resp onse and cancer cell death. 
Meanwhile, tumor progression may depend upon acquisition of tra its that allow cancer cells to 
evade immunosurveillance and escape effective innate and adapti ve immune responses.28,29,30
Current immunotherapy efforts attempt to break the apparent tol erance of the immune system to 
tumor cells and antigens by eith er introducing cancer antigens by therapeutic vaccination or by 
modulating regulatory checkpoints  of the immune s ystem. T-cell stimulation is a complex process 
involving the integration of numerous positive as well as negat ive co-stimulatory signals in 
addition to antigen recognition by the T-cell r eceptor (TCR).31Collectively, these signals govern 
the balance between T-cell activation and tolerance. 
PD-1 is a member of the CD 28 family of T-cell co -stimulatory re ceptors that also includes CD28, 
CTLA 4, ICOS, and BTLA.32PD-1 signaling has been shown to inhibit CD-28-mediated 
upregulation of IL-2, IL-10, IL-13, interferon-Î³ (IFN-Î³) and Bc l-xL. PD-1 expression also has been 
noted to inhibit T cell activatio n, and expansion of previously activated cells. Evidence for a 
negative regulatory  rol e of  PD-1 com e s  from  studi es of  PD-1 def icient mice, which develop a 
variety of autoimmune phenotypes.33These results suggest that PD-1 blockade has the potential 
to activate anti-self T -cell responses, but these responses are  variable and dependent upon various 
host genetic factors. Thus, PD-1 deficiency or inhibition is no t accompanied by a universal loss of 
tolerance to self-antigens.
In vitro, nivolumab (BMS-936558) binds to PD-1 with high affini ty (EC50 0.39-2.62 nM), and 
inhibits the binding of PD-1 to its ligands PD-L1 and PD-L2 (IC 50 Â±1 nM). Nivolumab binds 
specifically to PD-1 and not to relate d members of the CD28 fam ily such as CD28, ICOS, CTLA-4 
and BTLA. Blockade of the PD-1 pathway by nivolumab results in a reproducible enhancement 
of both proliferation and IFN-Î³ release in the mixed lymphocyte reaction (MLR). Using a CMV 
restimulation assay with human P BMC, the eff ect of nivo lumab on antigen specific recall response 
indicates that nivolumab augmented  IFN-Î³ secretion from CMV specific memory T-cells in a 
dose-dependent manner versus isotype-matched control. In vivo b lockade of PD-1 by a murine 
analog of nivolumab enhances the anti-tumor immune response and result in tumor rejection in 
several immunocompetent mouse tumor models (MC38, SA1/N, and PAN02).34
3.2.3 Ipilimumab Mechanism of Action
CTLA-4, an activation-induced T-cell surface molecule, is a mem ber of the CD28:B7 
immunoglobulin superfamily that competes with CD28 for B7. CTLA -4 mediated signals are 
Protocol Amendment No.: 06
Date: 08-Dec-2022 44
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
inhibitory and turn off T-cell-dependent immune responses.35Ipilimumab is a fully human 
monoclonal IgG1Îº that binds to the CTLA-4 antigen expressed on a subset of T cells from human 
and nonhuman primates. The proposed mechanism of action for ipilimumab is interference of the 
interaction of CTLA-4 with B7 molecules on APCs, with subsequen t blockade of the inhibitory 
modulation of T-cell activation promoted by the CTLA 4/B7 inter action.
3.3 Benefit/Risk Assessment
The current standard treatment for early stage (I-III) renal ce ll cancer (RCC) is surgery. While the 
prognosis of stage I tumors is excellent, stage II and stage II I have a high risk of recurrence and 
represent a high unmet medical need.
The potential benefit of adjuvant nivolumab plus ipilimumab over standard-of-care (observation) 
after nephrectomy in early stage RCC is not yet known. Nivolumab in combination with ipilimumab in CA209214 study has demonstrated significant 
clinical benefits with reversible and manageable toxicities tha t are consistent with the known 
IMAE profile of anti-PD-1 immune therapies. The magnitude of OS benefit from the combination 
is unprecedented in studies of m RCC for intermediate- and poor-r isk participants. Addition of 
ipilimumab to nivolumab as a comb ination regimen is expected to show an improvement of PFS 
over nivolumab monotherapy with a manageable increase in IMAEs.  However, emerging data are 
providi ng evidence of clinical efficacy using single agent checkpoint therapy in 1L advanced clear 
cell RCC with the benefit of reduced frequency of IMAEs.
36,37These results suggests the potential 
for improved clinical outcomes also in the adjuvant setting.
The use of ipilimumab 1 mg/kg with a lower frequency of administration (ie, Q6W) in combination 
with nivolumab has been found to result in improved safety as w ell as eff icacy compared to the 
N3 + I1 dosing schedule in a Phase 1 study in previously untrea ted advanced NSCLC (CA209012). 
Incorporating a dose of 1 mg/kg Q6W ipilimumab into the combina tion regimen  in the RCC 
adjuvant setting is expected t o optimize the safety profile of the combination, without impacting 
the overall efficacy of the combination. Further justification of the dose can be found in Section
5.5.
The safety profile of nivolumab and nivolumab plus ipilimumab i s characterized by immune-
related toxicities, such as diarrhea, rash, pneumonitis, liver toxicity, and endocrinopathies.26The 
frequencies and intensities of these events in the combination are variable and depend on the 
specific doses and schedule used ( Section 3.2.1 ). Overall, the safety profile of nivolumab in 
combination with ipilimumab is manageable and generally consist ent across completed and 
ongoing clinical trials. Most AEs are low-grade (Grade 1 to 2) w ith relatively few related high-
grade (Grade 3 to 4) AEs. A pattern of immune-related AEs has b een defined, for which 
management algorithms have been developed; these are provided in Appendix 6. Most high-grade 
events are manageable with the use of corticosteroids or hormon e replacement therapy 
(endocrinopathies) as instructed i n these algorithms. More deta iled information a bout the known 
and expected benefits and risks and reasonably anticipated AEs of nivolumab and ipilimumab may 
be found in the Nivolumab IB and will not be repeated herein.
Protocol Amendment No.: 06
Date: 08-Dec-2022 45
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
In Part B of the study, a nivolumab monotherapy arm of 240 mg Q 2W will be included to evaluate 
its impact on DFS compared to placebo and the contribution of i pilimumab to efficacy and safety.
In the US, nivolumab is approved at 240 mg Q2W for several diff erent tumor types including the 
treatment of participants with u nresectable or metastatic melano ma, adjuvant treatment of 
melanoma, metastatic NSCLC, and advanced RCC. Incorporating a f lat 240 mg dose of nivolumab 
into the monotherapy and combination regimens in the RCC adjuvan t setting is expected to 
simplify treatment with nivolumab monotherapy without impacting  the overall safety profile of 
the combination. The detailed rationale for the use of a flat 2 40 mg dose of nivolu mab is provided 
in Section 5.5 . 
Therefore this study will allow a dir ect evaluatio n of the be nefits and risks of combined nivolumab 
with ipilimumab and nivolumab monotherapy. In addition, clinical and biological parameters 
(biomarkers) will be explored to assess whether the risks and benefits are altered within specific 
risk subgroups.
4 OBJECTIVES AND ENDPOINTS
Table 4-1: Objectives and Endpoints
Objectives Endpoints
Primary
â€¢Part A: To compare disease-free survival 
(DFS) per Blinded Independent Central Review (BICR) of nivolumab combined with ipilimumab versus placebo infusions in participants with localized RCC, with a predominantly clear cell histology who have undergone a nephrectomy. 
â€¢Part B: To compare disease-free survival 
(DFS) per Blinded Independent Central 
Review (BICR) of nivolumab versus placebo infusions in participants with localized renal cell carcinoma, with a predominantly clear cell histology who have undergone nephrectomy.The primary endpoint is DFS. The primary endpoint of DFS will 
be programmatically determined based on the disease recurrence date provided by BICR. DFS is defined as the time from 
randomization to development of local disease recurrence (ie, recurrence of primary tumor in situ or occurrence of a secondary  
renal [RCC] primary cancer), distant metastasis, or death, whichever came first. See Table 10.3.1-1 for censoring rules.
Secondary
â€¢Part A: To compare OS, including the 5-
year OS rates, of nivolumab combined with ipilimumab versus placebo infusions in participants with localized RCC with a predominantly clear cell histology who have undergone a nephrectomy.
â€¢Part B: To compare overall survival (OS), including the 5-year OS rates, of nivolumab versus placebo infusions in participants with localized renal cell â€¢OS, defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the participants was known to be alive. 
Protocol Amendment No.: 06
Date: 08-Dec-2022 46
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 4-1: Objectives and Endpoints
Objectives Endpoints
carcinoma with a predominantl yclear cell 
histology who have undergone a 
nephrectomy.
â€¢Part B: To evaluate differences in disease-free survival (DFS) per Blinded Independent Central Review (BICR) and overall survival (OS) of contemporaneously randomizednivolumab combined with ipilimumab participants versus nivolumab participants with localized renal cell carcinoma, with a predominantly clear cell histology, who have undergone a nephrectomy. â€¢DFS and OS in contemporaneously randomized combination 
and monotherapy participants.
â€¢To describe the safety and tolerability of 
nivolumab combined with ipilimumab and nivolumab monotherapy up to 30 and100 days of last dose of study therapy.â€¢Safety and tolerability endpoint: type, incidence, severity (graded by the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE, Version 4.0], timing, seriousness, and relatedness, and laboratory abnormalities up to 30 and 100 days of last dose of study 
therapy in all treated participants.
Tertiary/Exploratory
â€¢To assess PFS2 (progression after 
recurrence) in participants with localized 
renal cell carcinoma with a predominantly 
clear cell histology who have undergone a 
nephrectomy.
â€¢To assess efficacy in the high and 
moderate risk subgroups.
â€¢To assess disease-related symptoms in each arm based on the National Cancer Comprehensive Network (NCCN)Functional Assessment of Cancer Therapy - Kidney Symptom Index (FKSI-19).â€¢PFS2.
â€¢DFS and OS by the high and moderate risk subgroups.
â€¢Change in FKSI-19 subscale and total scores relative to baseline.
â€¢To assess changes in global health status in each treatment arm based on EuroQoLâ€™s EQ-5D-3L.â€¢Change in scores from baseline in EQ-5D-3L in both the visual analog scale and the utility index.
â€¢To correlate the primary tumorâ€™s expression of PD-L1 with efficacy outcome (DFS, OS).â€¢DFS and OS as described above.
â€¢Assess association between PD-L1 status and DFS and OS.â€¢Selected biomarkers.
â€¢To analyze biomarkers in tumor and 
peripheral blood to evalu ate association 
with clinical efficacy or incidence of 
adverse events.
Protocol Amendment No.: 06
Date: 08-Dec-2022 47
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 4-1: Objectives and Endpoints
Objectives Endpoints
â€¢To assess the association between the gene 
signature recurrence score with efficacy outcomes (DFS, OS).
â€¢To characterize the pharmacokinetics of nivolumab and ipilimumab and explore exposure response relationships withrespect to safety and efficacy, if applicable.â€¢Gene-signature based recurrence score and its relationship with efficacy endpoints.
â€¢
â€¢Population PK parameters, exposure-response relationship 
between select PK measures of exposure and safety and 
efficacy endpoints, if applicable.
â€¢To characterize the immunogenicity of the combination of nivolumab and ip ilimumab
and nivolumab monotherapy.
â€¢To assess the impact of SARS-CoV-2 serologic status on participants receivingthe combination of nivolumab and ipilimumab or nivolumab monotherapy in the adjuvant setting for RCC  
â€¢To describe the safety of nivolumab combined with ipilimumab and nivolumab monotherapy beyond 100 days and up to 1 year of last dose of study therapy.â€¢Incidence of anti-nivolumab and anti-ipilimumab antibodiesand their potential relationship with safety and efficacy endpoints.
â€¢Exploratory measurements of SARS-CoV-2 serology (anti-SARS-CoV-2 total or IgG), from serum samples collected at C1D1, C12D1, follow-up visit 2 and upon 
occurrence of SARS-CoV-2 infection-related events and the potential association between these measurements and selected e ndpoints related to safety, efficacy, and/or 
biomarkers.
â€¢Safety endpoint: type, incidence, severity (graded by the NCI CTCAE, Version 4.0), timing, seriousness, and relatednessbeyond 100 days and up to 1 year of last dose of study therapy in all treated participants.
5 STUDY DESIGN
5.1 Overall Design
The original study design (Part A) is a double-blind, randomized trial of the nivolumab and 
ipilimumab combination therapy versus placebo infusions in part icipants with early stage localized 
RCC with a predominantly clear cell histology who underwent radic al or partial nephrectomy. 
Approximately 1000 participants will be screened, and approximately 800 participants will be 
randomized.
At the implementation of Revised Protocol 03, Part A of the stu dy remains identical to the original 
protocol design. The addition of P art B to the protocol include s a monotherapy nivolumab arm. A 
target of approximately 800 participants are planned to be rand omized between 3 arms in a 
1:1:2 ratio in Part B, with the primary endpoint of DFS and seco ndary endpoints of OS, and safety 
and toler ability. 
Approximately 1600 participants in total are expected to be ran domized in this study. 
Participants will be s tratified by pathology according to TNM staging per AJCC staging version 
2010 and Fuhrman nuclear  grading categories (described below) an d by type of nephrectomy 
procedure (partial versus radical). 
Protocol Amendment No.: 06
Date: 08-Dec-2022 48
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
TNM staging will be stratified according to the following chara cteristics:
â€¢pT2a, G3 or G4, N0, M0 and pT2b, G any, N0, M0 
â€¢pT3, G any, N0, M0 
â€¢pT4, G any, N0, M0 and pT any, G any, N1, M0
The study design schematic is presented in Figure 5.1-1 .
Figure 5.1-1: CA209914 Part A Study Design Schematic
Protocol Amendment No.: 06
Date: 08-Dec-2022 49
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Figure 5.1-2: CA209914 Part B Study Design Schematic
Screening Phase
Screening begins by establishi ng the particip antâ€™s initial elig ibility and signing of the informed 
consent form (ICF). Randomization must occur greater than 4 week s and less than (or equal to) 
12 weeks from the date of nephrectomy. 
Tumor tissue obtained within 3 months prior to enrollment, pref erably at the time of the 
nephrectomy, must be provided for biomarker analyses. Formal inf ixed, paraffin-
embedded- (FFPE) tumor blocks or unstained slides are required f or study assessment. Lo cal 
histopathology review and confirmation of eligibility is requir ed for randomization. 
Screening/baseline imaging should be performed at least 4 weeks  post-nephrectomy- and 
submitted to the radiology vendor for BICR confirmation of dise ase-free status. Pre-nephrectomy 
images are also requested, if available. Participant eligibilit y must be confirmed by BICR prior to 
randomization and will be based only on the review of the basel ine scans (and pre-nephrectomy 
scans if available). As a result, pre-nephrectomy scans, if ava ilable, and baseline scans are 
encouraged to be submitted to BICR within 8 weeks of the nephrectomy to allow for timely return 
of the decision from the BICR. 
During the Screening Phase, laboratory and other tests may be r epeated as needed. The most 
current result prior to ra ndomization is the value by which study inclusion will be asses sed (see 
Section 6.4.1 ).
The Screening Phase ends with either confirmation of full eligi bility and randomization for the 
participant or with the confirmation that the participant is a screen failure. 
Protocol Amendment No.: 06
Date: 08-Dec-2022 50
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Treatment Phase (Part A)
The Treatment Phase begins when the randomization call is made into the IRT. The participant is 
randomly assigned to 1 of the 2 treatment arms:
â€¢Arm A: Nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg ev ery 6 weeks (or every 
third nivolumab dose if dosing is delayed)
â€¢Arm B: Placebo infusions at the same frequency of nivolumab and  ipilimumab infusions
Note: Study treatment must begi n within 3 calendar days of randomizat ion.
Treatment Phase (Part B): 
The Treatment Phase begins when the randomization call is made into the IRT. The participant is 
randomly assigned to 1 of the 3 treatment arms: 
â€¢Arm A: Nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg ev ery 6 weeks (or every 
third nivolumab dose if dosing is delayed) 
â€¢Arm B: Placebo infusions at the same frequency of nivolumab and  ipilimumab infusions
â€¢Arm C: Nivolumab 240 mg every 2 weeks and ipilimumab Placebo ever y 6 weeks (or every 
third nivolumab dose if dosing is delayed) 
â€¢Note: Study treatment must begi n within 3 calendar days of randomizat ion.
Randomization can occur once IRT has received confirmation of e ligibilit y from  BICR. Each cycle 
will be 2 weeks (14 days ). Participants will r eceive study drug until the end of 12 cy cles 
(12 nivolumab doses and 4 ipilimumab doses), recurrence, unaccept able toxicity, 36 weeks from 
first dose, or withdrawal of cons ent, whichever occurs first. The first cycle will be a combination 
dose. See Table 7.1.1-2 for the dosing schedule. Study drug may be delayed for toxicity  (see 
Section 7.4.1 ). Treatment must be completed within 36 weeks after the first dose; any cycles not 
received within 36 weeks after the first dose will be omitted, and the participant w ill enter the 
Follow-up Phase.
A negative pregnancy test should be documented within 24 hours prior to the start of the first dose 
of the investigational product and every 4 weeks thereafter regardless of dosing. On-study 
laboratory assessments should be drawn within 72 hours prior to  dosing and will be assessed at the 
local laboratory. Results should be reviewed prior to administration of each dose of study drug.
Tumor assessments will occur in accordance with Table 2-2 until rec urrence has been identified 
by the investigator and is confirmed by BICR. Sites s hould submit all scans to the third-party 
vendor on a rolling basis, preferably within 7 business days of  scan acquisition, and submit any 
pertinent cytology/pathology results for central review. If rec urrence (defined in Section 9.1.1 ) is 
assessed by the investigator, the site will inform the radiology  vendor so that the BICR assessment 
of recurrence can be performed. The BICR assessment of recurren ce will be comp leted, and the 
results provided to the site within 10 business days of receipt of final images and any pertinent
pathology results as specified in Section 9.1.3 . BICR assessment of recurrence should only be 
requested upon recurrence diagnosis by the investigator per the criteria specified in Table 9.1.3.2-
Protocol Amendment No.: 06
Date: 08-Dec-2022 51
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
1. The first point of contact should be BMS Imaging Operations L ead and BMS Prot ocol Team if 
the site (the Investigator) disagrees with BICR results. The si te should not con tact the central 
imaging vendor to discuss or request any details of the BICR as sessment.
Participants whose recurrence is not confirmed by the BICR will  be required to continue tumor 
assessments (if clinically feasible) according to the protocol-sp ecified schedule or sooner if 
clinically indicate d. Investigators are strongly enc ouraged to wait for BICR confirmation of 
recurrence prior to breaking the blind and initiating any subse quent therapy. If the investigator 
feels that the immediate initiation of subsequent therapy is cli nically indicated and does not wish 
to wait for the confirmation of recurrence from the BICR, then the decision to break the blind must 
be discussed within the BMS Medical Monitor or designee pri or to doi ng so. See Section 7.3 for 
additional information regarding unblinding. 
PK and immunogenicity samples will be collected according to Table 9.5-1. Adverse event 
assessments should be documented at each clinic visit. 
Quality of Life will be assesse d using NCCN Functional Assessment of Cancer Therapy - Kidney 
Symptom Index (FKSI-19) and EuroQoLâ€™s EQ-5D-3L. These questionna ires should be completed 
according to Table 2-2. 
The Treatment Phase ends when the participant is discontinued f rom study therapy. 
Follow-up Phase
The Follow-up Phase begins at th e completion of 12 cycles, when the decision to discontinue a 
participant from study therapy is made (no further tr eatment w ith study the rapy), or 36 w eeks after 
the first dose, whichever comes first. Participants will have 2 follow-up visits (Follow-up 1 and 
Follow-up 2) for safety. Follow-up 1 will occur within 30 days from  the last dose ( Â±7 days) or 
coincide with the date of discontinuation ( Â±7 days) if date of discontinuation is greater than 
30 days after last dose. Follo w-up 2 will occur within 100 days ( Â±7 days) from the last dose of 
study therapy. Any ongoing treatment-related AEs w ill be followed until the toxicities resolve, 
return to baseline, or are deemed irreversible .The FKSI-19 and EQ-5D-3L will be comp leted as 
described in Table 2-3.
Participants who discontinue d study treatment without BICR confir med recurrence will continue 
to have tumor assessments performed according to the frequency described in Table 2-3, even if 
new anti-tumor therapy  has been initiated pri or to receipt of c onfirmation. If recurrence (defined 
in Section 9.1.1 ) is assessed by the investigator, the site will inform the rad iology vendor, so that 
the BICR assessment of recurrence can be performed. Participant s whose recurrence is not 
confirmed by the BICR w ill be required to continue tumor assessments (if clinically fe asible) 
according to the protocol-specified schedule or sooner if clini cally indicated until BICR confirms 
recurrence on a subsequent tumor assessment (see Section 9.1.3.3 for additional details).
After the Follow-up 2 Visit, all participants will be followed for OS status every 12 weeks 
(Â±1 week) until deat h, withdrawal of consent, lost to follow-up, or  end of study. Survival status 
may be ascertained by telephone contact if the participant is unab le to return to the site for a visit. 
If new anti-tumor therapy is init iated for either disease recurrence or a secondary malignancy a t 
Protocol Amendment No.: 06
Date: 08-Dec-2022 52
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
any time during this peri od, this and all other pertinent data obtain ed should be recorded on the 
appropriate Case Report Form (CRF).
5.1.1 Data Monitoring Committee and Other External Committees
When required, adjudicated events will be submitted to the DMC and Health Authori ties for review 
on a specified timeframe in accordance with the adjudication do cumentation.
5.1.1.1 Data Monitoring CommitteeA Data Monitoring Committee (DMC) w ill be established to provide oversight of safety and 
efficacy considerations in protocol CA209914. Additionally, the DMC will provide advice to the 
sponsor regarding actions the committee deems necessary f or the continuing protection of study 
participants. The DMC will be charged with assessing such actions in light o f an acceptable 
benefit/risk profile for nivolumab and ipilimumab. The DMC will  act in an advisory cap acity to 
BMS and will monitor participant safety and evaluate the availa ble efficacy data for the study. The 
oncology therapeutic area of BMS has primary responsibility for  design and conduct of the study.
5.1.1.2 Blinded Independent Central Review 
The BICR will review tumor images and pertinent clinical data (c ytology/pathology results) in all 
randomized participants to determin e recurrence for the DFS ana lyses. Details of the BICR 
responsibilities, procedures, composition, and process will be sp ecified in the BICR charter.
5.2 Number of Participants
Approximately 1600 participants in total (Parts A + B) will be r andomized in this study. 
Approximately 600 participants have been randomized in Part A wi th approximately 200 more 
expected to be randomized ( Figure 5.1-1). Approximately 800 participants are expected to be 
randomized in Part  B of this study ( Figure 5.1-2 ). Section 10.1 provides additional details. 
5.3 End of Study Definition
The start of the trial is defined as the first participantâ€™s fi rst visit. End of trial is defined as the last 
participantâ€™s last study visit or phone call. Study completion i s defined as the final date on which 
data for the primary endpoint was or is expected to be collecte d, if this is not the same.
5.4 Scientific Rationale for Study Design5.4.1 Rationale for Selection of Participants at Moderate to High Risk of 
Relapse
The current standard treatment for early stage (I-III) RCC is s urgery. While the prognosis of stage 
I tumors is excellent, stage II and particularly stage III have  a high risk of relap se and represent a 
high unmet medical need. The adjuvant tr eatment of patients with RCC remains an area of 
investigation, with patient se lection being a key aspect. Several organizations have guidelines for 
follow-up surveillance of higher-risk disease. The American Uro logical Association (AUA) 
stratifies risk of recurrence on the basis of tumor size and no dal status (low risk: pT1 N0 Nx; 
moderate to high risk: pT2-4N0, Nx, or any stage N+-),
38while the European Association of 
Urology (EAU) bases risk on prognostic nomograms rather than TN M stage.39
Protocol Amendment No.: 06
Date: 08-Dec-2022 53
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
In study CA209914, the primary endpoint, DFS, will be evaluated  in participants at moderate to 
high risk of recurrence as defined by the AUA. This population represents a pproximately 40% of 
the localized RCC population w ho has undergone surgery. Inclusi on of t his subset of participants 
for the primary endpoint of the study will allow for potential meaningful differences in efficacy to 
be detected earlier than if participants at lower risk of recur rence were included. Since 
approximately 90% of low risk participants will not have recurr ence after nephrectomy, their 
exclusion will also avoid unnecessary treatment in the vast maj ority of these low risk participants. 
Efficacy will also be assessed in the high and moderate risk su bgroups by using the following risk 
staging system:40
High risk: 
â€¢pT3, G3 or G4, N0M0
â€¢pT4, G any, N0M0
â€¢pT any, G any, N1M0
Moderate risk: â€¢pT2a, G3 or G4, N0M0
â€¢pT2b, G any, N0M0
â€¢pT3, G1 and G2, N0M0
Efficacy may a lso be assessed using a score based on stage, siz e, grade, and necrosis (the SSIGN 
score)
41in the intermediate (3-5) and high (â‰¥6) SSIGN score defined groups.40
5.4.2 Rationale for 6 Month Treatment Duration
There is no consensus regarding the optimal treatment duration f or patients in the adjuvant setting 
for localized RCC. Historic Phase 3 t rials of adjuvant targeted antiangiogenic therapies have 
continued treatment for 12 months. Because immunotherapy engage s the immune system to 
control the tumor, co ntinuous treatment, as is required with tar geted antiangiogenesis agents and
cytotoxic therapy, may not be necessary. Accumulating evidence f rom different clinical trials in 
different tumor types with nivolumab monotherapy or nivolumab c ombined with ipilimumab 
indicates that responses generally occur early, with a median ti me to response of 2-4 months, and 
are durable.42
In study CA209016, for example, responses in m etastatic RCC participants receiving nivolumab 
3 mg/kg /ipilimumab 1 mg/kg combination (n=47) occurred within th e first 3 months of treatment, 
and the median duration of response was 88.7 weeks.43
Since standard of care in lo calized RCC is observation post-nep hrectomy and to minimize potential 
toxicity while maintaining expected efficacy, treatment wit h nivolumab a nd ipilimumab or placebo 
in study CA209914 w ill be given for 24 weeks in absence of disease recurrence or unacceptable 
toxicity . 
Protocol Amendment No.: 06
Date: 08-Dec-2022 54
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
5.4.3 Rationale for 30 min Infusion Duration for Nivolumab and Ipilimumab
The current US label for nivolumab is approved for advanced RCC at 240 mg flat dose
administered intravenously over 60 minutes every 2 weeks. Previous clinical studies of nivolumab 
monotherapy have used a 60-minute infusion duration, and nivolumab has been safely 
administered up to 10 mg/kg over long treatment periods. Infusi on reactions including high-grade 
hypersensitivity reactions have b een uncommon across nivolumab clinical program. In CA 209010,
a dose association was observed for infusion site reactions and  hypersensitivity reactions (1.7% at 
0.3 mg/kg, 3.7% at 2 mg/kg, and 18.5% at 10 mg/kg). All the event s were Grade 1-2 and were 
manageable. An infusion duration of 30 minutes for 3 mg/kg nivo lumab (30% of the dose provided 
at 10 mg/kg) is not expected to present any safety concerns com pared to the prior experience at 
10 mg/kg nivolumab dose infused over a 60-minute duration. 
The safety of nivoluma b 3 mg/kg administered as a 30-minute infusion was assessed in CA209153 
in participants (n = 322) with previously treated advanced NSCLC. O verall, there were no 
clinically meaningful differences in the frequency of hypersensi tivity/infusion- related reactions 
(of any cause or treatment-related) in participants administered  nivolumab over a 30 minute 
infusion compared with that reported for participants with the 6 0-minute infusion. Thus, it was 
shown that nivolumab can be safely infused over 30 minutes.The risk/benefit profile for ipilimumab has primarily been inve stigated using a 90-minute infusion. 
Ipilimumab has been administered s afely at doses ranging up to 10 mg/kg over these treatment 
durations. Overall, infusion react ions including high-grade hyp ersensitivity reactions have been 
uncommon across multiple clinical studies, and all have been ma naged by following the safety 
algorithms. The shortened i nfusion duration of 30 minutes for ipilimumab is not expected to 
present additional safety concerns.
44
Both agents given as single agent are uncommonly associated with  infusion reactions: the 
incidence is less than 1% for ipilimumab45and 3% for nivolumab.26In the CA209069 study, 
hypersensitivity/infusion reactions were listed as 3.2% for the combination and 2.2% for 
ipilimumab. No Grade 3 or Grade 4 hypersensitivity/infusion rea ctions were observed in either the 
combination or single agent ipilimumab treatment groups.46Participants should be carefully 
monitored for infusion reactions during nivolumab/ipilimumab ad ministration.
In this study, nivolumab and ipilimumab will each be infused ov er 30 minutes. 
5.4.4 Rationale for Nivolumab Monotherapy
Nivolumab monotherapy was chosen as one of the tr eatment arms in Part B because of a favorable 
risk-benefit ratio assessed from 3 studies in participants with mRCC: CA209010, CA209009, and 
CA209025.
In CA209010, 168 participants who received at least 1 prior ant i-angiogenic therapy were 
randomized to receive nivolumab 0.3 mg/kg (n = 60), 2 mg/kg (n = 54), and 10 mg/kg (n = 54).18
Median PFS was 2.7 months, 4.0 mo nths, and 4.2 months at 0.3, 2, and 10 mg/kg, respectively. 
The ORR ranged from 20% to 22% acro ss dose levels. Median OS was 18.2 months at 0.3 mg/kg, 
but was not yet reached at the 2 highest dose levels. 
Protocol Amendment No.: 06
Date: 08-Dec-2022 55
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
CA209009 enrolled a similar population to CA 209010, but also included 24 participants with 
treatment-naive RCC. Am ong treatment-naive participants, all of whom r eceived nivolumab 10 
mg/kg Q3W, the ORR was 13% (3/23). CA209010 includes the larges t safety database for 
nivolumab monotherapy in mRCC. All treated participants (n = 16 7) were included in the safety 
analyses. Drug-related AEs o f any grade occ urred in  74.6%, 66.7 %, and 77.8% of participants 
treated at  0.3 mg/kg, 2 mg/ kg, and 10 mg/kg, respectively. Th e most commo n (â‰¥ 10% in any gr oup) 
drug-related AEs incl uded fatigue, dry skin, rash, pruritus, ar thralgia, nausea, diarrhea, decreased 
appetite, dry mouth, and hypersensitivity. Grade 3 drug-related  AEs occurred in 5.1%, 16.7%, and 
13% of participants treated at 0.3 mg/kg, 2 mg/kg, and 10 mg/kg,  respectively. Related Grade 3 
events in at least 2 participants across dose levels included na usea, (AST)/ALT increased, and 
anemia. No drug-related Grade 4 or Grade 5 events occurred. No dose-toxicity relationship was 
identified except for hypersensitivity/infusion r eaction, which occurred most frequently in the 10 
mg/kg treatment group.
Based on the clinical activity of nivolumab observed in these P hase 1 and 2 studies, a large Phase 
3 trial (CA209025) was conducted in 821 participants with advanced RCC previously treated with 
1 or 2 anti-angiogenic therapies who were randomized to receive  nivolumab 3 mg/kg every 
2 weeks (Q2W) or everolimus 10 mg daily. A planned interim analy sis, after a minimum follow-
up of 14 months, demonstrated a statist ically signif icant and clinically mean ingful improvement 
in OS of nivolumab monotherapy versus everolimus (median OS, 25 .0 months vs 19.6 months, 
respectively; hazard rati o [HR] 0.73 [98.5% confidence interval (CI), 0.57 to 0.93, p-value (P)  = 
0.002]). ORR was 25% for nivolumab v ersus 5% for everolimus. Am ong 756 participants with 
quantifiable PD-L1 tumor expression in pretreatment samples, 24 % had PD-L1 expression â‰¥ 1%. 
Among participants with PD-L 1 expression â‰¥ 1%, median OS was 21 .8 months in the nivolumab 
group a nd 18.8 months in the everolimus group (HR 0.79 [95% CI, 0.53 to 1.17]). Among 
participants with PD-L1 expression < 1%, the median OS was 27.4  months in the nivolumab group 
and 21.2 months in the evero limus group (HR, 0.77 [95% CI, 0.60 to  0.97]). No new safety 
concerns were identified, and nivolumab monotherapy showed a favorable safety profile as compared to everolimus, evidenced by the lower rates of drug-re lated AEs (all grades, 79% vs 
88%; Grade 3-4, 19% vs 37%, resp ectively) and drug-related AEs leading to discontinuation (all 
grades, 8% vs 13%, respectively) in the nivolumab group. These results were the basis for 
regulatory approval of nivolumab m onotherapy in advanced RCC.
As the treatment of RCC landscape continues to evolve, accumula tive evidence showed a single-
agent activity for anti-PD-1 or anti-PD-L1 monotherapy in the 1 L treatment of advanced RCC. If 
this observation is applicable then there could also be the pot ential for large improvements in DFS 
in the adjuvant RCC setting.
47,48,49
Based upon the totality of the s afety, efficacy, and exposure-r esponse data, a dos e of 240 mg Q2W 
was selected as the dose anticipated to achieve an appropriate balance of efficacy and risk in the 
monotherapy arm. In addition, by selecting the 240 mg Q2W, we are  aligning the same nivolumab
dose and schedule as utilized in both the combination arm and th e nivolumab monotherapy 
comparator arm.
For additional information on nivolumab monotherapy in RCC plea se refer to  section 3.2.1.1
Protocol Amendment No.: 06
Date: 08-Dec-2022 56
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
5.5 Justification for Dose
There are 4 completed or ongoing studies of nivolumab monothera py using body weight 
norm alized dosing (mg/kg) in advanced RCC: MDX1106-03, CA209009, CA209010, and 
CA209025. In study MDX1106-03, previ ously-treated RCC participan ts were administered 
nivolumab monotherapy with 1 or 10 mg/kg Q2W. In studies CA20900 9 (which included both 
previously-treated and previously  untreated RCC participants) a nd CA209010 (which included 
only previously-treated RCC participants), nivolumab doses of 0 .3, 2, or 10 mg/kg were given 
Q3W. As detailed in Section 3.2.1 , clinical activity was observed across all nivolumab dose leve ls 
in these studies, in both Q2W and Q3W schedules, and in both pre viously-treated and previously 
untreated participants. 
Nivolumab pharmacokinetics (PK) and exposures of participants i n these studies have been 
characterized by population pharmacokinetics (PPK) analysis of data collected from these studies, 
together with PK data from several Phase 1, 2, and 3 clinical studies of nivolumab in solid tumors. Based on PK modeling and the long half-life (25 days) of nivolu mab, the Q2W schedule was 
subsequently selected for CA209025 and resulted in sustained exposure between treatments. Study CA209025 demonstrated that nivolumab 3 mg/kg Q2W improved OS and  had a favorable safety 
profile compared to everolimus in previously-treated mRCC, leadi ng to regulatory approval in this 
population (see Section 3.2.1 ).
Nivolumab PK was determined to be linear, with dose proportiona l exposures over a dose range 
of 0.1 to 10 mg/ kg. Nivolumab clearance and volume of distribution was found to  increase with 
increasing body weight, but the increase was less than proporti onal, indicating that a mg/ kg dose 
represents an over-adjustment for the effect of body weight on nivolumab PK. Conversely, given 
the relationship between nivolumab PK and body weight, a flat dose is expected to lead to lower exposures in heavier patients, relative to the exposures in lig hter patients. Taken together, the PK, 
safety, and efficacy data indicate that the safety and efficacy  profile of 240 mg nivolumab will be 
similar to that of 3 mg/kg nivolumab, regardless of tumor type.  In the US, the 240 mg Q2W flat 
dose is now approved for the treatment of patients with unresec table or metastatic melanoma (as 
monotherapy or as maintenance therapy following nivolumab plus ipilimumab regimen), 
metastatic NSCLC, and advanced RCC.
The PK and safety of nivolumab have been evaluated in the Asian  population. The comparison of 
PK parameters in global and Japanese participants suggests that  the PK of nivolumab is similar in 
these populations. Nivolumab is shown to be safe and well toler ated in Japanese participants. The 
similar PK and safety profile of nivolumab between global and Japanese participants supports the 
use of similar dosing in the Asian population as is being used in global clinical studies.
5.5.1 Justification for Dosage in Combination Treatment of Nivolumab and 
Ipilimumab
The dose and schedule of nivolumab and ipilimumab for this stud y was selected based on the data 
observed in the CA209016 study and in the CA209012 study.
50As was previously mentioned in 
Section 3.2.1.3 , Study CA209016 demonst rated antitumor activity of nivolumab 3 m g/kg + 
ipilimumab 1 mg/kg Q3W for 4 doses, followed by nivolumab 3 mg/ kg Q2W (N3 + I1 schedule) 
Protocol Amendment No.: 06
Date: 08-Dec-2022 57
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
with an ORR of 36% in previously-untreated RCC par ticipants, which is higher than the efficacy 
with either nivolumab monotherapy (CA209009) or ipilimumab mono therapy (MDX010-11). In 
CA209012, a multi-cohort Phase 1 study in participants with advan ced NSCLC, multiple
nivolumab and ipilimumab combination schedules were evaluated i n order to optimize safety and 
efficacy. In addition to ev aluating the N3 + I1 schedule (identi cal to that given in CA209016) in 2 
cohorts , CA209012 evaluated nivolumab 3 mg/kg Q2W combined with ipilimumab 1 mg/kg either 
given Q6W or given Q12W in 2 other cohorts. Both the ipilimumab  Q6W and Q12W cohorts were 
associated with improved and manageable tolerability compared t o the cohort that received the N3 
+ I1 schedule. Both cohorts dem onstrated encouraging efficacy, yielding ORR of 38% to 47%, 
which is higher than the ORR observed in the nivolumab monother apy cohort (ORR 23%) or the 
N3 + I1 cohorts (ORR 20%, combining squamous and non-squamous co horts) in the same study. 
The CA209012 study demonstrated activity of the combination of nivolumab 3 mg/kg Q2W plus 
ipilimumab 1 mg/kg Q6W in both PD-L1+ and PD-L1- tumors, coupled with a manageable safety 
profile, and this combination regimen in being further evaluate d in the Phase 3 CA209227 in 
previously untreated advanced NSCLC. 
Given the demonstrated clinical activity of nivolumab monothera py in advanced RCC from 
CA209025 and the similar PK, eff icacy, and safet y of nivolumab 240 mg Q2W to 3 mg/kg Q2W, 
CA209914 will use a nivolumab flat dose of 240 mg Q2W as the backbo ne for the combination 
regimen with ipilimumab. With both ipilimumab 1 mg/kg Q6W and Q1 2W schedules showing a 
similar safety and efficacy profile when combined with nivolumab  3 mg/kg Q2W in CA209012, 
the ipilimumab 1 mg/kg Q6W schedule was chosen to combine with the nivolumab 240 mg 
backbone to avoid any potential l oss of efficacy with less freq uent ipilimumab dosing.
5.5.2 Justification for Dose of Nivolumab Monotherapy Treatment in Part B
Nivolumab will be  dosed at 240 mg Q2W in the monotherapy arm. Nivolumab is appro ved in the 
US and EU for advanced renal cell carcinoma at 240 mg Q2W or 480  mg Q4W.51These doses 
have comparable time-averaged c oncentrations over the respectiv e dosing intervals and were 
shown to have comparable benefit:risk to that of 3 mg/kg Q2W in  advanced renal cell carcinoma. 
The dose of 240 mg Q2W was s elected since this matches the same  dose and frequency of 
administration as that in the nivolumab and ipilimumab combinat ion arm. Having the same 
nivolumab dosing frequency for the monotherapy and combination arm will allow for a more 
complete assessment of contribution of ipilimumab to eff icacy and safety. Addition ally, having 
the same nivolumab dosing frequency will maintain the study bli nd by avoiding any operational 
challenges associated different dosing frequencies across treatment arms. 
6 STUDY POPULATION
For entry into the study, the following criteria MUST be met.
6.1 Inclusion Criteria
1) Signed Written Informed Consent
Protocol Amendment No.: 06
Date: 08-Dec-2022 58
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
a) Participants must have signed and dated an IRB/IEC approved w ritten ICF in accordance 
with regulatory and institutional guidelines. This must be obta ined before the performance 
of any protocol related procedures that are not part of normal participant care. 
b) Participants must be willing and able to comply with scheduled visits, treatment schedule, 
and laboratory testing.
2) Type of Participant and Target Disease Characteristics
a) Kidney tumor has been completel y resected with negative surgi cal margins obtained. The
randomization must occur gr eater than 4 weeks and less than (or equal to) 12 weeks from 
the date of nephrectomy. Partial nephrectomy is allowed provide d all inclusion criteria are 
met. 
b) Post-nephrectomy tumor shows RCC with a predominantly clear c ell histology, including 
participants with sarcomatoid features.
c) Pathological TNM staging per AJCC staging version 2010 (refer to Appendix 9 for 
correlations of classificati ons in cancer staging systems):
â™¦pT2a, G3 or G4, N0M0
â™¦pT2b, G any, N0M0
â™¦pT3 (a, b, c) , G any, N0M0
â™¦pT4, G any, N0M0
â™¦pT any, G any, N1M0
Note 1: Excisional biopsy of all regional lymph node(s) which a ppear abnormal on pre-
operative scans or at surgery.
In order to properly stratify pa rticipants, it is required that the investi gator designate the 
nodal status as either N0 or N1 according to the following crit eria which will be captured 
in the eCRF: 
oN0 requires that a participant have no abnormal regional lymph nodes on 
pre-operative scans or visualized at surgery, OR have regional lymph nodes 
biopsied with negative (no tumor present) result. 
oN1 requires that a participant have regional lymph nodes biopsied with one or more 
regional lymph nodes having positive (tumor present) results.
Note 2: Participants with ipsilateral multicentric RCC are eligible if the most advanced 
lesion per pT stage fulfils the aforementioned combinations of pathologic staging and 
Fuhrman nuclear grading. 
d) Participants must have no clinical or radiological evidence o f macroscopic residual disease 
or distant metastases (M0) after nephrectomy:
oBaseline tumor assessment, performed 4 to approximately 12 week s after 
nephrectomy, shows no metastasis or residual tumor lesions per local review and 
as confirmed by BICR. Results of BICR of the baseline tumor ass essment 
confirming absence of metastasis or residual tumor lesions must  be received before 
randomization. 
Protocol Amendment No.: 06
Date: 08-Dec-2022 59
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
oIf the  Investigator is  not certain the participant is disease free, the participant should 
1) not be consented or be enrolled into the study and 2) evalua tion for eligibility 
should not be submitted to BICR.
Note: participants with one or more regional lymph nodes identi fied with short axis 
â‰¥15 mm on the baseline (post-operative) tumor assessments are con sidered to have 
gross residual disease and are therefore ineligible. See Section 9.1.2 for guideline of 
imaging diagnosis for baseline disease-free status.
e) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1 ( Appendix 5 ).
f) Either a FFPE tissue block or unstained tum or tissue sections, ob tained within 3 months 
prior to enrollment, preferably from nephrectomy, with an assoc iated pathology report, 
must be submitted to the central laboratory prior to randomizat ion. FFPE block or
20 unstained slides is ideal, but a minimum of 10 unstained slide s will be acceptable if 
tumor tissue is limited. Biopsy should be excisional, incisiona l, or core needle. Fine needle 
aspiration is unacceptable for submission. Sites will be notifi ed if there is insufficient tissue 
for analysis by the central lab.
3) Age and Reproductive Status
a) Males and Females, ages â‰¥18 years or age of majority.
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units  of HCG) within 24 hours 
prior to the start of study treatment.
i) An extension up to 72 hours prior to the start of study treat ment is permissible in 
situations where results cannot be obtained within the standard  24-hour window.
ii) Additional requirements for pregnancy testing during and aft er study intervention are 
located in Section 2 , Schedule of Assessments.
iii) The investigator is res ponsible for review of medical history, menstrual history, and 
recent sexual activity to decrease the risk for inclusion of a woman with an early 
undetected pregnancy.
c) Women must not be pregnant or breastfeeding.d) WOCBP must agree to follow instructions for method(s) of cont raception and use a 
contraceptive method that is hi ghly effective (with a failure r ate of <1% per year), with low 
user dependency ( Appendix 4 and as described below and included in the ICF) for the 
duration of treatment with study t reatment(s) nivolumab plus 5 h alf-lives of study treatment
p l u s  3 0  d a y s  ( d u r a t i o n  o f  o v u l a t o r y  c y c l e )  f o r  a  t o t a l  o f  5  m o n ths post-treatment 
completion.i) WOCBP are permitted to use hormonal contraception methods (as  described in 
Appendix 4).
ii) WOCBP must agree not to donate eggs (ova, oocytes) for the purpose of reproduction 
during the intervention peri od and for at least 5 months.
iii) Women who are not of childbearing potential are exempt from  contraceptive 
requirements. 
iv) Women participants must have documented proof that they are not of childbearing 
potential.
Protocol Amendment No.: 06
Date: 08-Dec-2022 60
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
e)Not Applicable per Revised Protocol 04: Males who are sexually active with WOCBP 
must agree to follow instructions for method(s) of contraception ( Appendix 4 ) for the 
duration of treatment with study treatment(s) nivolumab plus 5 half-lives of the study 
treatment plus 90 days (duration of sperm turnover) for a total of 7 months post-treatment 
completion. In addition, male part icipants must be willing to r efrain from sperm donation 
during this time. 
f)Not Applicable per Revised Protocol 04: Azoospermic males are exempt from 
contraceptive requirements. Still applicable per Revised Protocol 04: WOCBP who are 
continuously not heterosexually active are also exempt from con traceptive requirements, 
and st ill must  undergo pregnancy testing as described in this section.
Investigators shall counsel WO CBP on the importance of pregnanc y prevention, the implications 
of an unexpected pregnancy, and the potential of f etal toxicity occ urring due to transmission of 
study drug to a developing fetus. Investigators shall advise on  the use of highly effective methods 
of contraception (Appe ndix 4), which have a failure rate of < 1 % when used consistently and 
correctly.
6.2 Exclusion Criteria
1) Medical Conditions
a) Known history of positive test for human immunodeficiency vir us (HIV) or known 
acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HI V must be performed 
at all sites where mandated by country  or local regulations (see Appendix 7 ). 
b) Any severe or serious, acute or chronic medical or psych iatric condition, or laboratory 
abnormality that may increase the risk associated with study participation or study drug 
administration, including ongoing or active infection requiring  parental antibiotics.
c) Participants with a condition requiring systemic treatment with  either corticosteroids 
(> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 
14 days prior to the first dose of study drug. Topical, ocular, intra-articular, intranasal, 
inhaled steroids, and adrenal replacement steroid doses > 10 mg  daily prednisone or the 
equivalent are permitted in the absence of active immune diseas e. 
d) Uncontrolled adrenal insufficiency.
e) Participants with an active known or suspected autoimmune dis ease. Participants with type 
I diabetes mellitus, hypothyroidism only requiring hormone repl acement, skin disorders 
(such as vitiligo, psoriasis, or alopecia) not requiring system ic treatment, or conditions not 
expected to recur in the absence of an external trigger are per mitted to enroll. 
f) Prior malignancy active within the previous 3 years except fo r locally curable cancers that 
have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder 
cancer, or carcinoma in situ of the prostate, cervix, or breast.
Note: Participants with a history of RCC who have been considered cured with a nephrectomy
or other s urgical procedure in the past, and now present with a new RCC, either on  the same 
kidney or the contralateral kidney , should not be enr olled into the study.
g) Treatment with any live / attenuated vaccine within 30 days of  first treatment.
Protocol Amendment No.: 06
Date: 08-Dec-2022 61
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
i) The use of inactivated vaccines, such as the seasonal influen za (eg, FluzoneÂ®) will be 
permitted on study without restriction.
h) Previous SARS-CoV-2 infection (either suspected or confirmed)  within 4 weeks prior to 
screening.
Acute symptoms must have  resolved and based on investigator ass essment in 
consultation with the medical monitor, there are no sequelae th at would place the 
participant at a higher risk of receiving investigational treat ment.
2) Prior/Concomitant Therapy
a) Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or  anti-CTLA-4 antibody, or 
any other antibody or dr ug specifically targeting T-cell co-stimulation or checkpoint 
pathways.
b) Prior systemic anti-cancer treatment, including chemotherapy,  antiangiogenic agents or 
investigational agents, given in the neoadjuvant, adjuvant, or metastatic setting for RCC.
c) Treatment with com plementary medications (eg, herbal supplemen ts or traditional Chinese 
medicines) to treat the disease under study within 2 weeks prior  to first study treatment. 
Such medications are permi tted if they are used as supportive care. Refer to Section 7.7.1 
for prohibited therapies.
d) Participants currently in other interventional trials, includ ing those for Coronavirus Disease 
2019 (COVID-19), may not participate in BMS clinical trials unt il the protocol specific 
washout period is achieved. If a study participant has received  an investigational 
COVID-19 vaccine or other investigational product designed to treat or prevent COVID-19
prior to screening, enrollment must be delayed until the biolog ic impact of the vaccine or 
investigational product is stabilized, as determined by discussion between the investigator 
and the BMS Medical Monitor.
3) Physical and Laboratory Test Findings
a) Any positive test result for hepatitis B virus or hepatitis C  virus indicating presence of 
virus, eg, Hepatitis B surface antigen (HBsAg) positive, or Hep atitis C antibody 
(anti-HCV) positive (except if HCV-RNA negative).
b) WBC < 2000/Î¼L
c) Neutrophils < 1500/Î¼Ld) Platelets <  100 x 10
3/Î¼L
e) Hemoglobin < 9.0 g/dL
f) Serum creatinine >1.5 x ULN unless creatinine clearance â‰¥ 40 mL/min (measured or using 
the Cockcroft-Gault formula)
g) AST/ALT > 3.0 x ULNh) Total bilirubin > 1.5 x ULN (except participants with Gilbert  Syndrome who must have a 
total bilirubin level of < 3.0 x ULN)
4) Allergies and Adverse Drug Reaction
a) History of severe hypersensiti vity to a monoclonal antibody.
b) History of allergy or hypersen sitivity to study drug componen ts.
Protocol Amendment No.: 06
Date: 08-Dec-2022 62
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
5) Other Exclusion Criteria
a) Prisoners or participants who are involuntarily incarcerated.  (Note: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to continue 
as a participant. Strict conditions apply and Bristol-Myers Squ ibb approval is required.)
b) Participants who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness.
Eligibility criteria for this study have been carefully conside red to ensure the safety of the study 
participants and that the results of the study can be used. It is imperative that participants fully 
meet all eligibility criteria.
6.3 Lifestyle Restrictions
Not applicable. No restrictions are required.
6.4 Screen Failures
Screen failures are defined as participants who consent to part icipate in the clinical study but are 
not subsequently randomized. A minimal set of screen failure in formation is required to ensure 
transparent reporting of screen failure participants, to meet t he Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements, and to respond to queries from regulatory 
authorities. Minimal information in cludes date of consent, demo graphy, screen failure details, 
eligibility criteria, and any serious AEs.
6.4.1 Retesting During Screening or Lead-In Period
Participant Re-enrollment: This study permits the re-enrollment  of a participant that has 
discontinued the study as a pre-treatment failure (ie, particip ant has not been randomized/has not 
been treated). If re-enrolled, the participant must be re-consen ted.
Retesting of laboratory parameters and/or other assessments wit hin the Screening or Lead-in 
period will be permitted (in addition to any parameters that re quire a confirmatory value).
The most current result prior to randomization is the value by which study inclusion will be 
assessed, as it represents the participantâ€™s most current, clin ical state.
Testing for asymptomatic SARS-CoV-2 infection, for example by R T-PCR or viral antigen is not 
required. However, some participants may develop suspected or c onfirmed symptomatic SARS-
CoV-2 infection, or be discovered to have asymptomatic SARS-CoV -2 infection during the 
screening period. In such cases, pa rticipants may be considered e ligible for the study after meeting 
all inclusion/exclusion criteria r elated to active infection, and after meeting the followi ng criteria: 
âˆ’At least 10 days (20 days for severe/critical illness) have pas sed since symptoms first 
appeared or positive RT-PCR or viral antigen test result, and
âˆ’At least 24 hours have passed since last fever without the use of fever-reducing 
medications, and
âˆ’Symptoms (eg, cough, shortness of breath) have resolved, and
Protocol Amendment No.: 06
Date: 08-Dec-2022 63
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
âˆ’In the opinion of the Investigator, there are no COVID-19-relate d sequelae that may place 
the participant at a higher risk of receiving investigational t reatment, and
âˆ’Negative follow-up test for SARS-CoV-2 RT-PCR or viral antigen t est based on 
institutional, local or regional guidelines
7 TREATMENT
Study treatment is defined as any investigational treatment(s),  marketed product(s), placebo, or 
medical device intended to be administered to a st udy participant acc ording to the st udy 
randomizatio n or treatment allocation.
Study treatment includes both Inve stigational [M edicinal] Produc t (IP/IMP) and 
Non-investigational [Medicinal] Product (Non-IP/Non-IMP) and ca n consist of the following:
An investigational product, als o known as investigational medic inal product in some regions, is 
defined a pharmaceutical form of a n active substance or placebo being tested or used as a reference 
in a clinical study, including products already with a marketin g authorization but used or 
assembled (formulated or packaged) differently than the authori zed form, or used for an 
unauthorized indication, or when used to gain further informati on about the authorized form.
In this protocol (see Table 7-1), the following are considered IP/IMP:
â€¢Nivolumab (BMS-936558)
â€¢Ipilimumab (BMS-734016)
â€¢Nivolumab-Placebo (0.9% Sodium Chloride Injection or 5% Dextrose  Injection)
â€¢Ipilimumab-Placebo (0.9% S odium Chloride In jection or 5% Dextrose Injection)
The 0.9% normal saline or 5% de xtrose to be used as placebo wil l not be provided by the Sponsor.
Other medications used as support or escape medicati on for preventative,  diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diag nosis, may be considered as non-
investigational products.
Protocol Amendment No.: 06
Date: 08-Dec-2022 64
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 7-1: Study Treatments for CA209914 
Product Description / 
Class and Dosage 
FormPotencyIP/Non-
IMPBlinded or 
Open Labela Packaging / AppearanceStorage 
Conditions
(per label)
Nivolumab Solutionb
for Injection100 mg (10 mg/mL)
or
40 mg (10 mg/mL)IP Open-label5 or 10 vials per carton
Or 
240 mg kits (two 100 mg vials and one 40 mg vial) 
Clear to opalescent colorless to pale yellow liquid. 
May contain particles2Â° to 8 Â°C. Protect 
from light and 
freezing
Ipilimumab 200 mg (5 mg/mL) IP Open-label4 vials per carton
Clear to opalescent colorless to pale yellow liquid. 
May contain particles2Â° to 8 Â°C. Protect 
from light and 
freezing
0.9% Sodium Chloride 
for InjectionNA IP Open-labelVarious (local commercial product) As per active IP
5%  Dextrose for 
InjectionNA IP Open-LabelVarious (local commercial product) As per active IP
aThe term â€œopen-labelâ€ refers to the medication as it is upon re ceipt at the pharmacy.  The trial will be conducted in a double -blinded fashion.
bNivolumab is labeled as  BMS-936558-01 Sol ution for Injection
Premedications used to treat i nfusion reactions should be s ourced by the investigative sites if av ailable and permitted by lo cal regulations.
Solutions used as diluent or placebo (ie, 0.9% Sodium Chloride Injection or 5% Dextrose Injection ) should also be sourced by 
investigative sites if available and permitted by local regulat ions  
Protocol Amendment No.: 06
Date: 08-Dec-2022 65
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
7.1 Treatments Administered
7.1.1 Administration
Participants should receive nivolumab at a dose of  240 mg as an a pproximately 30-minute infusion 
on Day 1 of each treatment cy cle until recurrence, unacceptable toxicity, withdrawal of cons ent, 
Week 36, or a maximum of 12 doses, whichever occurs first. Star ting with Cycle 1, ipilimumab 1 
mg/kg as an approximately 30-minute infusion s hould be ad ministered every third cycle (ie, Cycles 
1, 4, 7, and 10). Table 7.1.1-2 provides the dosing schedule. Par ticipants must begin study 
treatment within 3 calendar days of rando mization. 
Treatment cycles should be give n every 2 weeks (14 days). After  Cycle 1, dosing for subsequent 
dosing should be based on the actual date of administration of t he previous cycle. To permit 
scheduling flexibility (eg, to accommodate local holidays), dos es may be given up to 2 days early 
(ie, no less than 12 days after the previous cycle) or up to 17  days after the previous cycle. Doses 
given more than 17 days after the previous dose will be conside red delayed. 
For Cycles 1, 4, 7, and 10, when nivolumab and ipilimumab are t o be administered on the same 
day, nivolumab is to be administered first. Nivolumab infusion must be promptly followed by a 
0.9% normal saline or 5% dextrose flush to clear the line of ni volumab before starting the 
ipilimumab infusion. The second infusion will always be the ipi limumab study drug and will start 
after the infusion line has been flushed, filters changed, and t he participant has been observed to 
ensure no infusion reaction has occurred. Simultaneous i nfusions of nivolumab and ipilimumab 
will not be permitted.
Ipilimumab dosing calculations should be based on the body weig ht assessed at either the day of 
dosing or the last recorded weight, and if the participantâ€™s we ight on the day of dosing differs by 
> 10% from the weight used to calculate the dose, then the dose must be recalculated. All 
ipilimumab doses should be rounded to the nearest milligram. There will be no dose escalations or reductions of nivolumab or  ipilimumab allowed. 
Premedications are not recommended for nivolumab or ipilimumab on the first cycle. Participants 
should be carefully monitored for i nfusion r eactions during nivolumab and ipilimumab 
administration. If an acute infusion reaction is noted, partici pants should be managed according to 
Section 7.4.3 .
Doses of nivolumab and ipilimumab may be interrupted, delayed, o r discontinued depending on 
how well the participant tolerates the treatment. Dosing visits  are not to be skipped/omitted, only 
delayed if any dose delay criteria are met. Dose delay criteria  and criteria to resume treatment are 
discussed in Section 7.4 .
Any cycles not given within 36 weeks after the first dose will be omitted. Participants who have 
not completed all 12 cycles will discontinue study tr eatment at Week 36 and begin the Post-
Treatment Follow-Up Phase. The strength and route of administration are described in Table 7.1.1-1 and the timing of each dose 
is described in Table 7.1.1-2 .
Protocol Amendment No.: 06
Date: 08-Dec-2022 66
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 7.1.1-1: Strength  and Route of Study Treatment Administration
Study Treatment Unit dose strength(s)/Dosage level(s) Route of Ad ministration
Nivolumab 240 mg IV
Ipilimumab 1 mg/kg IV
Nivolumab-Placebo 0.9% Sodium Chloride or 5% Dextrose 
Injection)IV
Ipilimumab -Placebo 0.9% Sodium Chloride or 5% Dextrose 
Injection)IV
Protocol Amendment No.: 06
Date: 08-Dec-2022 67
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 7.1.1-2: Dosing S chedule for CA209914
ArmCycle 1
Day 1Cycle 2 
Day 1Cycle 3
Day 1Cycle 4
Day 1Cycle 5
Day 1Cycle 6
Day 1Cycle 7
Day 1Cycle 8
Day 1Cycle 9
Day 1Cycle 10
Day 1Cycle
11
Day 1Cycle 
12
Day 1
Arm A (Parts 
A and B)
Nivolumab +IpilimumabN240 
+
I1N240 N240N240 
+
I1N240 N240N240 
+
I1N240 N240N240 
+
I1N 240 N 240
Arm B (Parts 
A and B)
PlaceboN Placebo 
+ 
I PlaceboN 
PlaceboN 
PlaceboN Placebo 
+
I PlaceboN 
PlaceboN 
PlaceboN Placebo 
+ 
I PlaceboN 
PlaceboN 
PlaceboN Placebo 
+ 
I PlaceboN 
PlaceboN 
Placebo
Arm C (Part B only)
Nivolumab + 
I PlaceboN240 +
I PlaceboN240 N240N240 +
I PlaceboN240 N240N240 +
I PlaceboN240 N240N240 +
I PlaceboN240 N240
I1 = ipilimumab 1 mg/kg; I Placebo = ipilimumab placebo; N240 =  nivolumab 240 mg; N Placebo = Nivolumab Placebo.
Note: Time between end of nivolumab infusion and start of ipili mumab infusion should allow time for flushing of line, changing  of filters, and observation for 
infusion reaction.
Protocol Amendment No.: 06
Date: 08-Dec-2022 68
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
7.1.1.1 Nivolumab
Nivolumab Injection 100 mg/10 mL (10 mg/mL) and Nivolumab Injec tion 40 mg/4 mL 
(10 mg/mL) are to be administered as an approximately 30-minute I V infusion th rough a 0.2-
micron to 1.2-micron pore size, low-protein binding in-line fil ter at the protocol-specified doses. 
It is not to be administered as an IV push or bolus injection. Nivolumab injection can be infused 
undiluted (10 mg/mL) or diluted with 0.9% Sodium  Chloride  Injection or 5% Dextrose Inj ection. 
For instructions on dilution and infusion of nivolumab injectio n, please refer to the clinical 
protocol, current IB, pharmacy ma nual/binder, or pharmacy reference sh eet. Care must be taken 
to assure sterility of the prepared solution as the product doe s not contain any antimicrobial 
preservative or bacteriostatic agent. At the end of the infusio n, flush the line with a sufficient 
quality of 0.9% normal saline or 5% dextrose solution. 
Nivolumab infusions are compatible with polyvinyl chloride (PVC ) or polyolefin containers and 
infusion sets, and g lass bottles.
7.1.1.2 Ipilimumab
Ipilimumab injection can be used for IV administration without dilution after transferring to a 
PVC, non-PVC/non-DEHP or glass container and is stable for 24 h ours at 2-8Â°C or room 
temperature/room light (RT/RL). For ipilimumab storage instruct ions and additional preparation 
instructions, refer to Ipilimumab IB and/or pharmacy manual/ref erence sheets.
Separate infusion bags and filters should be used when administ ering nivoluma b and ipilimumab 
on the same day.
Ipilimumab is to be administered as an approximately 30-minute IV  infusion after the completion 
of the nivolumab infusion. A volumetric pump with a 0.2 to 1.2 m icron, low protein binding, in-
line filter is to be utilized. The drug can be diluted with 0.9 % normal saline or 5% Dextrose 
Injection to concentrations between 1 mg/mL and 4 mg/mL. It is not to be administered as an IV 
push or bolus injections. Care must be taken to assure sterilit y of the prepared solutions, since the 
drug product does not contain any antimicrobial preservatives o r bacteriostatic agents. At the end 
of the infusion, flush the line with a sufficient quantity of 0 .9% normal saline or 5% dextrose 
solution. 7.2 Method of Treatment Assignment
CA209914 is a double-b lind, rando mized trial. Participants with early stage localized RCC who 
underwent radical or partial nephrectomy will be eligible to pa rticipate. After the participantâ€™s 
initial eligibility is established and informed consent has bee n obtained, the participant must be 
enrolled into the st udy by calling the IRT to obtain a particip ant number. Every participant that 
signs the ICF must be assigned a participant number in IRT. Spec ific instructions for using IRT 
will be provided to the investigational site in a separate document. Th e investigator or designee 
will register the participant for enrollment by following the e nrollment procedures established by 
BMS.
Protocol Amendment No.: 06
Date: 08-Dec-2022 69
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
The following information is required for enrollment:
â€¢Date that informed consent was obtained
â€¢Date of birth, where applicable by local regulations
â€¢Gender at birth
Once enrolled in IRT participants who have met all elig ibility criteria will be ready to be 
randomized through IRT. The following information is required for participant randomization:â€¢Participant number
â€¢Date of birth, where applicable per local regulations
â€¢TNM staging per AJCC staging version 2010 and Fuhrman nuclear gra ding categories (refer 
to Appendix 9 for correlations of classifications in cancer staging systems):
âˆ’pT2a, G3 or G4, N0, M0
âˆ’pT2b, G any, N0, M0 
âˆ’pT3, G any, N0, M0 
âˆ’pT4, G any, N0, M0
âˆ’pT any, G any, N1, M0
â€¢Type of nephrectomy procedure (partial versus radical, includin g total nephrectomy).
â€¢Date of nephrectomy 
â€¢Confirmation that tumor tissue has been sent to the central lab.
â€¢Confirmation of disease-free st atus by BICR (radiographic only)
Refer to Section 6.1 for the definition of node status. The exact procedures for usi ng the IRT will 
be detailed in the IRT manual.
7.3 Blinding
Blinding of treatment assignment is critical to the integrity o f this clinical study. However, in the 
event of a medical emergency or pregnancy in an individual part icipant in which knowledge of the 
investigational product is critical to the participant's manage ment, the blind for that participant
may be broken by the investigator. The participantâ€™s safety tak es priority over any other 
considerations in determining if a treatment assignment should be unblinded.
Before breaking the blind of an individual participant's treatm ent, the investigator should 
determine that the unblinded information is necessary, ie, that  it will alter the participant's 
immediate management. In many cases, particularly when the emer gency is clearly not related to 
the investigational product, the problem may be properly managed by assuming that the participan t
is receiving active product. It is highly desirable that the de cision to unblind treatment assignment 
be discussed with the BMS Medical Monitor or designee, but the i nvestigator always has ultimate 
authority for the decision to unblind. The Principal Investigat or should only call in for emergency 
unblinding AFTER the decision to discontinue the participant has  been made.
Protocol Amendment No.: 06
Date: 08-Dec-2022 70
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Any request to unblind a participant for non-emergency purposes  should be discussed with the 
Medical Monitor or designee. 
For this study, the method of  unblinding for emergency purposes  is through the IRT. For 
information on how to unblind for emergency, please consult the  IRT manual.
In cases of accidental unblindi ng, contact the Unblinded Monitor  or designee and ensure every 
attempt is made to preserve the blind.Designated staff of Bristol-Myers Squibb Research & Development may be unblinded prior to 
database lock to facilitate the bioanalytical analysis of pharm acokinetic samples and 
immunogenicity. A bioanalytical scientist in the Bioanalytical S ciences department of Bristol-
Myers Squibb Research & Development (or a designee in the exter nal central bioanalytical 
laboratory) will be unblinded to  the randomized treatment assig nments i n order to minimize 
unnecessary bioanalytical analysis of samples.
7.3.1 Unblinding at the Time of Disease Recurrence
If a participant is assessed by the investigator to have RCC dis ease recurrence ( Section 9.1.3.2 ), 
the study treatment assignment for the participant can be obtained by the investigator through IRT 
for non-emergency unblinding in order to d etermine subsequent a nti-cancer treatments. The 
investigator should follow the procedures outlined in the IRT m anual to ob tain the participantâ€™s 
study treatment assignment.
Investigators are strongly encoura ged to wait for confirmation of recurrence from the BICR prior 
to non-emergenc y unblinding for the  purpose of initiating subsequent anti-canc er therapy, unless 
clinical considerations require immediate intervention (eg, sym ptomatic brain metastases). If a 
tumor biopsy collection at the time of suspected recurrence is planned, the request for unblinding 
should occur after pathology results are available. If subseque nt anti-cancer therapy (including 
systemic cancer therapy, radiotherapy, or tumor-directed surger y) is planned prior to BICR 
confirmation of recurrence, the  investigator must contact the B MS Medical Monitor or designee 
to discuss the case prior to the start of any of such therapy.If a participant is diagnosed with a non-RCC secondary cancer, blinding should be preserved 
unless specific circumstances, to be discussed with the BMS Med ical Monitor or designee, require 
that the blind be broken (eg, participant has metastases and cou ld enroll on a clinical trial but would 
be ineligible if he or she had prior checkpoint inhibitor thera py). 
For this study, the method of  unblinding for emergency purposes  is through the IRT. For 
information on how to unblind in an emergency, please see Section 7.3 .
7.4 Dosage Modification
Dose reductions or dose escalations are not permitted. All dose  modifications rules apply to both 
Arms A and B given the blinded nature of this study.  
7.4.1 Dose Delay Criteria for Study Treatment
Regardless of whether or not the event is attributed to Arm A, A rm B, or Arm C, all study drugs 
must be delayed until criteria to resume tr eatment ( Secti on 7.4.2 ) have been met, given the blinded 
Protocol Amendment No.: 06
Date: 08-Dec-2022 71
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
nature of this study. Tumor assessments for all participants s hould continue as per protocol even 
if dosing is delayed. If one drug is delayed, both study drugs must be delayed. 
Study drug administration should be delayed for a ny of the following:
â€¢Grade 2 non-skin, drug-related AE, with the excepti on of fatigue
â€¢Grade 2 drug-related creatinine, AST, ALT and/or Total Bilirubi n abnormalities
â€¢Grade 3 skin, drug-related AE
â€¢Grade 3 drug-related laboratory abnormality, with the following  exceptions: 
âˆ’Grade 3 lymphopenia or asymptomatic amylase or lipase does not require dose delay
âˆ’Grade â‰¥3 AST, ALT, Total Bilirubin will require dose discontinuation ( see Section 8.1 )
â€¢Any AE, laboratory abnormality, or intercurrent illness which, in the  judgment of the 
investigator, warrants delaying the dose of study medication.
â€¢SARS-CoV-2 infection (either suspected or confirmed).
Participants who require delay of study drug should be re-evalua ted weekly or more frequently if 
clinically indicated and resume study drug dosing when re-treat ment criteria are met. If a 
participant is delayed beyond 36 weeks of the first dose, treat ment will discontinue. 
7.4.2 Criteria to Resume Treatment
All criteria to resume study therapy apply to nivolumab, ipilim umab, and placebo, given the 
blinded nature of the study. Participants may resume treatment with study drug when the 
drug-related AE(s) resolve to Grade â‰¤1 or bas eline value and any systemic corticosteroids have 
been tapered to â‰¤ 10 mg pre dnisone equivalent. (See Section 7.7.3  for exception regarding adrenal 
replacement steroids.)
The following are exceptions to the above:
â€¢Participants may resume treatm ent in the presence of Grade 2 fa tigue
â€¢Participants who have not experienced a Grade 3 drug-related sk in AE may resume treatment 
in the presence of Grade 2 skin toxicity
â€¢For participants with Grade 2 AST, ALT and/or Total Bilirubin A bnormalities, dosing may 
resume when laboratory values return to baseline and management  with corticosteroids, if 
needed, is complete.
â€¢Drug-related pulmonary tox icity, dia rrhea or colitis must have resolved to baseline before 
treatment is resumed. Participants with persistent Grade 1 pneu monitis after completion of a 
steroid taper over at least 1 month may be eligible for retreat ment if discussed with and 
approved by BMS Medical Monitor or designee.
â€¢Participants with SARS-CoV-2 infection (either suspected or con firmed) may resume 
treatment after all of the following: 1) at least 10 days (20 days for severe/cr itical illness) have 
passed since symptoms first a ppeared or positive test result (e g, RT-PCR or viral antigen), 2)
resolution of acute symptoms (including at least 24 hours has pa ssed since last fever without 
fever-reducing medications), 3) evaluation by the Investigator with confirmation that there are 
Protocol Amendment No.: 06
Date: 08-Dec-2022 72
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
no sequelae that would place the participant at a higher risk o f receiving investigational 
treatment, and 4) con sultation by the Med ical Monitor. For suspected  cases, treatment may 
also resume if SARS-CoV-2 infection is ruled out and other crite ria to resume treatment are 
met.
If the criteria to resume treatment are met after a delay of Cyc le 4, 7, or 10, the n both nivolumab 
and ipilimumab must be resumed on the same day when the cycle is given. 
If treatment is delayed > 6 weeks from the previous dose, the par ticipant must be permanently 
discontinued from study therapy, except as specified in Section 8.1.1 .
Participants with drug-related endocrinopathies adequately cont rolled with only  physiologic 
hormone replacement may resume treatment after consultation wit h the BMS Medical Monitor or 
designee. Grade 3 or 4 drug-related adrenal insufficiency requi res discontinuation regardless of 
control with  hormone  replacement.
7.4.3 Treatment of Study Treatment-related Infusion Reactions
Since nivolumab and ipilimumab contain only human immunoglobuli n protein sequences, they are 
unlikely to be immunogenic and induce infusion or hypersensitiv ity reactions. However, if such a 
reaction were to occur, it might manifest with fever, chills, r igors, headache, rash, pruritus, 
arthralgias, hypotension, hypertension, bronchospasm, or other allergic-like reactions. Regardless 
of whether or not the event is attributed to the st udy drugs, all Grade 3 or 4 infusion r eactions 
should be reported within 24 hours to the study BMS Medical Mon itor or designee and reported 
as an SAE if it meets the criteria, given the blinded nature of  the study. Infusi on reactions should 
be graded according to NCI CTCAE (Version 4) guidelines.
Treatment recommendations are provided below and may be modifie d based on local treatment 
standards and guidelines, as appropriate:
For Grade 1 symptoms: (mild reaction; i nfusion interruption not indicated; intervention not 
indicated):
â€¢Remain at bedside and monitor participant until recovery from s ymptoms. The following 
prophylactic premedications are r ecommended for future infusions: diphenhydramine 50 mg 
(or equivalent) and/or acetaminophen/paracetamol 325 to 1000 mg  at least 30 minutes before 
additional study drug administrations.
For Grade 2 symptoms: (moderate reaction required therapy or in fusion interruption but responds 
promptly to symptomatic treatment [eg, antihis tamines, non-steroidal anti-inf lammatory drugs, 
narcotics, corticosteroids, bronchodilators, IV fluids]; prophy lactic medications indicated for â‰¤24 
hours):
â€¢Stop the study drug i nfusion, begin an IV infusio n of normal saline, and tr eat the participant 
with diphenhydramine 50 mg IV (or equivalent) and/or acetaminop hen/par acetamol 325 to 
1000 mg; remain at bedside and monitor participant un til resolution of symptoms. 
Corticosteroid and/or bronchodilator therapy may also be admini stered as appropriate. If the 
Protocol Amendment No.: 06
Date: 08-Dec-2022 73
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
infusion is interrupted, then restart the i nfusion at 50% of the original infusion r ate when 
symptoms resolve; if no further complications ensue after 30 mi nutes, the rate may be 
increased to 100% of the original infusion rate. Monitor partic ipant closely. If symptoms recur, 
then no further study drug will be administered at that visit.
â€¢For future infusions, the following prophylactic premedications are recommended: 
diphenhydramine 50 mg (or equi valent) and/or acetaminophen/para cetamol 325 to 1000 mg 
should be administered at least 30 minutes before study drug inf usions. If necessary, 
corticosteroids  (up to 25 m g of hydrocortisone or equiv alent) may be used.
For Grade 3 or 4 symptoms: (sev ere reaction, Grade 3: prolonged  [ie, not rapidly responsive to 
symptomatic medication and/or brief interruption of infusion]; recurrence of symptoms following 
initial improv ement; hospi talization ind icated for other clinical sequelae (eg, renal impairment, 
pulmonary infiltrates). Grade 4: Life-threatening; pressor or v entilatory support indicated):
â€¢Immediately discontinue infusion of study drug. Begin an IV inf usion of normal saline and 
treat the participant as follows: Recommend bronchodilators, ep inephrine 0.2 to 1 mg of a 
1:1000 solution for subcutane ous administrati on or 0.1 to 0.25 mg of a 1:10,000 solution 
injected slowly for IV administration, and/or diphenhydramine 5 0 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Participant should be monitored 
until the Investigator is comfortable that the symptoms will no t recur. Study  drugs will be 
permanently discontinued. Invest igators should follow their ins titutional guidelines for the 
treatment of anaphylaxis. Remain at bedside and monitor partici pant until recovery of the 
symptoms.
In case of late-occurring hypersen sitivity symptoms (eg, appear ance of a localized or generalized 
pruritus within 1 week after treatment), symptomatic treatment may be given (eg, oral 
antihistamine or corticosteroids).
7.5 Preparation/Handling/Storage/Accountability
The investigational product should be stored in a secure area a ccording to local regulations. It is 
the responsibility of the investigator to ensure that investiga tional product is only dispensed to 
study participants. The investigational product must be dispens ed only from official study sites by 
authorized personnel according to local regulations.
The product storage manager should ensure that the study treatm ent is stored in accordance with 
the environmental conditions (temperature, light, and humidity)  as determined by BMS. If 
concerns regarding the quality or appearance of the study treat ment arise, the study tr eatment
should not be dispensed and contact BMS immediately.Study treatment not supplied by BMS will be stored in accordance  with the package insert.
Investigational product documentation (whether supplied by BMS or not) must be maintained that 
includes all processes required to ensure drug is accurately ad ministered. This includes 
documentation of drug storage, administration a nd, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required dil uents, administration sets).
Protocol Amendment No.: 06
Date: 08-Dec-2022 74
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
â€¢Further guidance and information for final disposition of unuse d study treatment are provided 
in Appendix 2 and the CA209914 Pharmacy Manual.
7.5.1 Retained Samples for Bioavailability / Bioequivalence
Not applicable.
7.6 Treatment Compliance
Treatment compliance will be monitored by drug accountability a s well as the participantâ€™s 
medical rec ord and eCRF. This w ill be source data verified by the BMS Unblinded Site Monitor 
through regularly scheduled monitoring visits.
7.7 Concomitant Therapy
7.7.1 Prohibited and/or Restricted Treatments
The following medications are prohibited during the study (unle ss utilized to treat a drug-related 
AE):
â€¢Immunosuppressive agents
â€¢Immunosuppressive doses of systemic corticosteroids (except as stated in Section 7.7.3)
â€¢Any concurrent anti-neoplastic therapy (ie, chemotherapy, hormo nal therapy, immunotherapy, 
or standard or investigational agents given prior to discontinua tion of study treatment)
â€¢Any complementary medications (eg, herbal supplements or traditi onal Chinese medicines) 
intended to treat the disease under study. Such medications are permitted if they are used as
supportive care.   
â€¢Any live/attenuated vaccine (eg, varicella; zoster; yellow fever; r otavirus; oral polio; and 
measles, mumps, rubella [MMR]) during treatment, and until 100 d ays post last dose. 
âˆ’Note: The use of inactivated vaccines, such as seasonal influen za (eg, Fluzone), will be 
permitted on study without restriction.
Supportive care for disease-related symptoms may be offered to all participants on the trial.
7.7.2 Other Restrictions and Precautions
Participants with a condition requiring systemic treatment with  either corticosteroids (> 10 mg 
daily prednisone equivalent) or other immunosuppressive medicat ions within 14 days of 
randomization are excluded. Inhaled or topical steroids, and ad renal replacement steroid doses 
> 10 mg daily prednisone equivalent, are permitted in the absenc e of active autoimmune disease.
Investigators are strongly encoura ged to wait for confirmation of recurrence from the BICR prior 
to initiating subsequent systemic cancer therapy, radiotherapy,  or tumor-directed surgery for 
suspected recurrence unless clinical considerations require imm ediate intervention 
(eg, symptomatic brain metastases). If subsequent systemic cance r therapy, radiotherapy, or 
tumor-directed surgery is planned prior to BICR confirmation of  recurrence, the investigator must 
contact the BMS Medical Monitor or designee to discuss the case p rior to the start of any of these 
procedures.  
Protocol Amendment No.: 06
Date: 08-Dec-2022 75
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
7.7.3 Permitted Therapy
Participants are permitted the use of topical, ocular, intra-ar ticular, intranasal, and inhalational 
corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses, even if 
> 10 mg/day prednisone equivalents, are permitted. A brief (less than 3 weeks) course of 
corticosteroids for prophylaxis (eg, contrast dye allergy) or fo r treatment of non-autoimmune 
conditions (eg, delayed-type hypersensitivity reaction caused b y a contact allergen) is permitted.
Concomitant medications are rec orded at baseli ne, throughout the  treatment  phase of the study and 
within 100 days of the last dose date of study drug should be r ecorded in the  appropriate section 
of the CRF. All medications (prescriptions or over the counter medications) continued at the start 
of the study or starte d during the study and different from the study drug must be docu mented in 
the concomitant therapy section of the CRF.
7.8 Treatment After the End of the Study
At the end of the s tudy/Period (24 weeks), BMS will not continue to provide BMS supplied study  
treatment to par ticipants/investigators unless BMS chooses to ex tend the study. The investigator 
should ensure that the par ticipant receives appropriate standard of care to treat the condition under 
study.
8 DISCONTINUATION CRITERIA
8.1 Discontinuation from Study Treatment
Participants MUST discontinue  investigational product (and non- investigational product at the 
discretion of the investigator) for a ny of the following reasons:
â€¢Participantâ€™s request to stop study tr eatment. Par ticipants who request to discontinue study 
treatment w ill remain in the study and must continue to be followed for pr otocol specified 
follow-up procedures. The only exception to this is when a part icipant specifically withdraws 
consent for any further contact with him/her or persons previously authorized by participant to 
provide this information
â€¢Any clinical AE, laboratory a bnormality or intercurrent illness which, in the opinion of the 
investigator, indicates that continued participation in the stu dy is not in the best interest of the 
participant
â€¢Termination of the study by Bristol-Myers Squibb (BMS)
â€¢Loss of ability to fr eely provide consent through imprisonment or involuntarily inca rceration 
for treatment of either a psychiatric or physical (eg, infectio us disease) illness
â€¢Criteria listed in Section 8.1.1
â€¢Disease recurrence or occurrence of a secondary malignancy which requires systemic therapy or radiotherapy for treatment 
Refer to the Schedule of Activities for data to be collected at the time of treatment discontinuation 
and follow- up and for any further evaluations that can be compl eted.
In the case of pregnancy, the investigator must immediately not ify the BMS Medical 
Monitor/designee of this event. In the event a normal healthy fe male par ticipant become s pregnant 
Protocol Amendment No.: 06
Date: 08-Dec-2022 76
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
during a clinical trial, the study t reatment must be discontinue d immediately. In most cases, the 
study treatment will be permanently discontinued in an appropria te manner (eg, dose tapering if 
necessary for participant safety). Please call the BMS Medical M onitor or designee within 24 hours 
of awareness of the pregnancy. If the investigator determines a  possible favorable benefit/risk ratio 
that warrants continuation of study treatment, a discussion bet ween the investigator and the BMS 
Medical Monitor/designee must occur.
All participants who disc ontinue study treatment s hould comply with protocol specified follow-up 
procedures as outlined in Section 2 . The only exception to this requi rement is when a participant
withdraws consent for all study  procedures including post-treat ment study follow-up or loses the 
ability to consent fr eely (ie, is imprisoned or involuntarily i ncarcerated for the treatment of either 
a psychiatric or physical illness).
If study treatment is discontinued prior to the participantâ€™s co mpletion of the study, the reason for 
the discontinuation must be documented in the participantâ€™s med ical records and en tered on the 
appropriate CRF page.8.1.1 Study Treatment Discontinuation Criteria
â€¢All discontinuation criteria apply to nivolumab, ipilimumab, an d placebo given the blinded 
nature of the study. Treatment should be permanently discontinu ed for any of the following:
â€¢Any Grade 2 drug-related uveitis, eye pain or blurred vision th at does not respond to topical 
therapy and does not improve to Grade 1 severity within the re-t reatment period OR requires 
systemic treatment
â€¢Any Grade 3 non-skin, drug-related AE lasting > 7 days, or recur s with the following 
exceptions for laboratory abnormalities, diarrhea, colitis, neu rologic toxicity, drug-related 
uveitis, pneumonitis, bronchospasm, hypersensitivity reactions,  infusion r eactions, and 
endocrinopathies:
âˆ’Grade 3 drug-related diarrhea, colitis, neurologic toxicity, uv eitis, pneumonitis, 
bronchospasm, hypersensitivity reaction, or infusion r eaction of any duration requires 
discontinuation
âˆ’Grade 3 drug-related endocrinopathies, adequately controlled wit h only physiologic 
hormone replacement do not require discontinuation. 
âˆ’Grade 3 drug-related adrenal insufficiency requires discontinua tion . 
âˆ’Grade 3 drug-related laboratory a bnormalities do not require treatment discontinuation 
except:â™¦Grade 3 drug-related thrombocytopenia > 7 days or associated wi th bleeding requires 
discontinuation
â™¦Any drug-related liv er function test (LFT) abnormality that meet s the following criteria 
require discontinuation:
oGrade â‰¥3 drug-related AST, ALT or Total B ilirubin requires discontinua tion*
* In most cases of Grade 3 AST or ALT elevation, study d rug(s) w ill be 
permanently discontinued. If the investigator determines a poss ible favorable 
Protocol Amendment No.: 06
Date: 08-Dec-2022 77
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
benefit/risk ratio that warrant s continuation of study drug(s), a discussion between 
the investigator and the BMS Medical Monitor/designee must occu r.
oConcurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN
â€¢Any Grade 4 drug-related  AE or laboratory abnorm ality (including but not limited to 
creatinine, AST, ALT, or Total Bilirubin), requires discontinua tion 
â€¢Grade 4 drug-related adrenal in sufficiency or hypophysitis requ ires discontinuation 
â€¢The following Grade 4 events are exceptions and do not require d iscontinuation:
âˆ’Grade 4 neutropenia â‰¤7 days.
âˆ’Grade 4 lymphopenia or leukopenia or asymptomatic amylase or lipase.
âˆ’Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 72 hours 
of their onset.
âˆ’Grade 4 drug-related endocrinopathy AE, such as, hyper- or hypothyroidism, or glucose 
intolerance, which resolve or are adequately controlled with phy siologic hormone 
replacement (corticosteroids, thyroid hormones) or glucose-cont rolling agents, 
respectively, may not require discontinuation afte r discussion with an d approval from the 
BMS Medical Monitor or designee.
â€¢Any event that leads to delay in dosing lasting > 6 weeks from t he previous dose requires 
discontinuation, with the following exceptions:
âˆ’Dosing delays to allow for prolonged steroid tapers to manage drug-related AE are allowed.  
âˆ’Dosing delays lasting > 6 weeks from the previous dose that occu r for non-drug-related 
reasons may be allowed if approved by the BMS Medical Monitor or  designee.
â€¢Any AE, laboratory abnormality, or intercurrent illness which, in the  judgment of the 
Investigator, presents a substantial clinical risk to the parti cipant with continued nivolumab 
dosing.
Prior to re-initiating treatment in a participant with a dosing  delay lasting > 6 weeks, the BMS 
Medical Monitor or designee must be consulted. Tumor assessments  should continue per protocol 
schedule even if dosing is delayed. Periodic study visits to ass ess safety and laboratory studies 
should also continue every 4 weeks or more frequently if clinically indicated during such dosing 
delays.
Study treatment must be discontinued within 36 weeks after the first dose. Any cycles not given 
within 36 weeks after first dose will be omitted. 
8.1.2 Post Study Treatment Study Follow-up
In this study, DFS is a key endpoint of the study. Post study fo llow-up is of critical importance 
and is essential to preserving participant safety and the integ rity of the study. Participants who 
discontinue study treatment must continue to be followed for co llection of outcome and/or survival 
follow-up data as required and in line with Section 5 until death or the conclusion of the study.
Protocol Amendment No.: 06
Date: 08-Dec-2022 78
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
BMS may request that survival data be collected on all treated/ randomized participants outside of 
the protocol defined window (see Table 2-3). At the time of this request, each participant will be 
contacted to determine their survi val status unless the partici pant has withdrawn consent for all 
contacts or is lost to follow-up.
8.2 Discontinuation from the Study
Participants who request to discontinue study treatment will rem ain in the study and must continue 
to be followed for protocol sp ecified follow-up procedures. The  only exception to this is when a 
participant specifically withdraws consent for any further cont act with him/her or persons 
previously authorized by participant to provide this information . 
â€¢Participants should notify the investigator of the decision to withdraw consent from future 
follow-up in writing, whenever possible.
â€¢The withdrawal of consent should be explained in detail in the medical rec ords by the 
investigator, as to whether the withdrawal is from further trea tment with study treatment only 
or also from study proce dures and/or post treatment study follow-up, and entered on the  
appropriate CRF page.
â€¢In the event that vital status (whether the participant is aliv e or dead) is being measured, 
publicly available information s hould be used to determine vital status only as appropriately 
directed in accordance with local law.
â€¢If the participant withdraws consent for disclosure of future i nformation, the sponsor may 
retain and continue to use any data collected before such a wit hdrawal of consent.
8.3 Lost to Follow-Up
â€¢All reasonable efforts must be made to locate participants to d etermine and report their ongoing 
status. This include s follow-up with pers ons authorized by the participant.
â€¢Lost to follow-up is defined by the inability to reach the part icipant after a minimum of three
documented phone calls, faxe s, or emails as well as lack of response by participant to one 
registered mail letter. All attempts should be documented in th e participantâ€™s medical records.
â€¢If it is determined that the participant has died, the site will  use permissible local methods to 
obtain date and cause of death.
â€¢If investigatorâ€™s use of third-party representative to assist i n the follow- up portion of the study 
has been included in the participantâ€™s informed consent, then t he investigator may use a 
Sponsor retained third-party representative to assist site staf f with obtaining participantâ€™s 
contact information or other public vital s tatus data n ecessary to complete the follow-up 
portion of the study. 
â€¢The site staff and representative will consult publicly availab le sources, such as public h ealth 
registries and databases, in order to obtain updated contact in formation.
â€¢If after all attempts, the participant remains lost to follow-u p, then the last known alive date as 
determined by the investigator should be reported and documente d in the participantâ€™s medical 
records.
Protocol Amendment No.: 06
Date: 08-Dec-2022 79
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
9 STUDY ASSESSMENTS AND PROCEDURES
â€¢Study CT/MRI procedures and timing are summarized in the Section 9.1.2 .
â€¢Protocol waivers or exemptions are not allowed.
â€¢All immediate safety concerns must be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatment.
â€¢Adherence to the study design requirements, including those spe cified in the Schedule of 
Activities, is essential and required for study conduct.
â€¢All screening evaluations must be completed and reviewed to con firm that potential 
participants meet all eligibility criteria before randomization . The investigator will maintain a 
screening log to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, as applicable.
â€¢Procedures conducted as part of  the participantâ€™s routine clini cal management (eg, blood count) 
and obtained before signing of  informed consent may be utilized  for screening or baseline 
purposes provided the procedure meets the protocol-defined criteria and has been performed 
within the timeframe defined in the Schedule of Activities.
Additional measures, including non-study required laboratory te sts, should be performed as 
clinically ind icated or to comply with local regu lations. Laboratory toxicities (eg, suspected drug 
induced liver enzyme evaluations) will be monitored during the follow-up phase via  on site/local 
labs until all study drug related toxicities resolve, return to  baseline, or are deemed irreversible.
If a par ticipant shows pulmonary-r elated signs (hypoxia, fever) or symp toms (eg, dyspnea, cough, 
fever) consistent with possible pulmonary AE, the participant s hould be immediately evaluated to 
rule out pulmonary toxicity, according to the suspected pulmona ry toxicity management algorithm 
in the BMS-936558 (nivolumab) IB and in Appendix 6.
Some of the assessments referred to in this section may not be captured as data in the eCRF. They 
are intended to be used as safety monitoring by the treating ph ysician. Additional testing or 
assessments may be performed as clinically necessary  or where required by institutional or local 
regulations.
9.1 Efficacy Assessments
Study evaluations will take place i n accordance with the Schedu le of Activities in Section 2 .
9.1.1 Definitions of Recurrence
â€¢The primary endpoint of DFS is defined as time from randomizati on until death from any cause 
or recurrence of tumor as defined by either of the following:
â€¢Local disease recurrence refers to relapse of the primary tumor in -situ (site of original resected 
primary RCC tumor, eit her in the surgical bed of the resected kidney or in the residual kidney 
in partial nephrectomy) or occurrence of a secondary RCC primar y cancer
Protocol Amendment No.: 06
Date: 08-Dec-2022 80
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
â€¢Distant recurrence: any non-local m etastatic sites
â€¢The date of recurrence is defined as the date of the tumor asse ssment that demonstrated 
unequivocal recurrence. 
For participants wit h suspected diagnosis of secondary non-RCC primary tumor, the investigator 
should clearly document the tumor s ite(s). These events will no t be counted as an event under the 
primary study endpoint. 
9.1.2 Methods of Measurements
CT and MRI are an essential part of the work-up to establish re currence. Contrast-enhanced CT of 
the chest, abdomen, and pelvis s hould be performed. Images should be acquired with slice 
thickness of 5 mm or less with no intervening gap (contiguous).  
â€¢Should a participant have contraindication for CT intravenous c ontrast, a non-contrast CT of 
the chest and a contrast-enhanced MRI of the abdomen, pelvis, a nd other known/suspected 
sites of disease should be obtained.  
â€¢Should a participant have cont raindication for both MR and CT i ntravenous contrasts, a non-
c o n t r a s t  C T  o f  t h e  c h e s t  a n d  a  n o n - c o n t r a s t  M R I  o f  t h e  a b d o m e n ,  pelvis, and other 
known/suspected sites of disease should be obtained. 
â€¢Should a participant have cont raindication for MRI (eg, incompa tible pacemaker) in addition 
to contraindication to CT intravenous contrast, a non-contrast CT of the chest, abdomen, pelvis, 
and other known/suspected sites of disease is acceptable. 
â€¢Every attempt should be made to image each participant using an  identical acquisition protocol 
on the same scanner for all imaging time points. 
â€¢PET alone w ill not be consider ed adequate for the disease asses sment. Complementary CT 
and/or MRI or biopsy must be performed in such cases. 
Note: Use of CT component of a PET/CT scanner: Combined mod ality scanning, such as 
with FDG-PET/CT, is increasingly used in clinical care and is a m odality/ technology that 
is in rapid evolution; therefore, the recommendations outlined here may change rather 
quickly with time. At present, low-dose or attenuation c orrection CT portions of a 
combined FDG-PET/CT are of l imited use in anato mically-based efficacy assessments,
and it is, therefore, suggested that they should not be substitut ed for dedicated diagnostic 
contrast enhanced CT scans. However, if a site can document tha t the CT performed as part 
of a FDG-PET/CT is of identical diagnostic quality to a diagnos tic CT (with IV and oral 
contrast), then the CT portion of the FDG-PET/CT can be used. No te, however, that the 
FDG-PET portion of the CT introduces additional data which may bias an investigator if it 
is not routin ely or seri ally performed.
â€¢Histology or cytological evidence of recurrence should be attem pted in all cases except for 
brain metastases. Cytology and/or histology are mandatory to co nfirm recurrence in solitary or 
in equivocal lesions, any new lesions occurring in the kidney, and lymph nodes unless the 
lesion is too small to biopsy or the risk of biopsy is substant ial (eg, inter-aortal node with risk 
Protocol Amendment No.: 06
Date: 08-Dec-2022 81
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
of bleed after biopsy because of close proximity to the aorta an d IVC) in which case the 
recurrence must be confirmed with a repeat scan 4 weeks later. 
9.1.3 Imaging and Clinical Assessment 
9.1.3.1 Assessment of Baseline Disease-free Status
Screening/baseline imaging is to be performed greater than 4 we eks post-nephrectomy and 
submitted to the radiology vendor for BICR confirmation of dise ase-free status. Pre-nephrectomy 
images are also requested, if available.
Participant eligibility must be confirmed by BICR prior to rand omization, and randomization must 
occur within 12 weeks post-nephrectomy.
Therefore, sites are s trongly enc ouraged to submit pre-nephrecto my scans (if available) and 
baseline scans to BICR preferably prior to 8 weeks after the nep hrectomy to allow for return of 
the results from the BICR.9.1.3.2 Investigator Assessment of Recurrence 
The same method of assessment used at Screening s hould be used for on-study time points. 
Post-baseline assessments will be performed at the time points d escribed below until disease 
recurrence confirmed by BICR, death, o r withdrawal from the stud y. 
Timing for scans should be based on the date of first treatment, which is considered Week 1.
Tumor assessments for ongoing study treatment decisions will be  completed by the investigator.
1) First tumor assessm ent post-baseline s hould be performed at Week 23 ( Â±1 week). Use same 
imaging method as was used at screening/baseline.
2) Subsequent tumor assessments should occur at Weeks 36 and 52.  Allowable window for 
assessments is Â±1 week. After Week 52 (first year), tumor assessments s hould occur every 
6m o n t h s  ( Â±2 weeks) until Year 6 and then annually ( Â±2 weeks) for Year 6 to Year 10. 
3) Additional imaging of potential disease sites s hould be performed whenever disease recurrence 
or occurrence of a secondary malignancy is suspected. Brain CT or MRI with contrast or bone 
imaging during on-study treatment and follow-up periods should b e obtained if clinically 
indicated.
4) Tumor assessments can be discontinued when recurrence has bee n confirmed by BICR.  
General Considerations for Determining Recurrence:
1) The goal is to identify lesions suspicious for recurrence of RCC. If it is believed that a lesion 
is NOT malignant in nature (eg, infection, trauma ), it shoul d be noted in the med ical rec ords. 
The specified minimum size criteria s hould be combined with radiographic appearance 
consistent with recurrent tumor in the assessment of all suspicious lesions.
Protocol Amendment No.: 06
Date: 08-Dec-2022 82
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
2) Equivocal recurrence is upgraded to unequivocal recurrence (e xcept in cases of central nervous 
system [CNS] recurrence) by one or more of the following:
a) A subsequent scan not earlier than 4 weeks from the time when  recurrence was first 
suspected demonstrates that the lesion size is â‰¥ 5 mm over the si ze previously recorded, or 
the radiographic appearance of the lesion has become consistent  with tumor recurrence. If 
this occurs, the date of recurrence will be the date when the l esion was first suspected.
b) FDG PET demonstrates qualitative uptake consistent with malig nancy.
c) Positive histology/cytology.
3) Appearance of multiple new lesions in the same time point gene rally constitutes unequivocal 
recurrence, even though they may be from different organs (eg, one liver lesion, one lung 
lesion, and one enlarged lymph node).
The diagnosis by radiographic  recurrence of localized RCC or dis tant metastasis or occurrence of 
a secondary malignancy can be made only when the imaging finding s meet the acceptance criteria 
inTable 9.1.3.2-1 . Positive cytology or histology of a suspected lesion will als o confirm 
recurrence.
Table 9.1.3.2-1: Criteri a for Diagnosis of Radiographic Recurren ce
Anatomic Sites Criteria
Kidney1) Equivocal renal lesions include:
d) Equivocal secondary RCC primary tumor (eg, in contralateral k idney):
Any renal lesion measuring < 40 mm in LD or with radiographic appe arance 
equivocal for new primary RCC tumor noted by the reader.
e)Equivocal recurrent lesions:
Any new lesion of any size in the ipsilateral kidney (after partial nephrectomy) or 
nephrectomy bed (after radical nephrectomy).
2) Unequivocal renal lesions include:
a)Unequivocal secondary RCC primary tumor (eg, in contralateral  kidney):
One or more renal lesions measuring â‰¥ 40 mm in LD and with radiogr aphic 
appearance consistent with a new primary or recurrent tumor.
3) Unequivocal recurrent lesions:
a)Refer to the second bullet under the previous section, â€œGener al Considerations 
for Determining Recurrence.â€
Non-Nodal Soft 
Tissue (including visceral lesions)2) Equivocal lesions include:
b) Solitary lesion measuring â‰¤ 10 mm in LD or with radiographic 
appearance equivocal for tumor recurrence.
c) One or more lesions suggestive of intraperitoneal seeding/implants or port site 
recurrence (eg, in subjects who underwent prior laparoscopic or  robotic surgery).
4) Unequivocal lesions include:
One or more new lesions > 10 mm in LD with radiographic appearance  consistent 
with tumor recurrence (excluding intraperitoneal lesions).
Bone Lesions3) Equivocal lesions include:
a) Solitary lesion.
Protocol Amendment No.: 06
Date: 08-Dec-2022 83
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 9.1.3.2-1: Criteri a for Diagnosis of Radiographic Recurren ce
Anatomic Sites Criteria
b) Lesions identified on radionuclide bone scan. Findings on rad ionuclide bone scan 
must be confirmed by CT, MRI, or plain films in order to be upgraded to 
unequivocal.
5) Unequivocal lesions include:
Two or more new lesions consistent with tumor recurrence.
Lymph Nodesa4)Normal lymph nodes are defined as < 10 mm in the short-axis diame ter (SAD).
6) Equivocal lymph nodes include
a)Lymph nodes measuring 10 â€“ 14 mm SAD with radiographic appearance  
consistent with RCC recurrence.
b) Lymph nodes â‰¥ 15 mm SAD without radiographic appearance 
consistent with RCC recurrence.
7) Unequivocal proof of nodal recurrence includes:
One or more previously normal or equivocal lymph nodes that enl arge to â‰¥ 15 mm 
SAD and with radiographic appearance consistent with RCC recurr ence.
Fluid Collections
(eg, ascites, 
pleural/pericardial effusions)5) Presence of fluid alone, without pathological confirmation, does not constitute 
equivocal or unequivocal recurrence.
8) Unequivocal proof of recurrence is positive pathology of mali gnant cells from 
fluid(s).
CNSUnequivocal recurrence is defined as any new CNS lesion of any size on CT or MRI 
with a radiographic appearance consistent with tumor recurrence .
aFor lymph node with short axis 10-15 mm, consider biopsy when l ymph node is progressively enlarged as evidenced 
by 2 CT or MRI imagings separated by at least a 4-week interval .
9.1.3.3 BICR Assessment of Recurrence
Sites should submit all scans to a third-party vendor on a roll ing basis, preferably within 5 business 
days of scan acquisition throughout the duration of the study. When recurrence is diagnosed by 
the investigator per the criteria specified in Table 9.1.3.2-1 , the site will inform the radiol ogy 
vendor by indicating on the submission form that recurrence has  been identified, so that the BICR 
assessment of recurrence can be performed. Any relevant cytolog y/pathology results that support 
a diagnosis of recurrence should be promptly submitted to ICON Central Lab so they can be 
translated and de-identified before being sent to BICR. The BICR  review will be completed and 
the results provided to the s ame site with in 10 business days of r eceipt of the scans and any relevant 
cytology/pathological data, provided there are no pending imagi ng queries to the site. 
Participants whose recurrence is not confirmed by the BICR will be required to continue tumor 
assessments (if clinically feasible) according to the protocol- specified schedule or sooner if 
clinically indicated until the BICR confirms recurrence on a subsequent tumor assessment. 
If the investigator feels that the immediate initiation of subs equent therapy is clinically indicated 
and does not wish to wait for the results of the BICR, then the  decision to break the blind must be 
discussed with the BMS Medical Monitor or designee prior to doing so. When the blinding code 
Protocol Amendment No.: 06
Date: 08-Dec-2022 84
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
is broken, the reason must be fully documented in the site sour ce document. Please see Section 7.3
for additional information regarding unblinding. 
9.1.3.4 Date of Recurrence 
The first date when recurrence was observed should be taken into account regardless of the method 
of assessment. Please note the following general rules regarding the assessment of recurrence:
â€¢If recurrence is unequivocal (eg, multiple measurable lesions), confirmation with 
histology/cytology should be attempted, but not required.
â€¢If recurrence is equivocal (e g, lymph node only, so litary lesion, or in the kidneys), confirmation 
with histology/cytology must be attempted. If risk of biopsy is  too high or biopsy not feasible, 
either a follow-up CT or MRI scan showing progressive and measu rable disease or PET/CT 
demonstrating unequivo cal FDG uptake must c onfirm recurrence. I f confirmed, the date of 
initial scan showi ng recurrence will be recorded as the recurrence date.
â€¢Any pathological evidence of malignancy denotes recurrence (eve n if scans are equivocal or
not available).
â€¢If both pathology and imaging ar e available and meet the criter ia for recurrence, specified in
Table 9.1.3.2-1 , the date of recurrence is the date of which ever examination ca me first.
9.1.4 Imaging Restriction and Precautions
Table 9.1.4-1 provides a summary of the alternative methods, acceptable per protocol, in the event 
of contraindications for use of IV and oral contrast, and or/MRI . 
Table 9.1.4-1: Acceptable Imaging Assessment Methods for Different Anatomic 
Regions
Anatomic Region Preferred Method Alternative Methods
Chest, abdomen, and 
pelvisNote: Scan must cover 
lung apices to diaphragm, diaphragm through entire liver,and to below the pubic symphysisCT with IV 
contrastFor chest:
â€¢CT without contrast can be used only if the participant has a 
clinical contraindication for iodine-based IV contrast (eg, 
hypersensitivity, re nal insufficiency)
For abdomen and pelvis:
â€¢MRI with gadolinium-based IV contrast is the first alternative 
method if the participant has a clinical contraindication for iodine-based IV contrast
â€¢MRI without contrast can be used as the second alternative method only if the participant  has a clinical contraindication 
for both contrast-enhanced CT and MRI.
â€¢CT without contrast can be used as the third alternative 
method only if the participant  has a clinical contraindication 
for both contrast-enhanced CT and MRI.
BrainMRI with IV 
contrastâ€¢CT with IV contrast is the first alternative method if IV 
gadolinium is clinically contraindicated. 
Protocol Amendment No.: 06
Date: 08-Dec-2022 85
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 9.1.4-1: Acceptable Imaging Assessment Methods for Different Anatomic 
Regions
Anatomic Region Preferred Method Alternative Methods
â€¢MRI without contrast can be used as a second alternative 
method if a participant has clinical contraindications for both  
contrast-enhanced CT and MRI
Bone Bone scintigraphy PET (18F-fluoride NaF or FDG) and 99m Techneti um SPECT
Notes:
1. CT scans must be performed with slice thickness of â‰¤5 mm. The reconstruction inte rval should be equal to slice 
thickness to avoid gap. 
2. The same modality for a given anatomical coverage and the sa me scanning procedure (most importantly: 
reconstruction slice thickne ss, anatomic coverage, use of IV co ntrast) should be consistent between baseline and 
all subsequent follow-up scanning. If possible, the s ame sca nner or an equivalent scanners should be used 
throughout the study. 
3. For abdomen and pelvis CT scans, oral contrast is recommended as per institutional standards. 
4. MRI should include both T1 and T2-weighted sequences with T1 -weighted both and pre- and post-contrast. 
5. If bone scan shows hotspots indicative of metastases, furthe r investigation with X-ray, CT, or MRI is warranted. 
6. All scans generated should be exportable in electronic forma t (DICOM) to enable secure and rapid electronic 
transmission to the designated central imaging laboratory. 
The use of gadolinium-based contrast agents in participants wit h acute or chronic renal 
insufficiency, with a glomerular  filtration rate (GFR) less tha n 30 mL per minute per 1.73 m2or 
with any acute renal failure caused by hepatorenal syndrome or perioperative liver transplantation, 
is not recommended.
If gadolinium is contraindicated, proceed without contrast, but the reason for not using contrast 
must be documented. 
9.1.5 Outcomes Research Assessments 
The evaluation of patient-reported outcomes is an increasingly important aspect of clinical efficacy 
in oncology trials. Such data provide an understanding of the impact of treatment from the 
participantâ€™s perspective and offer insights into participant e xperience that may not be captured 
through physician reporting. Additionally, generic health-relat ed quality of life measures provide 
data needed for calculating utility values to i nform health economic models. Patient-re ported 
outcomes will be captured thr ough the use of 2 validated self-reported questionnaires: the N CCN 
Functional Assessment of Cancer Therapy - Kidney Symptom Index (FKSI-19) and the EuroQoL Groupâ€™s 3-level version of the EQ-5D (EQ-5D-3L). The questionna ires will be provided in the 
participantâ€™s preferred language and may be administered by tel ephone during follow-up visits 1 
and 2 and subsequent survival follow-up visits. All patient-repo rted outcome assessments should 
be completed prior to study-related procedures, if possible. The re exists a standardized guide that 
can be used to facilitate telephone administration of the EQ-5D -3L, though a similar guide does 
not exist for the FKSI-19. Participants will be provided with a hard copy of the latter scale to take home and use as a visual aid during telephone interviews.
Protocol Amendment No.: 06
Date: 08-Dec-2022 86
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
The NCCN FKSI-19 is a 19-item  scale that m easures tumor specifi c HrQoL in kidney cancer 
participants.52The symptom index questionnaire is broken into 4 subscales: dis ease-related 
symptoms-physical (DRS-P), disease-related symptoms-emotional ( DRS-E), treatment side-
effects (TSE), and general function and well-being (FWB). Addit ionally, a 9-item subset of 
disease-related symptoms knows as the FKSI-DRS will be examined . The FKSI-19 uses 5 Likert-
type response categories that range from â€œnot at allâ€ to â€œvery much.â€ Participants are asked to 
circle the response category that best characterizes their resp onse over the last 7 days on 19 items 
that include symptoms such as lack of energy, fatigue, appetite , coughing, shortness of breath, 
pain, nausea, and ability to work. The FKSI-19 uses a recall pe riod of the past 7 days.
The EQ-5D-3L is a standardized instrument used to measure self- reports of health status and 
functioning.53The instrumentâ€™s descriptive system consists of 5 dimensions: m obility, self-care, 
usual activities, pain/discomfort, and anxiety/depression. Each  dimension has 3 levels, reflecting 
"no health problems," "moderate health problems," and "extreme health problems." A dimension 
for which there are no problems is said to be at level 1, while  a dimension for which there are 
extreme problems is said to be at level 3. Thus, the vectors 11 111 and 33333 represent the best 
health state and the worst health s tate, respectively, desc ribed by the EQ-5D. Altogether, the 
instrument describes 35 = 243 h ealth s tates. Empirically derived weights can be applied to an 
individualâ€™s responses to the EQ-5D descriptive system to gener ate an index measuring the value 
to society of his or her current health. Such preference-weight ing systems have been developed 
for Japan, UK, US, Spain, Germany, and numerous  other populatio ns. In addition, the EQ-5D 
includes a visual analog scale that allows respondents to rate their own current  health on a 101-
point scale ranging from â€œbest imaginableâ€ to â€œworst imaginable â€ health. The EQ-5D is available 
for use in over 150 languages.
Table 2-2 and Table 2-3, provide i nformation regarding the timing of patient-reported outcomes 
assessments.
9.2 Adverse Events
The definitions of an AE or serious adverse event (SAE) can be found in Appendix 3 .
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally a uthorized repre sentative). 
The investigator and any designees are responsible for detectin g, documenting, and reporting 
events that meet the definition of an AE or SAE and remain resp onsible for following up AEs that 
are serious, considered related to the study treatment or the s tudy, or that caused the participant to 
discontinue before completing the study. 
Contacts for SAE reporting are specified in Appendix 3.
Immune-mediated adverse events are AEs consistent with an immun e-mediated mechanism or 
immune-mediated component for which non-inflammatory etiologies  (eg, infection or tumor 
progression) have been ruled out. IMAEs can include events with  an alternate etiology which were 
exacerbated by the induction of autoimmunity. I nformation suppo rting the assessment will be 
collected on the participantâ€™s CRF.
Protocol Amendment No.: 06
Date: 08-Dec-2022 87
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
9.2.1 Time Period and Frequency for Collecting AE and SAE Information
Non-serious AE Collection
The collection of non-serious AE information (with the exception  of non-serious AEs related to 
SARS-CoV-2 infection, which should begin co llection at the time of cons ent) should begin at 
initiation of study treatment until 100 days after the last dose at the time points specified in the 
Schedule of Activities ( Section 2 ). Non-serious AE informatio n should also be collected from the  
start of a placebo lead-in period or other observational period intended to establish a baseline status 
for the participants.
SAE Collection
Sections 5.6.1 and 5.6.2 in the IB represent the Reference Safety Information to determine 
expectedness of SAEs for expedited reporting. Following the part icipantâ€™s written consent to 
participate in the study, all SAEs, whether related or not rela ted to study drug, must be collected, 
including those thought to be associated with protocol-specifie d procedures.
All SAEs must be collected that occur during the Screening Phase  and within 100 days of 
discontinuation of dosing. If applicable, SAEs must be collecte d that relate to any later 
protocol-specified procedure (eg, a follow-up skin biopsy). For participants randomized/assigned 
to treatment a nd never treated with study drug, SAEs should be collected for 30 days from the date 
of randomization.The investigator must report any SAE that occurs after these ti me periods and that is believed to 
be related to study drug or protocol-specified procedure.
â€¢Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the appropriate section of the eCRF section.
â€¢All SAEs will be rec orded and reported to Sponsor or designee within 24 hours, as i ndicated 
in Appendix 3 . 
â€¢The investigator will submit any updated SAE data to the sponso r within 24 hours of this being 
available.
SARS-CoV-2 Infection-related AE Collection
All SAEs, and all AEs (SAEs and non-serious AEs) associated wit h confirmed or suspected 
SARS-CoV-2 infection must be collected from the d ate of the participantâ€™ s written consent until 
100 days following discontinuation of dosing.
Extended Collection of Study Treatment-related Non-Serious AEs
The time period for co llection for study tr eatment-related AEs is being extended to better 
characterize and understand late-onset AEs considered related t o study tr eatment. T his will provide 
important safety data in the adjuvant s etting and better understand the safet y prof ile. The collection 
of non-serious AEs considered related to the study treatment sh ould continue to be collected 
through S urvival Follow-up visits until approximately 1 year fo llowing discontinuation of study 
treatment. 
Protocol Amendment No.: 06
Date: 08-Dec-2022 88
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
However, if the non-serious AE has an onset date after 100 days since the last dose of study 
treatment and it occurs on or after the initiation of subsequent anti-cancer therapy, i t should not be 
reported.
Investigators are not obligated to actively seek AEs or SAEs in  former study participants. 
However, if the investigator learns of any SAE, including a dea th, at any time after a participant 
has been discharged from the study, and he/she considers the ev ent reasonably related to the study 
treatment or study participation, t he investigator must promptl y notify the sponsor.
The method of evaluating, and assessing caus ality of AEs and SAEs and the procedures for 
completing and reporting/transm itting SAE reports are provided i n Appendix 3 .
9.2.2 Method of Detecting AEs and SAEs
All non-serious AEs (not only those deemed to be treatment-relat ed) should be collected 
continuously during the tr eatment period a nd for a minimum of  100 days following discontinuation 
of study treatment.
Every adverse event must be assessed by the investigator with r egard to whether it is considered 
immune-mediated. For events which  are potentially immune-mediat ed, additional information will 
be collected on the participantâ€™s case report form.Adverse events can be spontan eously reported  or elicited  during open-ended questioning, 
examination, or evaluation of a participant. (In order to preve nt reporting bias, participants should 
not be questioned regarding the specific occurrence of one or more AEs.)
9.2.3 Follow-up of AEs and SAEs
â€¢Non-serious AEs should be followed to resolution or stabilizati on, or reported as SAEs if they 
become serious (see Appendix 3).
â€¢Follow-up is also required for non-serious AEs that cause inter ruption or discontinuation of 
study treatment and for those present at the end of study treat ment as appropriate.
â€¢ All identified non-serious AEs must be recorded and described o n the non-serious AE page of 
the CRF (paper or electronic). Completion of supplemental CRFs m ay be requested for AEs 
and/or laboratory abnormalities t hat are reported/identified du ring the course of the study.
After the initial AE/SAE report, the investigator is required t o proactively follow each participant 
at subsequent visits/contacts. All SAEs, and non-serious AEs of special interest (as defined in 
Section 9.2.1 ) and AEs (SAEs and non-serious AEs) associated with confirmed or  suspected
SARS-CoV-2 infection will be followed until resolution, until the  condition stabilizes, un til the 
event is otherwise explained, or until the participant is lost to follow-up (as defined in Section 8.3 )
or for suspected cases, until SARS-CoV-2 infection is ruled out.
After Follow-up visit 2 and through the survival follow-up phas e, all study treatm ent-related AEs 
(non-serious and SAEs) should be collected during the survival follow-up visits. However, if the 
non-serious AE has an onset date after 100 days since the last d ose of study treatment and it occurs
on or after the initiation of subsequent anti-cancer therapy, i t should not be re ported. After the 
initial AE/SAE re port, the investigator is required to proactively follow each p articipant at 
Protocol Amendment No.: 06
Date: 08-Dec-2022 89
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
subsequent visits/contacts. All AEs (SAEs and non-serious) cons idered related to study treatment 
will be followed until resolution, until the c ondition stabilizes, un til the event is otherwise 
explained, or until the participant is lost to follow-up (as de fined in Section 8.3 ).
Further informatio n on follow- up procedures is given in Appendix 3.
9.2.4 Regulatory Reporting Requirements for SAEs
â€¢Prompt notification by the investigator to the Sponsor of SAEs is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a 
product under clinical investigation are met.
â€¢An investigator who receives an i nvestigator safety report desc ribing SAEs or other sp ecific 
safety information (eg, su mmary  or listing of SAEs) from the S ponsor w ill file it along with 
the IB and will notify the IRB/IEC, if appropriate according to  local requirements.
Sponsor or designee w ill be reporting adverse events to regu latory authorities and ethics 
committees according to local applicable laws including Europea n Directive 2001/20/EC and FDA 
Code of Federal Regulations 21 CFR Parts 312 and 320. A SUSAR ( Suspected, Unexpected 
Serious Adverse Reaction) is a subset of SAEs and will be repor ted to the appropriate regulatory 
authorities and investigators following local and global  guidelines  and requirements.
9.2.5 Pregnancy
If, following initiation of the study treatment, it is subseque ntly discovered that a participant is 
pregnant or may have been pregnant at the time of study exposur e, including during at least 
5 half-lives after product administr ation, the investigator must immediately notify the BMS 
Medical Monitor/designee of this event and complete and forward  a Pregnancy Surveillance Form 
to BMS Designee within 24 hours of awareness of the event and in accordance with SAE reporting 
procedures described in Appendix 3.
In most cases, the study treatment will be permanently discontin ued in an appropriate manner (eg, 
dose tapering if necessary for participant safety). Please call the BMS Medical Monitor/designee
within 24 hours of awareness of the pregnancy.
Follow-up information regarding the course of the pregnancy, in cluding perinatal and neonatal 
outcome and, where applicable, offspring information must be re ported on the Pregnancy 
Surveillance Form.Note: The following paragraph is no longer applicable per Admini strative Letter 10. Any 
pregnancy that occurs in a female partner of a male study parti cipant should be reported to Sponsor 
or designee. In order for Spons or or designee to  collect any pregnancy surveillance information 
from the female partner, the female partner must sign an inform ed consent form for disclosure of 
this information. Information on th is pregnancy will be collect ed on the Pregnancy Surveillance 
Form.
Protocol Amendment No.: 06
Date: 08-Dec-2022 90
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
9.2.6 Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be ca ptured on the non-serious AE CRF 
page or SAE Report Form electronic, as appropriate. Paper forms are only intended as a back-up 
option when the electronic system is not functioning.
â€¢Any laboratory test result that is clinically significant or me ets the definition of an SAE 
â€¢Any laboratory test result abnormality that required the participant to have study treatment
discontinued or interrupted
â€¢Any laboratory test result abnormality that required the participant to receive specific corrective therapy
It is expected that wherever possible, the clinical rather than  laboratory term would be used by the 
reporting investigator (eg, anemia versus low hemoglobin value) .
9.2.7 Potential Drug Induced Liver Injury (DILI)
Wherever possible,  timely confirmation  of initial liver-rel ated laboratory  abnormalities s hould 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see Section 9.2 and Appendix 3  for reporting 
details).
Potential drug induced liver injury is defined as: 
1) AT (ALT or AST) elevation > 3 times upper limit of normal (UL N)
AND
2) Total bilirubin > 2 times ULN, without initial findings of ch olestasis (elevated serum alkaline 
phosphatase),
AND3) No other immediately apparent possible causes of AT elevation  and hyperbilirubinemia, 
including, but not limi ted to, viral hepatitis, pre-existing ch ronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
9.2.8 Other Safety Considerations
Any significant worsening noted during interim or final physica l examinations, electrocardiogram, 
x-ray filming, any other potential safety assessment required o r not required by protocol should 
also be recorded as a non-serious or serious AE, as appropriate , and reported accordingly.
9.2.9 Management Algorithms
Immuno-oncology (I-O) agents are associated with AEs that can d iffer in severity and duration 
than AEs caused by other therapeutic classes. Nivolumab is considered an immuno-oncology agent 
in this protocol. Early recognition and management of AEs assoc iated with immuno-oncology 
Protocol Amendment No.: 06
Date: 08-Dec-2022 91
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
agents may mitigate severe toxici ty. Management Algorithms have  been developed to assist 
investigators in assessing and managing the following groups of AEs:
â€¢Gastrointestinal
â€¢Renal
â€¢Pulmonary
â€¢Hepatic
â€¢Endocrinopathy
â€¢Skin
â€¢Neurological
â€¢Myocarditis
The above algorithms are found in the Nivolumab IB and in Appendix 6. 
9.3 Overdose
An overdose is defined as the accidental or intentional adminis tration of any dose of a product that 
is considered both excessive and medically important. All occur rences of overdose must be 
reported as an SAE (see Appendix 3 ).
9.4 Safety
Planned time points for all safety assessments are listed in the Schedule of Activities.
9.4.1 Clinical Safety Laboratory Assessments
Investigators must document their review of each laboratory saf ety report. See the Schedule of 
Activities for specific assessments and time points. 
9.4.2 Imaging Safety Assessment
Any incidental findings of potential clinical relevance that ar e not directly associated with the 
objectives of the protocol should be evaluated and handled by t he Study Investigator as per 
standard medical/clinical judgment. 
9.5 Pharmacokinetics
Samples for PK and immunogenicity assessments will be collected  for all participants as described 
in Table 9.5-1 . All time points are relative to the start of study drug admini stration. Placebo 
samples will not be analyzed. A ll on-treatment time points are i ntended to align with days on which 
study drug is administered. If it is known that a dose is going to be delayed, then the pre-dose 
sample should be collected just pri or to the delayed dose. Howe ver, if a pre-dose sample is 
collected but the dose is subsequently delayed, an additional p re-dose sample should not be 
collected. Further d etails of sample co llection, pro cessing, and shipment will be provided in the 
laboratory procedures manual. 
Blood samples s hould be drawn from a site other than the i nfusion site (ie, contralateral arm) on 
days of infusion. All samples collected pre-dose should be take n just prior to the administr ation 
from the contralateral arm (ie, the arm not used for the infusi on). If the infusion was interrupted, 
Protocol Amendment No.: 06
Date: 08-Dec-2022 92
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
the interruption details will also be documented on the CRF. Blo od samples will be processed to 
collect serum and stored according to the Laboratory Manual. 
Serum concentration analyses for nivolumab and/or ipilimumab wi ll be performed by validated 
immunoassay bioanalytical method(s) for nivolumab and ipilimuma b.
Samples collected from participants will be evaluated for the d evelopment of Anti-Drug Antibody 
(ADA) for nivolumab and/or ipilimumab by validated immunoassays . Samples with a positive 
ADA response may also be  analyzed for neutr alizing ADA response to nivolumab and/or 
ipilimumab. In addition, selected serum samples may be analyzed by an explo ratory method that measures 
nivolumab and ipilimumab, or detect anti-drug antibodies for te chnology exploration purposes; 
exploratory results will not be re ported. The corresponding serum samples designated for either 
PK, immunogenicity or biomarker assessments may also be used fo r any of those analyses, if 
required (eg, insufficient sample volume to complete testing or  to follow up on suspected 
immunogenicity related AE).
Protocol Amendment No.: 06
Date: 08-Dec-2022 93
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 9.5-1: Pharmacokinetic and Immunogenicity Sampling Schedul e for Nivolumab,  Ipilimumab 
and Placebo for all Study Parts and Arms
Study Daya
(1 Cycle = 2 
weeks)Event
(Relative 
to 
Dosing)
HourTime
(Relative To 
Dosing)
Hour: MinPharmacokinetic 
Blood Sample for 
Nivolumab/PlaceboImmunogenicity 
Blood Sample for 
Nivolumab/Placeb
oPharmacokinetic 
Blood Sample for 
Ipilimumab/Place
boImmunogenicity 
Blood Sample for 
Ipilimumab/Placebo
C1D1 Predoseb00:00 X X X X
C1D1(EOI-
PK)c 00:30 X X
C2D1 Predoseb00:00 X X X X
C5D1 Predoseb00:00 X X X X
C8D1 Predoseb00:00 X X X X
C11D1 Predoseb00:00 X X X X
Follow-up Samples 
(Follow-up 1 and Follow-up 2)- 30 and 100 days, respectively,from the last dose of study 
therapy (see 
Table 2-3 for 
additional details)NA NA X X X X
aIf a participant discontinues study drug treatment during the sa mpling period, they will move to sampling at the  follow-up visi ts.
bPredose: All predose samples for nivolumab (or placebo) and ipilimumab (or placebo) should be taken prior to the start of nivolumab (or placebo) i nfusion. It is 
acceptable to obtain predose samples with routine lab work if done on the same day as the infusion, provided accurate collection time is indicated for the sample. 
Protocol Amendment No.: 06
Date: 08-Dec-2022 94
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
If it is known that a dose is going to be delayed, then the pre dose sample should be collected just pri or to the d elayed dose. However, if a predose sample is 
collected but the dose is subsequently delayed, an additional p redose sample should not be collected.
c EOI-nivo and EOI-ipi: End of Infusion samples for nivolumab an d ipilimumab, respectively . EOI-PK collection instructions apply to the placebo arm as well.
. Since the end of infusion-PK (EOI-PK) sample is drawn with the  intent of accurately estimating the maximum concentration (Cma x) of the drug, draw the EOI-PK 
for both nivolumab and ipilimumab when all of the ipilimumab st udy drug (which is administered  after nivolumab) has been infus ed. If the site infuses drug 
without a flush, then collect the EOI-PK samples within approxi mately 5 minutes after end of infusion of ipilimumab. If a subsequent flush is administered to 
clear the IV lines of ipilimumab and to ensure delivery of the entire drug dose, then draw the EOI-PK sample within approximate ly 5 minutes after end of the 
flush. 
Do not draw EOI samples from the same IV access that the drug was administered.
Protocol Amendment No.: 06
Date: 08-Dec-2022 95
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
9.6 Pharmacodynamics
Refer to Section 9.8.
9.7 PharmacogenomicsRefer to Section 9.8.
9.8 Biomarkers
A variety of factors that could potentially predict clinical response and incidence of AEs to 
nivolumab + ipilumimab combined therapy and/or nivolumab monother apy will be investigated in 
peripheral blood and in tumor specimens taken from all particip ants prior to treatment and as 
outlined in the protocol. Data from these investigations will b e evaluated for associations with 
efficacy endpoints. In addition, these analyses will provide th e necessary data to identify and 
validate biomarkers with predictive versus prognostic value. Th e biomarker-sampling schedule for 
this study is provided in Table 9.8-1 . A separate manual outlining details of biomarker sample 
collection and handling will be provided to participating sites .
Table 9.8-1: Biomarker Sampling Schedule for Nivolumab, Ipilimum ab, and 
Placebo for All Study Parts and Arms
Study Day
(1 Cycle = 2 Weeks)Event
(Relative to 
Dosing)
HouraTumo
r 
BiopsyWhol
e 
Blood 
DNAPeriphera
l 
Blood 
RNAbMDS
CSerumbctDNA
cAnti-
SARS-
CoV-2
serolo
gyd
Screening X
C1D1 Predose X X X X X X
C2D1 Predose X
C4D1 Predose X
C5D1 Predose X
C7D1 Predose X X
C9D1 Predose X
C12D1 Predose X
Follow-up Visit 2 X
AE, adverse event; ctDNA, circulating tumor DNA; C, cycle; D, day; MDSC, myeloid-derived suppre ssor cells ; SAE, 
serious adverse event; SARS-CoV-2, severe acute respiratory syn drome coronavirus 2
aBaseline tumor samples are mandatory and an optional tumor sampl e will be collected upon recurrence.
bSample collection upon > Grade 3 non-laboratory drug-related AE and/or laboratory a bnormalities regarded as a 
drug-related SAE, to be collected when clinically safe and feas ible.
cSubsequent ctDNA sample collections will be aligned with tumor assessments performed on Weeks 23, 36, and 52 
(+/- 1 week window). If a tumor assessment is not performed, ctD NA sampling is not required.
dA sample is also collected approximately 4 weeks after a suspec ted or confirmed SARS-CoV-2 infection to be used 
for potential future measurements of anti-SARS-CoV-2 serol ogy (anti-SARS-CoV-2 total or immunoglobulin G 
(IgG)
Protocol Amendment No.: 06
Date: 08-Dec-2022 96
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
9.8.1 Additional Research Collection
This protocol will include residual sample storage for addition al research (AR).
For All US sites:
Additional research is mandatory for all investigational sites i n the US.
For non-US SitesAdditional research is optional for all study participants, exc ept where retention and/or collection 
is prohibited by local laws or regulations, ethics committees, or institutional requirements. 
This collection for additional research is intended to expand th e translational R&D capability at 
Bristol-Myers Squibb, and will s upport as yet undefined research aims that will advance our 
understanding of disease and options for treatment. It may also be used  
 for analysis, and advancement of pharmacodiagnostic development to better target drugs 
to the right patients. This may also include genetic/genomic ex ploration aimed at exploring disease 
pathways, progression and response to treatment etc. 
Sample Collection and Storage
All requests for access to samples or data for additional resea rch will be vetted through a diverse 
committee of the study sponsorâ€™s senior leaders in Research and Development (or designee) to 
ensure the research supports appropriate and well-defined scien tific research activities.
â€¢Residual DNA from whole blood, serum, circulating tum or DNA (ctDNA), peripheral blood 
RNA, and DNA and RNA from tumor biopsy tissue, (see Table 9.8.1-1 ) will also be retained 
for additional research purposes
Samples kept for future research will be stored at  
an independent, BMS-approved storage vendor.
The manager of these samples will ensure they are properly used  throughout their usable life and 
will destroy the samples at the end of the scheduled storage pe riod, no longer than fifteen (15) years 
after the end of the study or t he maximum allo wed by applicable law.
Transfers of samples by research sponsor to third parties will be subject to the recipientâ€™s 
agreement to establish similar storage procedures.
Samples will be stored in a coded fashion, and no researcher will have access to the key. The key 
is securely held by the Investigator at the clinical site, so t here is no direct ability for a researcher 
to connect a sample to a specific individual.
Further details of sample collection and processing w ill be provided to the site in the procedure
manual.
A variety of factors that could potentially predict clinical response and incidence of AEs to 
nivolumab and ipilimumab will be investigated in peripheral blo od and in tumor specimens taken 
Protocol Amendment No.: 06
Date: 08-Dec-2022 97
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
from all participants prior to ra ndomization. Data from these investigations w ill be evalu ated for 
associations with DFS, OS, and distant metastasis-free survival  and/or safety (adverse event) data. 
In addition, analyses of markers between the 2 treatment arms w ill provide the n ecessary data to 
identify and validate biomarkers with predictive vs prognostic value. All samples collected may 
also be used for future exploratory analyses (unless restricted  by local requirements and/or 
institutional policies) to assess biomarkers associated with RC C or immunotherapy treatment. 
Complete inst ructions on the collection, processing, handling a nd shipment of all samples 
described herein will be provided in a separate procedure manua l.
Table 9.8.1-1: Residual Sample Retention for Additional 
Research Schedule
Sample Type Timepoints for which residual samples will be retaine d
Whole blood (DNA) All
Serum All
ctDNA All
Peripheral Blood 
RNAAll
Tumor Biopsy (DNA 
and RNA)Screening and recurrence
9.8.2 Tissue Specimens
Sufficient tumor tissue specimen s collected withi n 3 months prio r to enrollment, preferably at the 
time of nephrectomy, will be required in the form of a FFPE tiss ue block or 20 unstained slides. A 
minimum of 10 slides will be acceptable if tumor tissue is limi ted. In these situations, it is 
recommended to consult with the protocol team to discuss the sp ecifics of the case.
The tumor sample may be used to assess putative predictive biom arkers of nivolumab and 
ipilimumab efficacy and/or to better characterize the tumor-imm une microenvironment. Various 
molecular markers with potential predictive value for the treat ment of RCC with nivolumab, 
ipilimumab and other immunotherapies are currently under invest igation and may be assessed in 
this study. These tumor tissue biomarkers include, but are not limited to PD-L1, PD-1, PD-L2, 
TILs or subpopulations of TILs, a Th1 immune mRNA expression sig nature. In addition, tumor 
samples will also be used for assessment of tumor recurrence sc ore based on gene signature 
analysis.54These tumor samples may also be used to further characterize the  tumor-immune 
microenvironment through assessment of markers that may be asso ciated with the efficacy of 
nivolumab and ipilimumab, including but not limited to other T cell checkpoint r eceptors and 
ligands (eg, Lag-3, Tim-3), and intratumoral immune cell subset s, including macrophages, natural 
killer (NK) cells and B cells.
In addition, it is recommended, although optional, for tumor tis sue samples to be collected upon 
recurrence. These samples may be used for the assessment of mark ers implicated in resistance to 
immunotherapeutic agents, includi ng but not limited to other T- cell checkpoint r eceptors and 
Protocol Amendment No.: 06
Date: 08-Dec-2022 98
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
ligands (eg, Lag-3, Tim-3) and intratumoral immune cell subsets , including but not limited to, 
T-regulatory cells and myeloid derived suppressor cells. These samples may also be used to 
investigate the effect of nivolumab and ipilimumab on the expre ssion of potentially relevant 
predictive and/or prognostic RCC bio markers. Both the nephrectomy tumor sample and the sample 
collected upon recurrence may be retrospectively assessed for th e expression of other 
immune-related genes, RNAs and/or proteins, or for the presence  of immune cell populations using 
a variety of methodologies inclusive of, but not limited to IHC , qRT-PCR, genetic mutation 
detection and fluorescent in-situ hybridization (FISH).
9.8.3 Exploratory Serum Biomarkers
Blood samples for exploratory serum biomarker analyses will be drawn at the time points specified 
in Table 2-2 and Table 2-3. Additionally, serum samples will be collected when clinically s afe and 
feasible, upon occurrence of a â‰¥ Grade 3 drug-related AE and/or  any lab abnormality regarded as 
a drug-related SAE, and upon recurre nce. Blood samples will be collected and processed for serum 
and then put in frozen storage. Serum samples may be assessed b y ELISA, seromics, microRNA 
profiling, ct DNA measur ements, metabolomics and/or other releva nt multiplex-based protein 
assay methods for immune or RCC-related f actors that w ill pred ict for nivolumab or ipilimumab 
benefit or correlate with nivolumab or ipilimumab-related AEs. Numerous potential serum-based 
biomarkers are currently under investigation for their potentia l to predict or c orrelate with safety 
or efficacy to nivolumab, ipilimumab or other immunotherapies, including but not limited to levels 
of soluble PD-L1, anti-tumor antibodies, cytokines, chemokines,  inflammatory factors, NKG2D 
ligands (eg, soluble MICA), ctDNA, and microRNAs (such as, but not limited to, miR-513 and 
miR19b).
9.8.4 Peripheral Blood RNA
Gene expression analyses of RNA derived from whole blood may pr ovide information on the 
broad effects of nivolumab and ipilimumab on immune modulation.  Thus, genomic e xpression 
patterns of whole blood collected at the time points in specifi ed in Table 2-2 and Table 2-3 may 
be assessed by Affymetrix microarray profiling, qRT-PCR or othe r gene expression profiling 
technology, with a particular emphasis on genes with relevant i mmune function. 
9.8.5 Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells (MDSCs) are an immune cell popu lation capable of suppressing 
T cell activation and proliferation. MDSCs will be measured at b aseline and on-treatment as 
described in Table 9.8-1 to assess pharmacodynamic changes or associations with outcome.  
9.8.6 Peripheral Blood DNA Mutation Research
The presence of cell-free DNA in circulating peripheral blood i s a well-docum ented phenomenon. 
Fragments of DNA are shed into the blood stream from proliferating cells or from cells undergoing
apoptosis or other forms of cell death. In patients with cancer , a fraction of this DNA is tumor-
derived and is termed ctDNA. Small fragments of DNA, averaging between 180 to 200 base-pairs 
and representing segments of specific genes, can be amplified w ith PCR and then sequenced. 
Moreover, several studies have detected mutations in ctDNA that  exactly correspond to mutations 
Protocol Amendment No.: 06
Date: 08-Dec-2022 99
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
from the parent tumor, using tissue and plasma from participants with  known driver mutations in 
melanoma or head and neck cancer. Beaming technology may be uti lized to count the frequency 
of mutations in the circulation. Correlation analyses with tumo r will be warranted where the data 
are available. ctDNA will be inve stigated as a prognostic and pr edictive biomarker and will be 
used to monitor changes in tumor mutations during treatment.
9.8.7 Whole Blood for Genotyping
Whole blood samples for exploratory pharmacogenetic assessment will be collected from all 
participants. Genomic DNA will be  extracted and subsequently as sessed for SNPs and other 
genetic variations in candidate genes that may predispose parti cipants to nivolumab or ipilimumab 
benefit or AEs (unless restricted by local requirements.) Such g enes include, but are not limited 
to, PD-1, PD-L1, PD-L2 and CTLA-4. Additional use of these data  may include correlative 
analyses aimed at identifying genotypic associations with clini cally relevant biomarkers identified 
by other methodologies described in this section. This sample ma y be assessed for whole exome 
sequencing (WES) and rearrangements in the TCR in T cells within  the peripheral blood. WES is 
an efficient way to identify genetic variants that alter protei n sequences. An assessment of somatic 
TCR rearrangements by PCR, sequencing or NextGen sequencing app roach will provide 
information regarding the clonali ty of a T cell repertoire, whi ch may change with nivolumab and/or 
ipilimumab tr eatment. In addition, bas eline T cell repertoire may be predictive of nivolumab and/or 
ipilimumab benefit.
9.8.8 Immunogenicity Assessments 
Blood samples for immunogenicity analysis will be collected. Sa mples collected from participants 
receiving nivolumab and/or ipilimumab will be evaluated for dev elopment of Anti-Drug Antibody 
(ADA) by a validated electrochemiluminescent (ECL) immunoassays .
Samples may also be analyzed for neutralizing antibodies and PK  samples (please refer to Table 
9.5-1 for immunogenicity sampling schedule) may be used for ADA analysis in the event of 
insufficient volume, to complete immunogenicity assessment, or to follow up on suspected 
immunogenicity-related AEs.
Further details of sample co llection, processing, and shipment w ill be provided in the laboratory 
procedures manual.
9.8.9 Other Assessments
Serum will be co llected for potential future measurements of anti-SARS-CoV-2 an tibodies by 
serology (anti-SARS-CoV-2 total or immunoglobulin G [IgG]) to exp lore potential association 
with safety, efficacy, and/or immune biomarkers.
9.9 Health Economics OR Medical Resource Utilization and Health 
Economics
Health Economics/Medical Resour ce Utilization and Health Econom ics parameters w ill not be 
evaluated in this study.
Protocol Amendment No.: 06
Date: 08-Dec-2022 100
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
10 STATISTICAL CONSIDERATIONS
10.1 Sample Size Determination 
The modification to the study design outlined in revprot03 adds a monotherapy arm (nivolumab) 
and roughly doubles the total sample size with the first approx imately 800 rando mized 1:1 
participants (Part A) to nivolumab + ipilimumab and placebo and t he approximately 
800 randomized 1:1:2 participants (Par t B) to nivolumab + ipilimum ab, placebo and nivolumab. 
Part A participants will be mutually exclusive from Part B parti cipants. The combination analysis 
in Part A is preserved comparing the nivolumab + ipilimumab arm  to the placebo arm in the first 
approximately 800 nivolumab + ipilimumab and placebo randomized  1:1 participants. Part B is 
added for the purposes 1) to compare monotherapy nivolumab to p lacebo and 2) to estimate the 
contribution of components for the combination of nivolumab + i pilimumab and monotherapy 
nivolumab.
This section is organized as follows. First, sample size calcul ations for Part A are presented. 
Second, the samp le size calculations for Part B are presented. The Part B monotherapy comparison 
is between the nivolumab (approximately 400 participants) and p lacebo (approximately 200 
participants) arms. The additional approximately 200 participan ts randomized to the nivolumab + 
ipilimumab arm in Part B will be included in the combination OS  analysis hierarchically if the 
DFS monotherapy test is successful (for more details, see Section 10.3.4 ). In addition, these 
nivolumab + ipilimumab Part B participants w ill be compared to the nivolumab participants to 
assess the contribution of components (CoC), i.e. to directly e stimate the ha zard ratio and variance 
for the contemporaneously randomized nivolumab + ipilimumab ver sus nivolumab arms.
10.1.1 Part A: Combination Comparison of DFS
The combination comparison sample size is driven by the compari son of DFS between participants 
randomized to receive nivolumab + ipilimumab versus pl acebo. Approximately 800 participants 
will be randomized to the nivolu mab + ipilimumab and placebo tr eatment arms in a 1:1 ratio with 
DFS medians of 111 and 72 months, respectively, rendering a 62- month study. Note the invocation 
of revprot03 w ill init iate the 1:1:2 (i.e. nivolumab + ipilimumab, placebo, nivolumab) 
randomizatio n (see next section on Monotherapy Compari son of DFS). 
Approximately 232 events among the approximately 800 contempora neously randomized 1:1 
participants are expected, ensuring 90% power to detect an average hazard ratio of 0.65 with an 
overall type I error of 0.05 (two-side d). The  number of events and power were calculated assuming 
an exponential distribution and a delayed treatment effect of 3  months. This design yields a 
minimal HR of 0.764 (P<0.041) when adjusting for interim analyse s using Lan-DeMets alpha 
spending function.
Given accrual rates of 22 participants per month on average for  the entire enrollment peri od, it is 
estimated that accrual of 800 participants (ie, 400 participant s in each arm) will take approximately 
36 months; it will take an additional approximately  26 months t o observe the required number of 
events for the final DFS analysis.
Protocol Amendment No.: 06
Date: 08-Dec-2022 101
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
There is 1 planned interim analysis of DFS. Stopping boundaries at the interim analyses will be 
derived based on the exact number of events using Lan-DeMets al pha spending function with 
Oâ€™Brien-Fleming boundaries. The DFS interim analysis is expecte d to occur at approximately 
56 months when approximately 204 events are expected to have occurred. This will provide 83% power to detect an overall interim DFS HR of 0.743 (P<0.034) at the pre-specified alpha level 
using the Lan-DeMets alpha spending function.
In the event that Part B enrollment is still ongoing at the time of observing the required number of 
events for the interim analysis and target number of events nee ded for the final analysis is projected 
in a shorter time interval (approximately within 4 months), then  the interim analysis of DFS will
not be performed and only one final analysis of DFS will be c onducted after observing 
approximately 227 DFS events (required number of events since there is no alpha spending for DFS interim analysis) among all ra ndomized particip ants. The 227 events are expected to provide 
90% power to detect a DFS HR of 0.65 at alpha 0.05 (two-sided).
Table 10.1.1-1 summarizes sample size design parameters and schedule of primar y endpoint 
analysis accounting for an interim and final analyses.
Table 10.1.1-1: Part A Summary of Samp le Size Parameters and Sche dule of 
Combination Analyses (with an Interim Analysis)
Primary Endpoint DFS
Primary analysis population All Randomized Participants
Accrual rate per month 22
Power 90%
Alpha0.05 2-sided (0.034 at interim analysis, 
0.041 at FA)
Hypothesized Median Control vs Experimental (Months) 72 vs 111
Hypothesize d Hazard Ratio 0.65
Critical HR (HR at which a statistically significant difference  would 
be observed) / Difference in median corresponding to a minimally 
significant effect size (Months)0.764 /  22 
Critical HR at interim analysis / Effect size (Months) 0.743 / 25
Expected events for interim analysis (percentage of target event s) 204 (88%)
Timing of interim analysis from FPFV (Months) 56
Accrual Duration (Months) 36
Timing of final analysis (FA) from FPFV (Months) 62
Sample sizea800
Target number of events (Event Goal) 232
aEast version 5.4 was used for sample size / power computation
Protocol Amendment No.: 06
Date: 08-Dec-2022 102
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 10.1.1-2 summarizes sample size design parameters and schedule of primar y endpoint
analysis with one final analysis alone.
Table 10.1.1-2: Part A Summary of S ample Size Parameters and Sch edule of 
Combination Analysis (without an Interim Analysis)
Primary Endpoint DFS
Primary analysis population All Randomized Participants
Accrual rate per month 22
Power 90%
Alpha 0.05 
Hypothesized Median Control vs Experimental (Months) 72 vs 111
Hypothesize d Hazard Ratio 0.65
Critical HR (HR at which a statistically significant difference  would 
be observed) / Difference in median corresponding to a minimally 
significant effect size (Months)0.771 / 21.4
Accrual Duration (Months) 36
Timing of final analysis (FA) from FPFV (Months) 61
Sample sizea800
Target number of events (Event Goal) 227
aEast version 5.4 was used for sample size / power computation
10.1.2 Part B: Monotherapy Comparison of DFS
The monotherapy comparison sample size is driven by the compari son of DFS between 
participants randomized to receive nivolumab versus pl acebo. A pproximately 600 par ticipants will 
be randomized to the nivolumab and placebo treatment arms in a 2:1 ratio (i.e. as part of the 1:1:2
ratio to nivolumab + ip ilimumab, placebo, nivolumab) with DFS medians of 106 and 72 months, 
respectively, for a total acc rual of approximately 56 months (2 0 additional months from the end of 
the combo test accrual).
Approximately 91 additional events are expected in the nivoluma b arm for a total of 153 events 
among the 600 participants, ensuring 60% power to detect an ave rage hazard ratio of 0.68 with an 
overall type I error of 0 .05 (two-sid ed). Note that since the P art B participants are mutually 
exclusive from Part A participants no hierarch ical testing for the primary endpoint is necessary 
(for more details, see Section 10.3.4 ). The number of events and power were calculated assuming 
an exponential distribution and a delayed treatment effect of 3  months. This design yields a 
minimal HR of 0.71 (P<0.043) when a djusting for interim analyses  using Lan-DeMets alpha 
spending function.Given accrual rates of 40 participants per month on average for  the entire monotherapy enrollment 
period (1:1:2, thus 30 per month for only the monotherapy and p lacebo arms), it i s estimated that 
Protocol Amendment No.: 06
Date: 08-Dec-2022 103
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
accrual of 600 participants (i.e., 400 participants to the nivo lumab arm and 200 to the placebo arm) 
will take approximately 20 months; it will take an additional ap proximately 28 months (84 months 
from study initiation) to observe the required number of events  for the final monotherapy DFS 
analysis.
There is 1 planned interim monotherapy analysis of DFS. Stopping  boundaries at the interim 
monotherapy analysis will be derived based on the exact number of events using Lan-DeMets 
alpha spending function with Oâ€™Brien-Fleming boundaries. The DFS interim monotherapy 
analysis is expected  to occur at approx imately 76 months when approximately 122 events in the 
monotherapy and contemporaneous placebo arms are expected to have occurred. This will provide 
40% power to detect an overall interim DFS HR of 0.65 (p<0.025)  at the pre-specified alpha level 
using the Lan-DeMets alpha spending function.
In the event that the target number of events for the interim a nalysis and final analysis are projected 
in a shorter time interval (approximately within 6 months), the n the interim analysis of DFS will 
not be performed and only one final analysis of DFS will be con ducted after observing 
approximately 149 DFS events among the randomized participants in the nivolumab and placebo 
arms (required number of events since there is no alpha spendin g for DFS interim analysis). The 
149 events are expected  to provide  60% power to detect a DFS HR  of 0.68 at alpha 0.05 (two-
sided).
Table 10.1.2-1 summarizes sample size design parameters and schedule of primar y endpoint 
analyses planned in this study.
Table 10.1.2-1: Part B Summary of Sample Size Parameters and Sch edule of 
Monotherapy Analyses (with an Interim Analysis)
Primary Endpoint DFS
Primary analysis populationAll Randomized Participants in 
Nivolumab and Placebo Arms
Accrual rate per month 40 (or 30 2:1 to N and P)
Power 60%
Alpha0.05 2-sided (0.025 at mono interim 
analysis and 0.043 at mono final 
analysis)
Hypothesized Median Control vs Experimental (Months) 72 vs 106
Hypothesize d Hazard Ratio 0.68
Critical HR (HR at which a statistically significant difference  would 
be observed) / Difference in median corresponding to a minimally 
significant effect size (Months)0.71 / 29 
Critical HR at mono interim analysis / Effect size (Months) 0.65 / 39
Expected events for mono interim analysis (percentage of target 
events)122 (80%)
Timing of mono interim analysis from FPFV (Months) 76
Protocol Amendment No.: 06
Date: 08-Dec-2022 104
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 10.1.2-1: Part B Summary of Sample Size Parameters and Schedule of 
Monotherapy Analyses (with an Interim Analysis)
Primary Endpoint DFS
Accrual Duration (Months) 20
Timing of final analysis (FA for mono) from FPFV (Months) 84
Sample sizea600
Target number of events (Event Goal) 153
aEast version 5.4 was used for sample size / power computation
Table 10.1.2-2 summarizes sample size design parameters and schedule of primar y endpoint 
analysis with one final analysis alone.
Table 10.1.2-2: Part B Summary of Sample Size Parameters and Schedule of 
Monotherapy Analyses (without an Interim Analysis)
Primary Endpoint DFS
Primary analysis populationAll Randomized Participants in
Nivolumab and Placebo Arms
Accrual rate per month 40 (or 30 2:1 to N and P)
Power 60%
Alpha 0.05 2-sided
Hypothesized Median Control vs Experimental (Months) 72 vs 106
Hypothesize d Hazard Ratio 0.68
Critical HR (HR at which a statistically significant difference  would 
be observed) / Difference in median corresponding to a minimally 
significant effect size (Months)0.71 / 29 
Accrual Duration (Months) 20
Timing of final analysis (FA for mono) from FPFV (Months) 84
Sample sizea600
Target number of events (Event Goal) 149
aEast version 5.4 was used for sample size / power computation
Protocol Amendment No.: 06
Date: 08-Dec-2022 105
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
10.1.3 Contribution of Components Analysis of DFS:
The contribution of components (CoC) w ill be assessed. The manner in which CoC will be 
measured is based on the hazard ratio and variance estimates co mputed for the contemporaneously 
randomized (approximately 200 vs 400) nivolumab + ipilimumab arm versus the nivolumab arm.
10.2 Populations for Analyses
For purposes of analysis, the following populations are defined :
Population Description
All enrolled participants â€¢All participants who signed an informed consent form and were registered 
into the IRT.
All enrolled Part A participants â€¢All Part A participants who signed an informed consent form and  were 
registered into the IRT.
All enrolled Part B participants â€¢All Part B participants who signed an informed consent form and were 
registered into the IRT.
All treated participants â€¢All participants who received at least 1 dose of study drug.
All treated Part A participants â€¢All Part A participants who received at least 1 dose of study d rug. This is 
the primary dataset for the Part A drug exposure and safety ana lysis.
All treated Part B participants â€¢All Part B participants who received at least 1 dose of study d rug. This is 
the primary dataset for the Part B drug exposure and safety ana lysis.
All randomized participants â€¢All participants who were randomized to any treatment arm in th e study. 
This population is considered the population for the combinatio n overall 
survival analysis contingent on the primary DFS monotherapy ana lysis (for 
more details, see Section 10.3.4 ). 
All randomized Part A 
participantsâ€¢All Part A participants who were randomized to any treatment ar m in the 
study. This population is considered  for Part A as the primary e fficacy 
analysis population. Analysis of demogra phy, protocol deviations, baseline 
characteristics, e fficacy analysis and outcome research analysi s will be 
performed in this population.
All randomized Part B participantsâ€¢All Part B participants who were randomized to any treatment ar m in the 
study. This population is considered for Part B as the primary e fficacy 
analysis population. Analysis of demography, protocol deviations, baseline 
characteristics, e fficacy analysis and outcome research analysi s will be 
performed in this population.
PK participants â€¢All randomized participants with available serum time-concentra tion data.
PK Part A participants â€¢All Part A randomized participants with available serum time-concentration data.
PK Part B participants â€¢All Part B randomized participants with available serum time-concentration data.
Immunogenicity Evaluable 
Participants â€¢Nivolumab ADA Evaluable Participants: all treated participants with 
baseline and at least 1 post-baseline pre-infusion nivolumab 
immunogenicity assessment. 
â€¢Ipilimumab ADA Evaluable Participants: all treated participants  w i t h  
baseline and at least 1 post-baseline pre-infusion ipilimumab immunogenicity assessment. 
Protocol Amendment No.: 06
Date: 08-Dec-2022 106
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Population Description
Immunogenicity Part A 
Evaluable Participants â€¢Nivolumab ADA Part A Evaluable Participants: all Part A treated  
participants with baseline and at least 1 post-baseline pre-infu sion
nivolumab immunogenicity assessment. 
â€¢Ipilimumab ADA Part A Evaluable Participants: all Part A treate d 
participants with baseline and at least 1 post-baseline pre-infus ion
ipilimumab immunogenicity assessment. 
Immunogenicity Part B 
Evaluable Participants â€¢Nivolumab ADA Part B Evaluable Participants: all Part B treated  
participants with baseline and at least 1 post-baseline pre-infu sion
nivolumab immunogenicity assessment. 
â€¢Ipilimumab ADA Part B Evaluable Par ticipants: all Part B treated 
participants with baseline and at least 1 post-baseline pre-infu sion
ipilimumab immunogenicity assessment. 
Biomarker participants: All randomized participants with availab le biomarker data (PD-L1 expression 
status and other assays).
Biomarker Part A participants: All Part A randomized participant s with available biomarker data (PD-L1 
expression status and other assays).
Biomarker Part B participants: All Part B randomized participants with available b iomarker data (PD-L1 
expression status and other assays).
All analyses will be performed u sing the treatment arm as rando mized (intent to tr eat), with the 
exception of dosing and safety, for which the treatment arm as received will be used:
â€¢All randomized participants who take at least 1 dose of double-b lind study treatment.
â€¢Participants will be included in the tr eatment group they were randomized to, eg, data in this 
data set will be analyzed based on randomized treatment, except  in the following cases:
âˆ’If a participant received the same incorrect treatment througho ut the study, then the 
participant will be analyzed based on the treatment received.
âˆ’If a participant received study  drug from more than 1 treatment group, and none of the 
administrations were consistent with the assigned randomized treatment group, then the 
participant will be analyzed based on the first treatment received.
Protocol Amendment No.: 06
Date: 08-Dec-2022 107
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
10.3 Statistical Analyses
10.3.1 Efficacy Analyses
Endpoint Statistical Analysis Methods
Primar y The primary DFS analyses will be conducted using a 2-sided log-r ank test stratified by 
pathological T Stage and N Stage status and type of nephrectomy at screening in randomized 
participants. The hazard ratio and corresponding 2-sided (1- Î±)%  CI (adjusted for interim) will 
be estimated using a Cox proportion al hazards model, with treat ment group as a single 
covariate, stratified by the above factors. DFS curves, DFS media ns with 95% CIs, and DFS
rates at 6, 12, 18, 24, and 60 months with 95% CIs will be estimated using Kaplan-M eier 
methodology.
Note that upon completion of study enrollment, 2 of the 6 strat a levels have less than 20 
participants. To avoid unreliable estimates, the strata levels w ith partial and radical 
nephrectomy will be combined for stratified analysis purposes. In other words, stratified 
analysis will be conducted based only on 1 stratification facto r (pathological T Stage and N 
Stage status).
For censoring rules, please refer to Table 10.3.1-1 .
Secondary The secondary OS analysis will be conducted using a 2- sided log-rank test stratified by 
pathology status and histology at screening in randomized parti cipants. The hazard ratio and 
corresponding 2-sided (1- Î±)% CI (adjusted for interim) will be e stimated using a Cox 
proportional hazards model, with treatment arm as a single cova riate, stratified by the above 
factors. OS curves, OS medians with 95% CIs and OS rates at 12,  24, 36, 48, a nd 60 months 
with 95% CIs will be estimated using Kaplan Meier methodology.Note that upon completion of study enrollment, 2 of the 6 strat a levels have less than 20 
participants. To avoid unreliable estimates, the strata levels with partial and radical 
nephrectomy will be combined for stratified analysis purposes. In other words, stratified 
analysis will be conducted based only on 1 stratification facto r (pathological T Stage and N 
Stage status).
Exploratory Will be described in the statistical analysis plan finalized before database lock.
Censoring rules for the primary definition of DFS are presented  i n  Table 10.3.1-1 .Sensitivity 
analyses of DFS will be described in the statist ical analysis plan. 
Table 10.3.1-1: Censoring Scheme Used in Primary Definition of DFS
Situation Date of Progression or Censoring Outcome
Recurrence Date of first recurrence Event
Death from any cause without recurrence Date of death Event
No baseline disease assessment Date of randomization Censored
No on-study disease assessments and no 
deathDate of randomization Censored
No recurrence and no deathDate of last evaluable disease 
assessmentCensored
Protocol Amendment No.: 06
Date: 08-Dec-2022 108
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Table 10.3.1-1: Censoring Scheme Used in Primary Definition of DFS
Situation Date of Progression or Censoring Outcome
New systemic anticancer therapy, tumor-
directed radiotherapy, or tumor-directed 
surgery received without recurrence 
reported prior to or on the same dayDate of last evaluable disease 
assessment prior to or on the same 
date of initiation of subsequent 
therapyCensored
Second non-RCC primary cancer reported 
without recurrence reported prior to or on 
the same dayDate of last evaluable disease 
assessment prior to or on the same 
date of diagnosis of secondary non-
RCC primary cancerCensored
10.3.2 Safety Analyses
Endpoint Statistical Analysis Methods
Secondary Safety analyses w ill be performed in all treated participants. Descriptive statistics of safety will 
be presented using NCI CTCAE version 4.0 by treatment group. All on-study AEs, treatment-
related AEs, SAEs, and treatment-related SAEs up to 30 and 100 days of last dose of study 
therapy will be tabulated using worst grade per NCI CTCAE v 4.0 criteria by system organ 
class and preferred term. On- study lab par ameters including hematology, chemistry, liver 
function, and renal function will be summarized using worst gra de NCI CTCAE v 4.0 criteria.
Exploratory Will be described in the statistical analysis plan, which will be finalized before database lock.
10.3.3 Other Analyses 
10.3.3.1 Pharmacokinetic AnalysesThe nivolumab and ipilimumab concentration versus time data obt ained in this study will be 
combined with data from other studies in the clinical development program to develop a population 
PK model. This model will be used to evaluate the effects of in trinsic and extrinsic (if applicable) 
covariates on the PK of nivolumab and ipilimumab to determine m easures of individual exposure 
(such as peak, trough and time-averaged concentration following  a single dose or at steady state). 
Pharmacokinetic drug-drug interaction between nivolumab and ipi limumab will be studied by
population PK approach as appropriat e. Model determined exposur es may be used for 
exposure -response analyses of selected efficacy and safety endp oints, if appropriate. The results 
of population PK, phar macokinetic drug interaction and exposure  response analyses will be 
reported separately, as needed.
10.3.3.2 Biomarker Analyses
Methodology for exploratory biomar ker analyses will be described in the statistical analysis plan.
10.3.3.3 Outcomes Research Analyses
Descriptive summary statistics  of quality of life assessments w ill be presented at baseline and each 
on-study time points unless otherwise sp ecified. Mean changes from baseline for each of the 
2 assessments and all associated subscores will be calculated for each tr eatment arm at each on-
Protocol Amendment No.: 06
Date: 08-Dec-2022 109
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
study time point. More specifically, summary scores of the FKSI- 19 subscale and total scores, the 
9-item FKSI-DRS score, and the EQ-5D-3L utility index and VAS a t baseline and on-study time 
points and the 95% CIs will be c onducted. For the EQ-5D-3L ut ility index, the UK preference 
weightings will be analyzed.55In addition, participant compliance will be described per time point 
by the proportion of  participants who filled out the QoL assess ments over the numbers of 
participants known to be alive and eligible for assessment at t hese time points. 
Additionally, t-tests w ill be c onducted to evaluate the differences between nivolumab combined  
with ipilimumab versus placebo infusions treatment arms as well  as the nivolumab versus placebo 
infusions tr eatment arms at each time point, and 95% CIs will a lso be presented.
10.3.4 Interim Analyses and Hierarchical Testing
The Statist ical Analysis Plan w ill further describe the planned interim analyses.
Part A Combination Analyses Timing
One formal DFS interim combination analysis will be conducted a t the time when approximately 
88% (204) of the total DFS events in the combination and placebo arms have occurred and the 
time when the total enrollment of both Part A and Part B is exp ected to be complete. This formal 
comparison of DFS will allow for early st opping for superiority. The stopping boundaries at the 
interim and final analyses will be derived based on the exact n umber of DFS events using Lan-
DeMets alpha spending function with Oâ€™Brien-Fleming boundaries.  Note that if Part B enrollment 
is still ongoing at the time of observing the required number o f events for the interim analysis and 
target number of events needed for the final analysis is projec ted to occur in a shorter time interval
(approximately within 4 months), then the interim analysis of DF S will not be performed and only 
one final analysis of DFS will be conducted after the completion of enrollment in Part A and Part B (statistical significance of  only one final an alysis of DFS is 0.05 [two-sided]).
If the DFS combination analysis is  significant, the OS combinat ion analysis will be tested 
hierarchically. Formal OS interim combination analyses will be conducted at the time when the 
interim or final DFS combination analysis is significant. This formal comparison of OS will allow 
for early stoppi ng for superiority. 
The OS combination analyses occurring at the time when the DFS combination analysis is 
significant either after the Part A (approximately 800) partici pants randomized to the nivolumab 
+ ipilimumab and placebo arms have a minimum of 20 or 26 months  of follow-up, which are 
expected to occur at approximately 56 (62% of the total events)  and 62 (70% of the total events) 
months from study initiation, respectively. These are at equiva lent times when the DFS 
combination analyses of Part A are expected to occur. However, in the situation when the DFS 
combination analysis is significant at 56 months but OS is not significant at th at time, the  62 month 
DFS analysis will not be necessary and so the second OS combina tion interim analysis will occur 
at 70 months (82% of the total events) rather than 62 months (7 0% of the total events). At the 56-
and 62-month (or 70-month) OS combination analyses, approximate ly 178 and 201 (or 235) events 
are expected providing 41% and 53% (or 68%) power to detect ove rall interim OS HRs of 0.68 (P 
Protocol Amendment No.: 06
Date: 08-Dec-2022 110
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
< 0.009) and 0.70 (P < 0.012) (or 0.74, P < 0.023), respectivel y, at the pre-specified alpha level 
using the Lan DeMets alpha spending function.
The final OS combination analysi s will take place after the Par t A (approximately 800) participants 
randomized to the nivolumab + ipilimumab and placebo arms have a minimum of 48 months of 
follow-up, which is expected to occur approximately 84 months f rom the start of the study. At the 
time of the final OS combination analysis, approximately 287 even ts are expected ensuring 85% 
overall power to detect a final OS hazard ratio of 0.79 (P<0.04 5).
Part B Monotherapy Analyses Timing
Similarly, 1 formal DFS interim monotherapy analysis will be con ducted at the time when 
approximately 80% (122) of the total DFS events in the monother apy and contemporaneous 
placebo arms have occurred. This formal comparison of DFS will allow for early stopping for 
superiority. The stopping boundaries at the interim and final analyses will be derived based on the 
exact number of DFS events using Lan-DeMets alpha spending func tion with Oâ€™Brien-Fleming 
boundaries. Note that if the target number of events for the interim analysis and final analysis are projected to occur in a shorter time interval (approx imately within 6 months), then the interim 
analysis of DFS will not be performed and only one final analys is of DFS w ill be c onducted 
(statistical significance of only one final analysis of DFS is 0.05 [two-sided]).
If the interim or final DFS monotherapy analysi s is significant, the OS monotherapy analy sis will 
be tested hierarchically. The final OS analysis will take place  with approximately 182 events 
among all randomized Part B participants in nivolumab and place bo arms, which is expected to be 
at approximately 104 months from the start of the study, providi ng a minimum of 48 months of 
follow-up. Approximately 182 events are expected, ensuring 44% overall power to detect a HR of 0.73 (P < 0.045). Two formal OS interim monotherapy analyses wil l be conducted, which will 
allow for early stopping for superiority. The first and second interim analyses of OS are planned 
to occur with 102 events (56% of the targeted OS events) and 146 events (80% of the targeted OS 
events) among the randomized participants in nivolumab and place bo arms, which are expected to 
be at approximately 76 months and 90 months from the start  of the study. Approximately 102 and 
146 events are exp ected providing 8% and 27% power to detect ov erall interim OS HRs of 0.56 
(P < 0.006) and 0.67 (P < 0.023), respectively, at the pre-spec ified alpha level using the Lan 
DeMets alpha spending function.
In addition to the formal planned interim analyses for DFS and OS , the DMC will have access to 
periodic unblinded interim reports of efficacy and safety to al low a risk/benefit assessment. Details 
will be included in the DMC charter.
Protocol Amendment No.: 06
Date: 08-Dec-2022 111
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
11 REFERENCES
1Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden  of cancer in 2008: 
GLOBOCAN Int J Cancer 2008;127:2893â€“917
2Siegel RL, Miller KD, Jemal A CA .Cancer statistics, 2016. Canc er J Clin. 2016;66(1):7 
3Ferlay J, Steliarova-Foucher E, et al. . Cancer incidence and m ortality p atterns in Europe: 
estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6 ):1374-403. Epub 2013 Feb 
26. 
4Siegel R, Naishadham D, Jem al A. Cancer statistics, 2012. CA Ca ncer J Clin. 2012;62(1):10-
29.
5Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet.  2009;373(9669):1119-1132.
6Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal 
masses: a need to reassess treatment effect. J Natl Cancer Inst . 2006;98(18):1331 -1334.
7Chin AI, Lam JS, Figlin RA, B elldegrun AS. S urveillance strateg ies for renal cell carcinoma 
patients following nephr ectomy. Rev Urol. 2006;8(1):1-7.
8Belldegrun AS, Chamie K, Kloepfer P, et al. ARISER: A randomized double blind phase III study to evaluate adjuvant  cG250 tr eatment ve rsus pl acebo in patients with high-risk ccRCCâ€”
Results and implications for adjuvant clinical trials. J Clin Oncol 2013;31 (suppl; abstr 4507).
9Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafe nib for high-risk, non-
metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-bli nd, placebo-controlled, 
randomised, phase 3 trial. Lancet. 2016; 387: 2008â€“16. 
10Ravaud A, Motzer RJ, Pandha HS, et al for the S-TRAC Investigat ors. Adjuvant Sunitinib in 
High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med.  2016 Published online 
ahead of print. DOI: 10.1056/NEJMoa1611406
11Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafe nib for high-risk, non-
metastatic renal-cell carcinoma (ECOG-ACRIN E2805); a double-bl ind, placebo-controlled, 
randomized, phase 3 trial. Lancet. 2016; 387(10032):2008-16.
12Motzer RJ, Haas NB, Donskov F, et al. Randomized Phase III Tr ial of Adjuvant Pazopanib 
Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal 
Cell Carcinoma. J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi:  
10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.
13Gross-Goupil M, Kwon TG, Eto M, Y et al. Axitinib versus placebo  as an adjuvant treatment 
of renal cell carcinoma: results from the phase III, randomized  ATLAS trial. Ann Onc ol. 2018 
Dec 1;29(12):2371-2378. doi : 10.1093/annonc/mdy454.
Protocol Amendment No.: 06
Date: 08-Dec-2022 112
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
14Chamie K, Donin NM, KlÃ¶pfer P, et al. Adjuvant Weekly Girentuxima b Following
Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Rand omized Clinical Trial.
JAMA Oncol. 2017 Jul 1;3(7):913 -920. doi: 10.1001/jamaoncol.201 6.4419.
15TQG Eisen, Frangou E, Smith B, et al. Primary efficacy analysis results from the SORCE trial 
(RE05): Adjuvant sorafenib for renal cell carcinoma at intermed iate or high risk of relapse: An 
international, randomised double-blind phase III trial led by t he MRC CTU at UCL. Presented 
at: European Society of Medical Oncology (ESMO) Congress 2019; September 27-October 3, 
2019: Barcelona, Spain. Abstract LBA56.
16NCCN Guidelines for Kidney Cancer V.2.2018
17McDermott DF, Drake CG, Sznol M, et al. Survival, Durable Respo nse, and Long-Term Safety 
in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J 
Clin Oncol 2015; 33(18): 2013-20.
18Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for Metastat ic Renal Cell Carcinoma: 
Results of a Randomized Phase II Trial. J Clin Oncol 2015; 33(1 3): 1430-7.
19Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti-
PD-1 Antibody in Cancer. N Engl J Med 2012.
20Choueiri TK FM, Escudier BJ, Kim JJ,et al. ;. Immunomodulatory activity of nivolumab in 
previously treated and untreated metas tatic renal cell carcinoma (mRCC): Biomarker-based 
results from a randomized clinical trial. J Clin Oncol 32:5s, 2 014 (suppl; abstr 5012)
21Ref Keynote 427: Pembrolizumab monotherapy as first-line therap y in advanced clear cell 
renal cell carcinoma: Results from cohort A of KEYNOTE-427. McD ermott DF, Lee JL, 
Szczylik C, et al J Clin Oncol. 2018;36S:ASCO #4500. 
https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4500
22Ref TITAN: ESMO 2019, https://www.urotoday.com/conference-highl ights/esmo-
2019/esmo-2019-kidney-cancer/115250-esmo-2019-tailored-immunoth erapy-approach-with-
nivolumab-for-advanced-renal-cell-carcinoma-titan-rcc.html
23A Phase 2 Open-label Study of Single Agent Ipilimumab for the T reatment of IL-2 Refractory 
or IL-2 Ineligible Patients with Stage IV Renal Cancer; NCT0005 7889; Final Clinical Study 
Report 930025954 v1.0 (28-January-2008)
24Yang JC, Hughes M, Kammula U et al. Ipilimumab (Anti-CTLA4 Antib ody) causes regression 
of metastatic renal cell cancer associated with enteritis and h ypophysitis. J Immunother 2007; 
30(8): 825-830
25A Phase 2 Open-label Study of Single Agent Ipilimumab for the Treatment of IL-2 Refractory 
or IL-2 Ineligible Patients with Stage IV Renal Cancer; NCT0005 7889; Final Clinical Study 
Report 930025954 v1.0 (28-January-2008)
26Nivolumab Investigator Brochure. Version 15. Bristol-Myer Squib b Research and 
Development. Princeton, NJ. June 206. Document Control No. 930038243.
Protocol Amendment No.: 06
Date: 08-Dec-2022 113
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
27VOLUME 20, ISSUE 2, P297-310, FEBRUARY 01, 2019 Patient-reported  outcomes of 
patients with advanced renal cell carcinoma treated with nivolu mab plus ipilimumab versus 
sunitinib (CheckMate 214): a randomised, phase 3 trial. 
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045 (18)30778-2/fulltext
28Pardoll D. Does the immune system see tumors as foreign or self ? Annu Rev Immunol. 
2003;21:807-39.
29Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveil lance: immunoselection 
and immunosubversion. Nat Rev Immunol. 2006;6:715-27.
30Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to 
tumor escape. Nat Immunol. 2002;3:991-8.
31Greenwald RJ, Freeman GH, Sharpe AH. The B7 family revisited. An nu Rev Immunol. 
2004;23:515-48.
32Freeman FJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immu nohibitory receptor by a 
novel B7 family member l eads to negative regu lation of lymphocyte activation. J Exp Med 
2000; 192(7): 1027-34.
33Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programme d cell d eath 1 and its 
ligands in regulating autoimmunity and infection. Nature Immuno l. 2007;8:237-45.
34Wolchok JD, Hoos A, Oâ€™Day S, et al. Guidelines for the evaluati on of immune therapy activity 
in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-20.
35Postow MA,  Harding J, Wolchok JD. Targeting immune checkpoints : Releasing  the   restraints 
on anti-tumor immunity for patients with m elanoma. Cancer J 2012; 18:153-159.
36McDermott DF, Lee JL, Szczylik C, et al. Pembrolizumab monother apy as first-line therapy 
in advanced clear cell renal cell carcinoma (accRCC): Results f rom cohort A of KEYNOTE-
427. J Clin Oncol 2018;36 (suppl; abstr 4500).
37Atkins MB, McDermott DF, Powles T, et al. IMmotion150: a phase II trial in untreated 
metastatic renal cell carcinoma (mRCC) patients (pts) of atezol izumab (atezo) and 
bevacizumab (bev) vs and following atezo or sunitinib. J Clin O ncol. 2017;35 (suppl; abstr 
4505).
38Donat SM, Diaz M, Bishoff JT, et al. Follow-up for Clinically L ocalized Renal Neoplasms: 
AUA Guideline. J Urol. 2013; 19: 407-416.
39Ljungberg B, Bensalah K, Bex A, et al: Guidelines on renal cell  carcinoma. 
http://uroweb.org/wp-content/uploads/EAU-Guidelines-Renal-Cell- Cancer-2015-v2.pdf
40Francesco Massari, Vincenzo Di Nunno, Ve ronica Mo llica, Jeffrey Graham, Lidia Gatto, 
Daniel Heng: Adjuvant Tyrosine Kinase Inhibitors in Treatment o f Renal Cell Carcinoma: A 
Meta-Analysis of Available Clinical Trials. Clinical Genitourin ary Cancer: 2019.
41Leibovich BC, Blute ML, Cheville JC, et al. Prediction of p rogression after radical 
nephrectomy for patients w ith clear cell renal cell carcinoma: a str atification tool for 
prospective clinical trials. Cancer 2003; 97:1663-71.
Protocol Amendment No.: 06
Date: 08-Dec-2022 114
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
42Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipilimum ab versus Ipilimumab in 
Untreated Melanoma. N Engl J Med 2015;372:2006-17.
43Hammers HA, Plimack ER, Infante JR, et al. Updated Results from a Phase 1 Study of 
Nivolumab in Combination with Ipilimumab in Metastatic Renal Ce ll Carcinoma: The 
CheckMate 016 Study. Presented at the 2016 A nnual Meeting of the European Society of 
Medical Oncologists, October 7-11, 2016, Copenhagen, Denmark. 
44Momtaz P, Park V, Panageas KS, et al. Safety of Infusing Ipilim umab Over 30 Minutes.
Journal of Clinical On cology 2015 33: 30, 3454- 3458.
45Yervoy prescribing information. Bristol-Myers Squibb Research a nd Development. Princeton, 
NJ. October 2015.
46Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipilimumab versus Ipilimumab in 
Untreated Melanoma.  N Engl J Med. 2015;372(21):2006-17.
47https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2 019-kidney-
cancer/115245-esmo-2019-a-tailored -immunotherapy-approach-with- nivolumab-in-
advanced-renal-cell-carcinoma-in-the-titan-
trial.html?utm_source=newsletter_7020&utm_medium=email&utm_camp aign=esmo-2019-
breaking-genitourinary-malignancy-highlights-impacting-clinical -care Ref for KN427
48Ref Keynote 427: Pembrolizumab monotherapy as first-line therap y in advanced clear cell 
renal cell carcinoma: Results from cohort A of KEYNOTE-427. McD ermott DF, Lee JL, 
Szczylik C, et al J Clin Oncol. 2018;36S:ASCO #4500. 
49Ref TITAN: ESMO 2019, https://www.urotoday.com/conference-highl ights/esmo-
2019/esmo-2019-kidney-cancer/115250-esmo-2019-tailored-immunoth erapy-approach-with-
nivolumab-for-advanced-renal-cell-carcinoma-titan-rcc.html
50Hellmann, MD, Gettinger, SN, Goldman, JW, et al. CheckMate 012:  Safety and efficacy of 
first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. J Clin 
Oncol 34, 2016 (suppl; abstr 3001).
51OPDIVO prescribing information. Bristol-Myers Squibb Compa ny. Prin ceton, NJ. Updated 
March 2019. 
52Rothrock, N. E., Jensen, S. E., Beaumont, J. L., Abernethy, A. P., Jacobsen, P. B., Syrjala, K., 
& Cella, D. (2013). Development and init ial validation of the NCCN/FACT symptom index 
for advanced kidney cancer. Value in Health, 16(5), 789-796.
53EuroQol, G. (1990). EuroQol--a new fac ility for t he measur ement of health-related quality of 
life. Health policy (Amsterdam, Netherlands), 16(3), 199.
54Rini B, Goddard A, Knezevic D, et al. A 16-gene assay to predic t recurrence after surgery in 
localised renal cell carcinoma: development and validation stud ies. Lancet Oncol. 
2015;16(6):676-685. doi:10.1016/S1470-2045(15)70167-1.
55Dolan P. Modeling valuations for EuroQol health states. Medical  Care 1997;35: 1095-1108  
Protocol Amendment No.: 06
Date: 08-Dec-2022 115
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
12 APPENDICES
Protocol Amendment No.: 06
Date: 08-Dec-2022 116
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
APPENDIX 1 ABBREVIATIONS AND TRADEMARKS
Term Definition
AE adverse event
ALT alanine aminotransferase
ANC absolute neutrophil count
AST aspartate aminotransferase
AT aminotransaminases
AUC area under the concentration-time curve
BMI body mass index
BMS Bristol-Myers Squibb
BP blood pressure
BUN blood urea nitrogen
C Celsius
CBC complete blood count
CFR Code of Federal Regulations 
CI confidence interval
C1- chloride
CLcr creatinine clearance
COVID-19 Coronavirus Disease 2019
CNS central nervous system
CRF Case Report Form, paper or electronic
ctDNA circulating tumor DNA
DFS disease-free survival
DMC Data monitoring committee
ECG electrocardiogram
eCRF Electronic Case Report Form
EDC Electronic Data Capture
eg exempli gratia (for example)
EOI-PK end of infusion-pharmacokinetics
ESR Expedited Safety Report
FDA Food and Drug Administration
Protocol Amendment No.: 06
Date: 08-Dec-2022 117
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Term Definition
FSH follicle stimulating hormone
gg ram
GCP Good Clinical Practice
GFR glomerular filtration rate
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HIPPA Health Insurance Portability and Accountability Act of 199 6
HIV Human Immunodeficiency Virus
HR heart rate
HRT hormone replacement therapy
ICD International Classification of Diseases
ICH International Conference on Harmonisation 
ie id est (that is)
IEC Independent Ethics Committee
IgG immunoglobulin G
IgM immunoglobulin M
IMAE immune-mediated adverse event
IMP investigatio nal medicin al products
IRB Institutional Review Board
IRT Interactive Response Technology
IU International Unit
IV intravenous
K+ potassium
kg kilogram
L liter
LAM Lactation amenorrhea method
LDH lactate dehydrogenase
mg milligram
min minute
Protocol Amendment No.: 06
Date: 08-Dec-2022 118
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Term Definition
mL milliliter
mmHg millimeters of mercury
MTD maximum tolerated dose
Î¼g microgram
N number of subjects or observations
N/A not applicable
NIMP non-investigational medicinal products 
OS overall survival
PD pharmacodynamics
PK pharmacokinetics
SAE serious adverse event
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
TAO Trial Access Online, the BMS implementation of an EDC capabi lity
T-HALF Half life
Tmax, TMAX time of maximum observed concentration
WBC white blood cell
WES whole exome sequencing
WHO World Health Organization
WOCBP women of childbearing potential
Protocol Amendment No.: 06
Date: 08-Dec-2022 119
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
APPENDIX 2 STUDY GOVERANCE CONSIDERATIONS
The term â€˜Participantâ€™ is us ed in the protocol to refer to a person who has consented to participate 
in the clinical research study.  The term â€˜Subjectâ€™ used in the  CRF is intended to refer to a person 
(Participant) who has consented to participate in the clinical research study.
REGULATORY AND ETHICAL CONSIDERATIONS
GOOD CLINICAL PRACTICE
This study will be conducted in accordance with:
â€¢Good Clinical Practice (GCP)
â€¢as defined by the International Council on Harmonisation (ICH)
â€¢in accordance with the ethical principles underlying European U nion Directive 2001/20/EC
â€¢United States Code of Federal Regulations, Title 21, Part 50 (2 1CFR50) 
â€¢applicable local requirements
The study will be conducted in compliance with the protocol. Th e protocol and any amendments 
and the participant informed consent will r eceive approval/favorable opinion by Institutional 
Review Board/Independent Ethics Co mmit tee (IRB/IEC), and regulatory authorities according to 
applicable local regulations prior to initiation of the study.
All potential serious breaches must be reported to the Sponsor or  designee immediately. A 
potential serious breach is defined as a Quality Issue (eg, protoco l deviation, etc) that is likely to 
affect to a significant degree one or more of the following: (1) the physical,  safety or  mental 
integrity of one or more subjects/participants; (2) the scientifi c value of the trial (eg, reliability and 
robustness of generated data). Items (1) or (2) can be associat ed with either GCP Regulation(s) or 
Trial protocol(s).
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where s anctions have been invoked or where 
there has been scientific misconduct or fraud (e.g., loss of me dical licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and  dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, participant re cruitment materials (eg, 
advertisements), and any other written information to be provided to subjects/participants. The 
investigator or BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or 
product labeling information to be provided to subjects/partici pants and any updates. 
The investigator, Sponsor or designee should provide the IRB/IEC with reports, updates and other 
information (eg, expedited safety reports, amendments, and admi nistrative letters) according to 
regulatory requirements or institution procedures.
Protocol Amendment No.: 06
Date: 08-Dec-2022 120
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not imp lement any deviation or change t o the protocol without prior 
review and documented approval/favorable opinion of an amendmen t from the IRB/IEC (and if 
applicable, also by local health authority) except where necessa ry to elimin ate an immediate 
hazard(s) to study subjects/participants. 
If a deviation or change to a protocol is implemented to elimin ate an immediate hazard(s) prior to 
obtaining relevant  approval/favorable opinion(s) the deviation  or change will be submitted, as 
soon as possible to:
â€¢IRB/IEC for
â€¢Regulatory Authority(ies), if applicable by local regulations ( per national requirements)
Documentation of approval/favorable opinion signed by the chair person or designee of the 
IRB(s)/IEC(s) and if applicable, also by local health authority  must be sent to BMS.
If an amendment substantially alters the study design or increa ses the potential risk to the 
participant: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review 
and approval/favorable opinion; (2) the revised form must be us ed to obtain consent from 
subjects/participants currently enrolled in the study if they ar e affected by the amendment; and (3) 
the new form must be used to obtain consent from new subjects/p articipants prior to enrollment.
If the revision is done via an administrative letter, investiga tors must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Investigators and su b-Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit comp lete and 
accurate financial certification or disclosure statements to th e appropriate h ealth aut horities. 
Investigators are responsible fo r providing information on financial interests during the course of 
the study and for 1 year after completion of the study.
INFORMED CONSENT PROCESS
Investigators must ensure that subjects/participants are clearly and fully informed a bout the 
purpose, potential risks, and other critical issues regarding c linical studies in which they volunteer 
to participate. 
In situations where consent cannot be given to subjects/partici pants, their legally acceptable 
representatives (as per country guidelines) are clearly and ful ly informed about the purpose, 
potential risks, and other critical issues regarding clinical s tudies in which the participant 
volunteers to participate. Sponsor or designee will provide the investigator with an appro priate (i.e., Global or Local) sample
informed consent form which will include all elements required by ICH, GCP and applicable
regulatory requirements. The sample informed consent form will adhere to the ethical principles 
that have their origin in the Declaration of Helsinki.
Protocol Amendment No.: 06
Date: 08-Dec-2022 121
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Investigators must:
â€¢Provide a copy of the consent form and written information abou t the study in the language in 
which the participant is most proficient prior to clinical study participation. The language must 
be non-technical and easily understood. 
â€¢Allow time necessary for participant or participant's legally a cceptable representative to 
inquire about the details of the study.
â€¢Obtain an informed consent signed and personally dated by the p articipant or the participant's 
legally acceptable representative and by the person who conduct ed the informed consent 
discussion. 
â€¢Obtain the IRB/IECâ€™s written approval/favorable opinion of the written informed consent form 
and any other information to be provided to the subjects/partic ipants, pri or to the beginning of 
the study, and after any revisions are completed for new inform ation.
If informed consent is initially given by a participantâ€™s legal ly acceptable representative or legal 
guardian, and the participant subsequently becomes capable of m aking and communicating his or 
her informed consent during the study, consent must additionally be obtained from the participant.
Revise the informed consent whenever important new information becomes available that is 
relevant to the participant's consent. The investigator, or a p erson designated by the investigator, 
should fully inform the participant or the participant's legall y acceptable representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
participant's willingness to continue participation in the stud y. This commun ication should be 
documented. The confidentiality of records that could identify subjects/par ticipants must be protected, 
respecting the privacy and confidentiality rules applicable to regulatory requirements, the 
subjects'/participantsâ€™ signed ICF and, in the US, the subjectsâ€™ /participantsâ€™ signed HIPAA 
Authorization.The consent form must also include a statement that BMS and reg ulatory authorities have direct 
access to participant records. Subjects/participants unable to give their written consent (e.g. , stroke or subjects/participants with 
or severe dementia) may only be enrolled in the study with the consent of a legally acceptable 
representative. The participant must also be informed about the  nature of the study to the extent 
compatible with his or her understanding, and should this parti cipant become capable, he or she 
should personally sign and date the consent form as soon as pos sible. The explicit wish of a 
participant who is unable to give his or her written consent, b ut who is capable of forming an 
opinion and assessing information to refuse participation in, or  to be withdrawn from, the clinical 
study at any time should be considered by the investigator.The rights, safety, and well-being of the study subjects/partic ipants are the most important 
considerations and should prevail over interests of science and society.
Protocol Amendment No.: 06
Date: 08-Dec-2022 122
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SOURCE DOCUMENTS
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attr ibutable, whether the data ar e hand-written on paper or entered 
electronically. If source  data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computer ized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such s ystems must be compliant with all 
applicable laws and regulations governing use of electronic rec ords and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments , and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A ce rtified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes a nd information as the original. 
STUDY TREATMENT RECORDS
Records for study treatments place bo infusions (whether supplied by BMS, its vendors, or the site) 
must substantiate study treatm ent integrity and traceability fro m receipt, preparation, 
administration, and through destruction or return. Records must  be made available for review at 
the request of BMS/designee or a Health Authority.
If Then
Supplied by BMS (or 
its vendors):Records or logs must comply with applicable regulations and gui delines and should 
include:
â€¢amount received and placed in storage area
â€¢amount currently in storage area
â€¢label identification number or batch number
â€¢amount dispensed to and returned by each participant, including  unique 
participant identifiers
â€¢amount transferred to another area/site for dispensing or storage
â€¢nonstudy disposition (e.g., lost, wasted) 
â€¢amount destroyed at study site, if applicable
â€¢amount returned to BMS
â€¢retain samples for bioavailability/bioequivalence/biocomparabil ity, if 
applicable 
â€¢dates and initials of person responsible for Investigational Product 
dispensing/accountability, as per the Delegation of Authority Form.
Protocol Amendment No.: 06
Date: 08-Dec-2022 123
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
If Then
Sourced by site, and 
not supplied by BMS 
or its vendors 
(examples include IP 
sourced from the sites 
stock or commercial 
supply, or a specialty 
pharmacy)The investigator or designee accepts responsibility for documenting traceability and 
study drug integrity in accordance with requirements applicable under law and the 
SOPs/standards of the sourcing pharmacy.   
These records should include:
â€¢label identification number or batch number 
â€¢amount dispensed to and returned by each participant, including unique 
participant identifiers
â€¢dates and initials of person responsible for Investigational Product 
dispensing/accountability, as per the Delegation of Authority Form.
BMS or designee will provide  forms to facilitate inventory cont rol if the investigational site does not have an 
established system that meets these requirements.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other d ata pertinent to the investig ation on each individual treated 
or entered as a control in the investigation. Data that are der ived from source documents and 
reported on the CRF must be consistent with the source document s or the discrepancies must be 
explained. Additional clinical information may be collected and  analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the Sponsor or designee electronic data capture tool, electronic CRFs w ill be 
prepared for all data collection fields except for fields speci fic to SAEs and pregnancy, which will 
be reported on the electronic SAE form and Pregnancy Surveillan ce form, respectively.  If 
electronic SAE form is not av ailable, a paper SAE form can be used. Spaces may be left blank  
only in those circumstances permitted by study-specific CRF com pletion guidelin es provi ded by 
Sponsor or designee. The confidentiality of records that could identify subjects/par ticipants must be protected, 
respecting the privacy and confidentiality rules in accordance w ith the applicable regulatory 
requirement(s).The investigator will maintain a signature sheet to document si gnatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF, SAE/pregnancy CRFs, must be promptly reviewed , signed, and dated by the 
investigator or qualified physician who is a subinvestigator an d who is delegated this task on the 
Delegation of Authority Form. Subinvestigators in Japan may not  be delegated the CRF approval 
task. For electronic CRFs, review and approval/signature are compl eted electronically through the 
BMS electronic data capture tool. The investigator must retain a copy of the CRFs including 
records of the changes and corrections.
Each individual electronically si gning electronic CRFs must meet S ponsor or designee training 
requirements and must only access the BMS electronic data captu re tool using the unique user 
account provided by Sponsor or designee. User accounts are not to be shared or reassigned to other 
individuals.
Protocol Amendment No.: 06
Date: 08-Dec-2022 124
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
MONITORING
Sponsor or designee representativ es will review data centrally t o identify potential issues to 
determine a schedule of on-site visits for targeted review of s tudy records. 
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity . On site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with th e investigator, and verify that the 
facilities remain acceptable. Certain CRF pages and/or electron ic files may serve as the source 
documents.
In addition, the study may be evaluated by Sponsor or designee in ternal auditors and government 
inspectors who must be allowed access to CRFs, source documents , other study files, and study 
facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of a ny inspections scheduled by regulatory aut horities, 
and promptly forward copies of inspection reports to Sponsor or  designee.
RECORDS RETENTION
The investigator (or head of the study site in Japan) must reta in all study records and source 
documents for the maximum period required by applicable regulat ions and guidelines, or 
institution procedures, or for the period specified by BMS or d esignee, whichever is longer. The 
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records 
associated with the study.
BMS or designee will notify the investigator (or head of the st udy site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study (e.g., relocation,  retirement), the records sh all be 
transferred to a mutually agreed upon designee (e.g., another investigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee. 
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by BMS, a vend or or sourced by the investigator) 
such as partially used study treatment containers, vials and sy ringes may be destroyed on site. 
If.. Then
Study treatments supplied by BMS (including 
its vendors)Any unused study treatments supplied by BMS can only be 
destroyed after being inspected and reconciled by the 
responsible Study Monitor unless study treatments containers 
must be immediately destroyed as required for safety, or to 
meet local regulations (e.g., cytotoxics or biologics).
If study treatments will be returned, the return will be arranged 
by the responsible Study Monitor.
Study treatments sourced by site, not supplied 
by BMS (or its vendors) (examples include 
study treatments sourced from the siteâ€™s stock 
or commercial supply, or a specialty pharmacy)It is the investigatorâ€™s or designeeâ€™s responsibility to dispos e of 
all containers according to the institutional guidelines and 
procedures.
Protocol Amendment No.: 06
Date: 08-Dec-2022 125
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
It is the investigatorâ€™s or designeeâ€™s responsibility to arrang e for disposal, provided that procedures 
for proper disposal have been e stablished according to applicab le federal, state, local, and 
institutional guidelines and procedures, and provided that appr opriate records of disposal are kept. 
The following minimal standards must be met:
â€¢On-site disposal practices must not expose humans to risks from  the drug.
â€¢On-site disposal practices and procedures are in agr eement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
â€¢Written procedures for on-site disposal are available and follo wed. The procedures must be 
filed with the siteâ€™s SOPs and a copy  provided t o BMS upon requ est.
â€¢Records are maintained that allow for traceability of each cont ainer, including the date 
disposed of, quantity disposed, and identif ication of the person disposing the containers. The 
method of disposal, i.e., incinerator, licensed sanitary landfi ll, or licensed waste disposal 
vendor must be documented.
â€¢Accountability and disposal records are complete, up-to-date, a nd available for the Monitor to 
review throughout the clinical trial period.
It is the investigatorâ€™s or designeeâ€™s responsibility to arrang e for disposal of all empty containers.
If conditions for destruction cannot be met the responsible Stu dy Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors) . Destruction of non- study 
treatments sour ced by the site, not supplied by BMS, is solely the responsibility of the investigator 
or designee.
CLINICAL STUDY REPORT 
A Signatory Investigator must be selected to sign the clinical study report. 
â€¢External Principal Investigator designated at protocol developm ent
â€¢National Coordinating Investigator 
â€¢Study Steering Committee chair or their designee
â€¢Participant recruitment (e.g., among the top quartile of enroll ers)
â€¢Involvement in trial design
â€¢Regional representation (e.g., among top qua rtile of enro llers from a specified region or 
country)
â€¢Other criteria (as determined by the study team)
SCIENTIFIC PUBLICATIONSThe data collected during this study are confident ial and proprietary to Spons or or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTAg) governing [Study s ite or Investigator] participation in 
the study. These requirements include, but are not limited to, submitting proposed publications to 
Protocol Amendment No.: 06
Date: 08-Dec-2022 126
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Sponsor or designee at the earliest practicable time prior to submission or presentation and 
otherwise within the time period set forth in the CTAg.
Scientific Publications (such as abstracts, congress podium presentations and posters, and 
manuscripts) of the study results will be a collaborative effor t between the study Sponsor and the 
external authors. No public presentation or publication of any interim results may be made by any 
principal investigator, sub-investigator or any other member of  the study staff without the prior 
written consent of the Sponsor. 
Authorship of publications at BMS is aligned with the criteria of the International Committee of 
Medical Journal Editors (ICMJE, www.icmje.org). Authorship sele ction is based upon significant 
contributions to the study (ie, ICMJE criterion #1). Authors mu st meet all 4 ICMJE criteria for 
authorship:1) Substantial intellectual contribution to the conception or de sign of the work; or the acquisition 
of data (ie, evaluable subjects with qualit y data), analysis , or interpretati on of data for the work 
(eg, problem solving, advice, evaluation, insights and conclusi on); AND
2) Drafting the work or revising it critically for important int ellectual content; AND
3) Final approval of the version to be published; AND
4) Agreement to be accountable for all asp ects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropria tely investigated and resoved.
Those who make the most significant contributions, as defined a bove, will be considered by BMS 
for authorship of the primary publication. Sub-investigators wi ll generally not be considered for 
authorship in the primary publication. Geographic representatio n will also be considered.
Authors will be lis ted by order of significant contributions (h ighest to lowest), with the exception 
of the last author. Authors i n first a nd last position ha ve provided the most signif icant contributions 
to the work.
For secondary analyses and related publications, author list an d author order may vary from 
primary to reflect additional contributions.
Protocol Amendment No.: 06
Date: 08-Dec-2022 127
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW UP AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) is defined as any new untoward medical oc currence or worsening of a 
preexisting medical condition in a clinical investigation parti cipant administered study treatment
and that does not necessarily hav e a causal relati onship with t his treatment. 
An AE can therefore be any unfavorable and unintended sign (suc h as an abnormal laboratory 
finding), symptom, or disease temporally associated with the us e of study treatment, whether or 
not considered related to the study treatment.
Events Meeting the AE Definition
â€¢Any abnormal laboratory test results (hematol ogy, clinical chem istry, or urinalysis) or 
results from other safety assessments (eg, ECG, radiological sc a n s ,  v i t a l  s i g n s  
measurements), including those that worsen from baseline, consi dered clinically significant 
in the medical and scie ntific judgment of the investigator. Note  that abnormal lab tests or 
other safety assessments should only be reported as AEs if the final diagnosis is not 
available. Once the final diagnosis is known, the reported term  should be updated to be the 
diagnosis.
â€¢Exacerbation of a chronic or intermittent pre-existing conditio n including either an increase 
in frequency and/or intensity of the condition.
â€¢New conditions detected or diagnosed after study intervention a dministration even though it 
may have been present before the start of the study.
â€¢Signs, symptoms, or the clinical sequelae of a suspected drug-d rug interaction.
â€¢Signs, symptoms, or the clinical sequelae of a s uspected overdo se of either study intervention 
or a concomitant medication. Overdose, as a verbatim term (as r eported by the investigator), 
shoul d not be reported as an AE/SAE unless it is an intentional  overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae and 
should specify "intentional overdose" as the verbatim term
Events NOT Meeting the AE Definition
â€¢Medical or surgical proce dure (eg, endoscopy, appendectomy): th e condition that leads to 
the procedure is the AE.
â€¢Situations in which an untoward medical occ urrence did not occur (so cial and/or 
convenience admission to a hospital).
DEFINITION OF SAE
If an event is not an AE per definition above, then it cannot b e an SAE even if serious conditions 
are met.
Protocol Amendment No.: 06
Date: 08-Dec-2022 128
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SERIOUS ADVERSE EVENTS
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the participa nt was at risk of  death at the time 
of the event; it does not refer to an event which hypotheticall y might have caused death if it were 
more severe)
Requires inpatient hospitalization or causes prolongation of ex isting hospitalization (see NOTE 
below)
NOTE: 
The following hospitalizations are not  considered SAEs in BMS c linical studies: 
â€¢a visit to the emergency room or other hospital department < 24 hours, that does not result 
in admission (unless considered an important medical or life-th reatening event)
â€¢elective surgery, planned prior to signing consent
â€¢admissions as per protocol for a planned medical/surgical proce dure
â€¢routine health assess ment requiring admission for baseline/tren ding of health status (e.g., 
routine colonoscopy)
â€¢medical/surgical admission other  than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases
â€¢admission encountered for another life circumstance that carrie s no bearing on health status 
and requires no medical/surgical intervention (e.g., lack of ho using, economic inadequacy, 
caregiver respite, family circumstances, administrative reason)
â€¢admission for administr ation of anticancer therapy in the absence of any other SAEs (applies 
to oncology protocols)
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect
Is an important medical event (defined as a medical event(s) th at may not be immediately life-
threatening or result in death or hospitalization but, based up on appropriate medical and 
scientific judgment, may jeopardize the participant or may requi re intervention [e.g., medical, 
surgical] to prevent one of the other serious outcomes listed i n the definition above.) Examples 
of such events include, but are not limited to, intensive treat ment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or co nvulsions that do not result in 
hospitalization.) Potential  drug induced liver injury (DILI) is  also considered an important 
medical event. (See Section 9.2.7 for the definition of potential DILI.) 
Pregnancy and potential drug induced liver injury (DILI) must fo llow the same transmission timing 
and processes to BMS as used for SAEs (see section 9.2.5 for reporting pregnancies).
Protocol Amendment No.: 06
Date: 08-Dec-2022 129
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Any component of a study endpoint that is considered related to  study therapy should be reported 
as SAE (e.g., death is an endpoint, if death occurred due to an aphylaxis, anaphylaxis must be 
reported).
EVALUATING AES AND SAES
Assessment of Causality
â€¢The investigator is obligated to assess the relationship betwee n study intervention and each 
occurrence of each AE/SAE.
â€¢A â€œreasonable possibilityâ€ of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relat ionship cannot be ruled out.
â€¢The investigator will use clinical judgment to determine the re lationship.
â€¢Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to s tudy intervention administration 
will be considered and investigated.
â€¢The investigator will also consult the Investigatorâ€™s Brochure  (IB) and/or Product 
Information, for mark eted products, in his/her assessment.
â€¢For each AE/SAE, the investigator must document in the medical n otes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality .
â€¢There may be situations in which an SAE has occurred and the in vestigator has minimal 
information to include in the initial report to Sponsor. Howeve r, it is very important that the 
investigator always make an assessment of causality for every e vent before the initial 
transmission of the SAE data to Sponsor.
â€¢The investigator may change his/her opinion of causality in lig ht of follow-up information 
and send a SAE follow-up report with the updated causality asse ssment.
â€¢The causality assessment is one  of the criteria used when deter mining regulatory reporting 
requirements.
Follow-up of AEs and SAEs
If only limited information is i nitially available, follow- up reports are required. (Note: Follow-
up SAE reports must include the same investigator term(s) initi ally reported.) 
If an ongoing SAE changes in its intensity or relationship to s tudy treatment or if new 
information becomes available, the SAE report must be updated a nd submitted within 24 hours 
to BMS (or designee) using the same procedure used for transmit ting the initial SAE report.
All SAEs must be followed to resolution or stabilization.
Protocol Amendment No.: 06
Date: 08-Dec-2022 130
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
REPORTING OF SAES TO SPONSOR OR DESIGNEE
â€¢SAEs, whether related or not r elated to study treatment, and pre gnancies must be reported 
to BMS (or designee) immediately within 24 hours of awareness o f the event.
â€¢SAEs must be recorded on the SAE Report Form.
âˆ’The required method for SAE data reporting is through the eCRF.
âˆ’The paper SAE Report Form is only intended as a back-up option when the electronic 
data capture (EDC) system is unavailable/not functioning for tr ansmission of the eCRF 
to BMS (or designee).
â™¦In this case, the paper form is transmitted via email or confir med facsimile (fax) 
transmission
â™¦When paper forms are used, the original paper forms are to remain on site
â€¢Pregnancies must be recorded on a paper Pregnancy Surveillance Form and transmitted via email or 
confirmed facsimile (fax) transmission 
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.SAE Telephone Contact (required for SAE and pregnancy reporti ng): Refer to Contact 
Information list
Protocol Amendment No.: 06
Date: 08-Dec-2022 131
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until beco ming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hy sterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered WOCBP
â€¢Premenarchal
â€¢Premenopausal female wi th 1 of the following:
âˆ’Documented hysterectomy
âˆ’Documented bilateral salpingectomy
âˆ’Documented bilateral oophorectomy
Note: Documentation can come from the site personnelâ€™s review of  the participantâ€™s medical 
records, medical examination, or m edical history interview.
â€¢Postmenopausal female
âˆ’A postmenopausal state is defined as 12 months of ame norrhea in a woman over age 
45 years in the absence of other biological or physiological cau ses. In addition, females 
under the age of 55 years must have a serum follicle stimulatin g hormone, (FSH) level 
> 40 mIU/mL to confirm menopause.
Note: Females treated with hormone replacement thera py, (HRT) are likely to have artificially 
suppressed FSH levels and may require a washout period in order  to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the inves tigators should use their 
judgement in checking serum FSH levels. 
â€¢1 week minimum for vaginal hormonal products (rings, creams, gels)
â€¢4 week minimum for transdermal products
â€¢8 week minimum for oral products
Other parenteral products may require washout periods as long a s 6 months. If the serum FSH 
level is > 40 mIU/ml at any time during the washout period, the woman can be considered 
postmenopausal.
End of Relevant Systemic Exposure
â€¢End of relevant systemic exposure is the time point where the I MP or any active major 
metabolites has decreased to a concentration that is no longer considered to be relevant for 
human teratogenicity or fetotoxici ty. This should be evaluated i n context of safety margins 
from the no-observed adverse effect level (NOAEL) or the time r equired for 5 half-lives of the 
IMP to pass.
Protocol Amendment No.: 06
Date: 08-Dec-2022 132
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
METHODS OF CONTRACEPTION
Local laws and regulations may require use of alternative and/o r additional contraception methods.
Highly Effective Contraceptive Methods That Are User Dependent
Failure rate of < 1% per year when used consistently and correctly.a
â€¢Combined (estrogen- and progestoge n-containing) hormonal contrac eption associated with 
inhibition of ovulation and/or implantation (This method of cont raception can only be used 
by WOCBP participants in studies where hormonal contraception i s permitted by the study 
protocol)b 
âˆ’oral (birth control pills)
âˆ’intravaginal (vaginal birth c ontrol suppositories, rings, cream s, gels)
âˆ’transdermal
â€¢Combined (estrogen-and progest ogen-containing) hormonal contrac eption must begin at 
least 30 days prior to initiation of study therapy
â€¢Progestogen -only hormonal contraception associated with inhibition of ovulation (This method of 
contraception can only be used by WOCBP participants in studies where hormonal contraception is 
permitted by the study protocol)b 
âˆ’oral 
âˆ’injectable
â€¢Progestogen-only hormonal contraception must begin at least 30 days prior to initiation of 
study therapy
Highly Effective Methods That Are User Independent
â€¢Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulation and/or implantation (This method of contraception can only be used by WOCBP 
participants in studies where hormonal contraception is permitt ed by the study protocol)b
â€¢Intrauterine device (IUD)
â€¢Intrauterine hormone-releasing system (IUS) (This method of cont raception can only be 
used by WOCBP participants in studies where hormonal contraception is permitted by the 
sudy protocol)b,c
â€¢Bilateral tubal occlusion
â€¢Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. 
â€¢Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
Protocol Amendment No.: 06
Date: 08-Dec-2022 133
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
â€¢Continuous abstinence must begin at least 30 days prior to init iation of study therapy
â€¢It is not necessary to use any other method of contraception whe n complete abstinence is 
elected. 
â€¢WOCBP participants who choose complete abstinence must continue to have pregnancy 
tests, as specified in Section 2 . 
â€¢Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP participants chooses to forego complete abst inence
â€¢Periodic abstinence (including but not limited to calendar, sym ptothermal, post-ovulation 
methods), withdrawal (coitus interruptus), spermicides only, an d lactational amenorrhoea 
method (LAM) are not acceptable methods of contraception for th is study.
NOTES: 
aTypical use failure rates may differ from those when used consi stently and correctly. Use should be consistent 
with local regulations regarding the use of contraceptive metho ds for participants participating in clinical studies. 
bHormonal contraception may be susceptible to interaction with t he study tre atment, which may reduce the 
efficacy of the contraceptive method. Hormonal contraception is  permissible only when there is sufficient 
evidence that the IMP and other study med ications will not alter hormonal e xposures such that contracept ion 
would be ineffective or result in increased exposures that coul d be potentially hazardous.  In this case, alternative 
methods of contraception should be utilized. 
cIntrauterine hormone releasing systems are acceptable methods o f contraception in the absence of definitive drug 
interaction studies when hormone exposures from intrauterine devices do not alter contraception effectiveness
Less Than Highly Effective Contraceptive Methods That Are User D ependent
â€¢Male or female condom with or without spermicide. Male and fema le condoms cannot be 
used simultaneously
â€¢Diaphragm with spermicide
â€¢Cervical cap with spermicide
â€¢Vaginal Sponge with spermicide
â€¢Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action (This method of contraception cannot  be used by WOCBP 
participants in studies where hormonal contraception is prohibited)
Unaccetpatble Methods of Contraception 
â€¢Periodic abstinence (calenda r, symptothermal, post- ovulation me thods)
â€¢Withdrawal (coitu s interruptus).
â€¢Spermicide only
â€¢Lactation amenorrhea method (LAM)
Protocol Amendment No.: 06
Date: 08-Dec-2022 134
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnanc y Information and outcome of  pregnancy on the Pregnancy 
Surveillance Form is provided in Section 9.2.5  and Appendix 3 , Adverse Events and Serious 
Adverse Events: Definitions and Procedures for Recording, Evalu ating, Follow-up and Reporting.
Protocol Amendment No.: 06
Date: 08-Dec-2022 135
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
APPENDIX 5 ECOG PERFORMANCE STATUS 
ECOG PERFORMANCE STATUS a
0 Fully active, able to carry on all pre-disease performance wit hout restriction
1Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light house work, office work
2Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair mor e than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
aOken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET,  and Carbone PP. Toxicity and Response 
Criteria of the Eastern Cooperative Oncology Group. Am J Clin O ncol 1982; 5: 649-655.
Protocol Amendment No.: 06
Date: 08-Dec-2022 136
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
APPENDIX 6 MANAGEMENT ALGORITHMS FOR STUDIES UNDER CTCAE 
VERSION 4.0
These general guidelines constitu te guidance to the Investigato r and may be supplemented by 
discussions with the Medical Monitor representing the Sponsor. The guidance applies to all 
immuno-oncology agents and regimens.
A general principle is that differential diagnoses should be di ligently evaluated according to 
standard medical practice. N on-inflammatory etiologies s hould be consider ed and appropriately 
treated.
Corticosteroids are a primary t herapy for immuno-oncology drug- related adverse events. The oral 
equivalent of the recommended IV doses may be considered for am bulatory patients with low-
grade toxicity. The lower bioavailability of oral corticosteroi ds should be taken into account when 
switching to the equivalent dose of oral corticosteroids.Consultation with a medical or surgical specialis t, especially prior to an invasive diagnostic or 
therapeutic procedure, is recommended.The frequency and severity of the related adverse events covered by these algorithms will depend 
on the immuno-oncology agent or regimen being used.
Protocol Amendment No.: 06
Date: 08-Dec-2022 137
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
6HS
Protocol Amendment No.: 06
Date: 08-Dec-2022 138
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
6HS
Protocol Amendment No.: 06
Date: 08-Dec-2022 139
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
6HS
Protocol Amendment No.: 06
Date: 08-Dec-2022 140
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
6HS
Protocol Amendment No.: 06
Date: 08-Dec-2022 141
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
6HS
Protocol Amendment No.: 06
Date: 08-Dec-2022 142
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
6HS
Protocol Amendment No.: 06
Date: 08-Dec-2022 143
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
6HS
Protocol Amendment No.: 06
Date: 08-Dec-2022 144
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
6HS
Protocol Amendment No.: 06
Date: 08-Dec-2022 145
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
APPENDIX 7 COUNTRY-SPECIFIC REQUIREMENTS
Criterion to exclude HIV positive participants where country or  local regulations require 
testing:
Country-specific language
Section 2 Flow Chart/Time and Events
Schedule, Table 2-1 : Screening
Assessments- Laboratory TestsAdd â€œHIVâ€ to the list of laboratory tests
Section 6.2 Exclusion
Criteria, Exclusion criterion 1.aâ€œKnown history of testing positive for human
immunodeficiency virus (HIV) or known acquired
immunodeficiency sy ndrome (AIDS)â€t o be replaced with
â€œPositive test for HIVâ€.
Protocol Amendment No.: 06
Date: 08-Dec-2022 146
7.0 Approved 930108721 7.0v Approved 1.0 v
C l i n i c a l  P r o t o c o l C A 2 0 9 9 1 4 
BM S - 9 3 6 5 5 8 n i v o l um a b 
A P P E N D I X  8  P RO TO CO L  AM E N DM E N T  S UMM A R Y  O F  C H A NG E  H I S TO R Y 
O v e r a l l  R a t i o n a l e  f o r  t h e  R e v i s e d  P r o t o c o l  0 5 ,  1 3 - F e b - 2 0 2 2 
T h e  p u r p o s e  o f  P r o t o c o l  Am e n dm e n t  0 5  i s  t o  a d d r e s s  t h e  t im i n g  o f  i n t e r im  a n d  f i n a l  d i s e a s e - f r e e  
s u r v i v a l  ( D F S )  a n a l y s e s  i n  P a r t  A ,  w h i c h  w e r e  i n i t i a l l y  p l a n n e d  t o  o c c u r  w i t h i n  6  m o n t h s  o f  e a c h  
o t h e r .  H o w e v e r ,  t h e  e a r l i e r  v e r s i o n s  o f  t h e  p r o t o c o l  d i d  n o t  c a p t u r e  t h e  s c e n a r i o  w h e r e  i n  w h i c h  
t h e  i n t e r im  a n d  f i n a l  a n a l y s e s  o f  D F S  i n  P a r t  A  o c c u r r i n g  i n  a  s h o r t e r  t im e  i n t e r v a l  t h a t  c o u l d  o c c u r  
i n  t h e  f o l l o w i n g  i n s t a n c e s :  
â€¢t h e  n um b e r  o f  D F S  e v e n t s  n e e d e d  f o r  f i n a l  a n a l y s i s  c a n  b e  o b s e r v e d  s o o n e r  a f t e r  o b s e r v i n g  
t h o s e  n e e d e d  f o r  i n t e r im  a n a l y s i s . 
â€¢t h e  t o t a l  e n r o l lm e n t  o f  b o t h  P a r t  A  a n d  P a r t  B  i s  e x p e c t e d  t o  b e  c om p l e t e  c l o s e r  t o  t h e  d a t e  
o f  D F S  f i n a l  a n a l y s i s  a n d  t h e  c r i t e r i a  t o  c o n d u c t  t h e  D F S  i n t e r im  a n a l y s i s  ( 2 0 4  D F S  e v e n t s  
a n d  e n r o l lm e n t  c l o s e  f o r  t h e  s t u d y )  i s  n o t  m e t . 
T h e  am e n dm e n t  i s  b a s e d  o n  t h e  n e e d  t o  a d d r e s s  h o w  t h e  f o rm a l  i n t e r im  a n a l y s i s  o f  D F S  i n  P a r t  A  
w o u l d  b e  h a n d l e d  f o r  t h e  a b o v e  s c e n a r i o . 
W i t h  a  m i l e s t o n e  b l i n d e d  d a t a  t r a n s f e r  r e c e i v e d  f r om  t h e  B I C R  v e n d o r  t h r o u g h  t h e  e n d  o f  J a n u a r y  
2 0 2 2 ,  BM S  o b s e r v e d  2 0 2  D F S  e v e n t s  i n  P a r t  A .  B e c a u s e  t h e  e n r o l l m e n t  i n  P a r t  B  w a s  o n g o i n g  
( a n d  s t i l l  o n g o i n g  a t  t h e  t im e  o f  t h i s  am e n dm e n t ) ,  t h e  p r e - s p e c i f i e d  c r i t e r i a  t o  p e r f o rm  t h e  d a t a b a s e  
l o c k  w a s  n o t  m e t  f o r  c o n d u c t i n g  t h e  i n t e r im  a n a l y s i s  o f  D F S  i n  P a r t  A .  C o n s e q u e n t l y ,  BM S  c o u l d  
n o t  p r o c e e d  w i t h  a  d a t a b a s e  l o c k  f o r  t h e  i n t e r im  a n a l y s i s  o f  D F S  i n  P a r t  A .  T h e  e v e n t  p r o j e c t i o n s  
h a v e  s h o w e d  t h a t  t h e  t a r g e t  n um b e r  o f  e v e n t s  f o r  f i n a l  D F S  a n a l y s i s   i s  e x p e c t e d  a p p r o x im a t e l y  
w i t h i n  4  m o n t h s  f r om  t h e  t im e  o f  o b s e r v i n g  t h e  e v e n t s  n e e d e d  f o r  t h e  i n t e r im  D F S  a n a l y s i s .  D u e  
t o  t h e s e   r e a s o n s ,   BM S   b e l i e v e s   t h a t  t h e r e   a r e  o p e r a t i o n a l   c h a l l e n g e s   t o   p e r f o rm   a n   i n t e r im   a n d  
f i n a l   a n a l y s i s   c l o s e   t o  o n e   a n o t h e r .   H o w e v e r ,  t h e   s c e n a r i o   t o   p r o c e e d   d i r e c t l y   t o  t h e   f i n a l   D F S  
a n a l y s i s  i n  P a r t  A  w a s  n o t  p r e - s p e c i f i e d  i n  t h e  e a r l i e r  v e r s i o n s  o f  t h e  p r o t o c o l .  A s  a  r e s u l t ,  BM S  i s  
i s s u i n g  a  p r o t o c o l  am e n dm e n t  t o  i n c l u d e  t h i s  s c e n a r i o  w i t h  D F S  f i n a l  a n a l y s i s  o n l y .  T a b l e  1 0 . 1 . 1 2  
g i v e s  d e t a i l s  o n  t h e  a l p h a ,  c r i t i c a l  h a z a r d  r a t i o ,  t a r g e t  n um b e r  o f  e v e n t s  f o r  t h e  n e w l y  a d d e d  D F S  
f i n a l  a n a l y s i s  o n l y  s c e n a r i o  i n  P a r t  A .  
T h i s  am e n dm e n t  i n c o r p o r a t e s  t h e  c h a n g e s  f r om  t h e  a p p r o v e d  A dm i n i s t r a t i v e  L e t t e r s  0 9  a n d  1 0 ,  
w h i c h  a r e  d e t a i l e d  i n  t h e  D o c um e n t  H i s t o r y  b u t  n o t  l i s t e d  i n  t h e  S umm a r y  o f  K e y  C h a n g e s  b e l o w .  
A d d i t i o n a l   r e v i s i o n s ,   i n c l u d i n g   s e c t i o n s   o f   t h e   p r o t o c o l   s y n o p s i s ,   h a v e   b e e n   m a d e   t o   a l i g n   t h e  
p r o t o c o l  w i t h  r e s p e c t  t o  t h e s e  c h a n g e s .  M i n o r  f o rm a t t i n g  a n d  t y p o g r a p h i c a l  c o r r e c t i o n s  h a v e  b e e n  
m a d e ,  t h e r e f o r e  h a v e  n o t  b e e n  s umm a r i z e d . 
S UMM A R Y  O F  K E Y  C H A NG E S  FO R  P RO TO CO L  AM E N DM E N T  0 5 
S e c t i o n  N um b e r  &  T i t l e  D e s c r i p t i o n  o f  C h a n g e B r i e f  R a t i o n a l e 
S e c t i o n  1 0 . 1 . 1 :  P a r t  A :  
C om b i n a t i o n  C om p a r i s o n  o f  
D F S P a r am e t e r s  a n d  s c h e d u l e  o f  a n a l y s i s  
f o r  f i n a l  D F S  a n a l y s i s  a l o n e  i n  P a r t  
A  w e r e  a d d e d .  A l s o ,  s umm a r y  
T a b l e  1 0 . 1 . 1 - 2  w a s  a d d e d . I n  t h e  e v e n t  t h a t  P a r t  B  e n r o l lm e n t  i s  
s t i l l  o n g o i n g  a t  t h e  t im e  o f  o b s e r v i n g  
t h e  r e q u i r e d  n um b e r  o f  e v e n t s  f o r  t h e  
i n t e r im  a n a l y s i s  a n d  t a r g e t  n um b e r  o f  
P r o t o c o l  Am e n dm e n t  N o . :  0 6 
D a t e :  0 8 - D e c - 2 0 2 2 1 4 7 
7 . 0 A p p r o v e d  9 3 0 1 0 8 7 2 1 7 . 0 v A p p r o v e d  1 . 0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 05
Section Number & Title Description of Change Brief Rationale
Table 10.1.1-2: Part A Summary 
of Sample Size Parameters and Schedule of Combination Analysis (without an Interim Analysis)
Section 10.3.4: Interim Analyses 
and Hierarchical Testing events needed for the final analysis is projected in a shorter time interval (approximately within 4 months), the interim analysis of DFS will not be performed and only one final analysis of DFS will be conducted.
Table 10.1.1-1: Part A Summary 
of Sample Size Parameters and 
Schedule of Combination Analyses (with an Interim Analysis) Table title has been updated and 
primary analysis population is 
clarified in the table.
Clarification is provided to reflect the 
population to be used.
Table 10.1.2-1: Part B Summary 
of Sample Size Parameters and Schedule of Monotherapy AnalysesPrimary analysis population is clarified in the table.
Table 10.3.1-1: Censoring Scheme Used in Primary 
Definition of DFS Text in Situation column of the 
table was added to include tumor-
directed surgery.To align with the Statistical Analysis Plan.
Overall Rationale for the Revised Protocol 04, 27-Oct-2020
This revised protocol removes Interim Analysis 1 for disease-fr ee survival (DFS), which was 
scheduled to take place at 43 mont hs for Part A and 68 months for Part B, and delays the remaining 
interim analysis for DFS from Part A (previously referred to as Interim Analysis 2) from 52 to 
56 months, which is the time when the total enrollment is expect ed to be complete. This will allow 
for improved follow-up and data maturit y for the DFS analyses. For both Part A and Part B, overall 
survival (OS) w ill be hierarch ically analyzed at the same time as the interim or final analysis for 
DFS in the same group of subjects. In addition, protocol clarif ications and/or updates are provided 
to sections indicated.
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 04
Section Number 
& TitleDescription of Change Brief Rationale
Title page, document 
historyChanged the original protocol date to 14-Feb-
2017.This correction was made because 
Revision 03 had an incorrect original 
protocol date.
Section 1, Synopsis, 
Study PopulationAdded reference to Appendix 9.
Added â€œ(a, b, c)â€ after pT3.This update was made to better 
characterize the TNM staging for our 
study population.
Section 1, Synopsis, 
Objectives and 
EndpointsAdded clarification regarding the time periods 
which will be assessed for safety and 
tolerability in the objective and endpoint. These updates were made to clarify 
the time periods which will be 
Protocol Amendment No.: 06
Date: 08-Dec-2022 148
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 04
Section Number 
& TitleDescription of Change Brief Rationale
assessed for safety and tolerability in 
the objective and endpoint.
Section 1, Synopsis, 
Overall DesignAdded clarification surrounding the timing 
and window permitted for follow up visits.This update was made to ensure 
consistency and alignment across the 
protocol regarding the timing and 
permitted window for follow up 
visits.
Section 1, Synopsis, 
Figure 1 and Figure 2Updated figures to add â€œ(a, b, c)â€ after pT3.This update was made to better 
characterize the TNM staging for our 
study population.
Section 1, SynopsisAdded language to clarify the timing and 
permitted window for follow up visits. This update was made to ensure 
consistency and alignment across the 
protocol regarding the timing and 
permitted window for follow up 
visits.
Section 1, Synopsis Removed list of references.References were moved from this 
section of the protocol to the 
References section
Section 2 Schedule of 
Activities, Table 2-1Added note about documentation of vaccine 
use.This update was made to ensure 
appropriate documentation of vaccine 
use for study participants.
Section 2, Schedule 
of Activities, 
Table 2-1Added a note to Serious Adverse Events 
Assessment row to include the collection of 
all AEs (SAEs and non-serious AEs) 
associated with suspected or confirmed to 
SARS-CoV-2 infection from time of consent.Additional criteria for AE assessment 
was incorporated to include the 
collection all AEs (SAEs or 
non-serious AEs) associated with 
SARS-CoV-2 infection from time of 
consent.
Section 2, Schedule 
of Activities, 
Table 2-2Added clarification to AE and SAE 
Assessment row to include the collection of 
AEs (SAEs and non-serious AEs) associated 
with SARS-CoV-2 infection during the 
treatment period.All AEs (SAEs and non-serious AEs) 
associated with SARS-CoV-2 
infection should be collected 
continuously during the treatment 
period.
Section 2, Schedule 
of Activities, 
Table 2-2Added a note in the laboratory results section 
regarding the review of laboratory test results 
that is required prior to each dose.This note was added to emphasize 
protocol procedure and requirement 
outlined in the protocol Section 5.1.
Section 2, Schedule 
of Activities, 
Table 2-2Added clarifying language to ctDNA notes 
column and removed the notation to collect 
samples in Cycles 4, 7, & 10 Day 1.Clarifying language was added to 
address ctDNA collection alignment with the tumor assessment schedule. 
The incorrect notation to collect 
samples in Cycles 4, 7, & 10 Day 1 
was removed, as this was entered in 
error. 
Section 2, Schedule 
of Activities, 
Table 2-2Added row for SARS-CoV-2 serology 
collection. Samples are to be collected at 
C1D1 and C12D1 for all participants, and SARS-CoV-2 serology will be 
collected to assess the impact of 
SARS-CoV-2 serologic status on 
Protocol Amendment No.: 06
Date: 08-Dec-2022 149
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 04
Section Number 
& TitleDescription of Change Brief Rationale
approx imately 4 weeks after a suspected or 
confirmed SARS-CoV-2 infection.participants receiving the 
combination of nivolumab and 
ipilimumab or nivolumab 
monotherapy in the adjuvant setting 
for RCC  
Section 2, Schedule 
of Activities, 
Table 2-3Outlined the required time period for 
collection and follow up for SAEs, non-
serious AEs of special interest, all AEs (SAEs 
and non-seri ous AEs) associated with 
suspected or confirmed SARS-CoV-2 
infection and study treatment-related 
non-serious AEs.Additional clarification was provided 
regarding the follow up for 
designated AEs in the post-treatment 
period.
The time period for collection for 
study treatment-related AEs is being 
extended to better characterize and 
understand late-onset AEs considered 
related to study treatment
Section 2, Schedule 
of Activities, 
Table 2-3Added row for ctDNA collection.An additional ctDNA collection was 
added in order to align with tumor 
assessment schedule and to evaluate 
whether ctDNA is predictive of tumor 
burden.
Section 2, Schedule 
of Activities, 
Table 2-3Added row for SARS-CoV-2 serology
collection. Samples are to be collected at 
follow-up visit 2 and approximately 4 weeks 
after a suspected or confirmed SARS-CoV-2 
infection.SARS-CoV-2 serology will be 
collected to assess the impact of 
SARS-CoV-2 serologic status on 
participants receiving the 
combination of nivolumab and 
ipilimumab or nivolumab 
monotherapy in the adjuvant setting 
for RCC  
Section 2, Schedule 
of Activities, 
Table 2-3Clarified that timing for scans should be based 
on date of first treatment, which is considered 
Week 1.Language was added to provide 
clarification regarding tumor 
assessment schedule calculations to 
ensure alignment with the study 
protocol criteria.
Section 2, Schedule 
of Activities, 
Table 2-3Clarified PRO assessment timing in notes 
column and within footnotes.Language was added to clarify the 
timing of PRO assessments.
Section 2, Schedule 
of Activities, 
Table 2-3Updated the footnote regarding timing for 
follow up visits.This update was made to ensure 
consistency and alignment across the 
protocol regarding the timing and 
permitted window for follow up 
visits.
Section 3, 
IntroductionUpdated the text and references within the 
section.Text and references were updated to 
better capture and cite the information 
provided in the introduction.
Protocol Amendment No.: 06
Date: 08-Dec-2022 150
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 04
Section Number 
& TitleDescription of Change Brief Rationale
Section 3, 
Introduction, 
Table 3-1Added 3 studies.These 3 studies were included in 
version 2 of the protocol but were 
subsequently removed. For 
consistency purposes, we are 
including them again in this revision.
Section 4, Objectives 
and Endpoints, 
Table 4-1Added clarification regarding the time periods 
which will be assessed for safety and 
tolerability in the secondary objective and 
endpoint. These updates were made to clarify 
the time periods which will be 
assessed for safety and tolerability in 
the secondary objective and endpoint.
Section 4, Objectives 
and Endpoints, 
Table 4-1Added an exploratory objective and endpoint 
to assess the association between the 
recurrence score with efficacy outcomes.Gene-signature based score will be 
assessed in relation to efficacy 
endpoints.
Section 4, Objectives 
and Endpoints, 
Table 4-1Added an exploratory objective and endpoint 
regarding SARS-CoV-2 serologic status.SARS-CoV-2 serology will be 
collected to assess the impact of 
SARS-CoV-2 serologic status on 
participants receiving the 
combination of nivolumab and 
ipilimumab or nivolumab 
monotherapy in the adjuvant setting 
for RCC  
Section 4, Objectives 
and Endpoints, 
Table 4-1Added an exploratory objective and endpoint 
regarding safety of nivolumab combined with 
ipilimumab and nivolumab monotherapy 
beyond 100 days and up to 1 year of last dose 
of study therapy.Safety information will be collected 
for study treatment-related AEs 
beyond 100 days and up to 1 year of 
last dose of study therapy.
Section 5.1, Overall 
Design, Figure 5.1-1 
and Figure 5.1-2Updated figures to add â€œ(a, b, c)â€ after pT3.
Removed â€œOriginalâ€ from Figure 5.1-1 title.This update was made to better 
characterize the TNM staging for our 
study population.
Section 5.1, Overall 
DesignAdded language about BICR recurrence 
assessment process.Language was added to provide 
guidance on requesting BICR 
assessment of recurrence and for 
when there is a discrepancy between 
the Investigator and the BICR 
recurrence interpretation.
Section 5.1, Overall 
DesignAdded clarifying language regarding the 
timing and permitted window for follow up 
visits. This update was made to ensure 
consistency and alignment across the 
protocol regarding the timing and 
permitted window for follow up 
visits.
Section 5.4.1, 
Rationale for 
Selection of 
Participants at 
Moderate to High 
Risk of RelapseAdded a potential efficacy assessment using 
the SSIGN score.SSIGN score assessments may be 
performed to ide ntify SSIGN 
intermediate and high score 
subgroups.
Protocol Amendment No.: 06
Date: 08-Dec-2022 151
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 04
Section Number 
& TitleDescription of Change Brief Rationale
Section 6.1, Inclusion 
CriteriaAdded reference to Appendix 9.
Added â€œ(a, b, c)â€ after pT3.This update was made to better 
characterize and align the TNM 
staging for our study population.
Section 6.1, Inclusion 
CriteriaAdded a note regarding the assessment of 
disease status for participants being 
considered to enter the study. This note was added to ensure the 
safety of the participants, as a 
participant should not be consented or 
enrolled into the study if the 
Investigator is not certain the 
participant is disease free. 
Section 6.1, Inclusion 
CriteriaThe following updates were made:
â€¢Added sub criteria (i,ii, and iii) to 
Criterion 3b)
â€¢Added clarification to Criterion 3c
â€¢Added clarification to Criterion 3d) and added sub criteria (i,ii, iii, and iv) to Criteria 3d)
â€¢Criterion 3e) is no longer applicable
â€¢The first sentence in Criterion 3f) is no longer applicable (the second sentence pertaining to WOCBP is still applicable)
â€¢Removed text related to male contraception in the last paragraph and added a statement regarding transmission of study drug to a developing fetusThese changes were made to: 
â€¢Provide clarification and 
additional details regarding 
inclusion and contraception requirements for both WOCBPand for women who are not of childbearing potential
â€¢Remove contraceptive 
requirements for male 
participants based on current safety information
Section 6.2, 
Exclusion CriteriaAdded a note about enrollment of patients 
with past nephrectomy or other surgical 
procedure.This note was added to better clarify 
the exclusion of patients with a 
history of RCC and who have been 
considered cured after a nephrectomy 
or other surgical procedure in the past 
and now present with a new RCC.
Section 6.2, 
Exclusion CriteriaAdded a note regarding the use of inactivated 
vaccines. Clarification was added regarding the 
use of inactivated vaccines.  
Section 6.2, 
Exclusion CriteriaAdded a criterion regarding SARS-CoV-2 
infection.This exclusion criterion was added to 
exclude participants with 
SARS-CoV-2 infection (either 
suspected or confirmed) within 
4 weeks prior to screening.
Section 6.2, 
Exclusion CriteriaRevised the criterion regarding the use of 
botanical preparations. This exclusion criterion was revised 
to provide clarification regarding the 
complementary medications that are 
not permitted within 2 weeks prior to 
first study treatment.
Section 6.2, 
Exclusion CriteriaAdded a criterion regarding participation in 
other interventional trials, including those for 
COVID-19, and receipt of an investigational This exclusion criterion was added 
regarding participation in 
interventional trials, including those 
Protocol Amendment No.: 06
Date: 08-Dec-2022 152
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 04
Section Number 
& TitleDescription of Change Brief Rationale
COVID-19 vaccine or other investigational 
product designed to treat or prevent 
COVID-19. for COVID-19, and receipt of an 
investigational SARS-CoV-2 vaccine 
or other investigational product 
designed to treat or prevent 
COVID-19.
Section 6.4.1, 
Retesting During 
Screening or Lead-In 
PeriodAdded statement regarding re-enrollment, 
specifically that this study permits the 
reenrollment of a participant that has 
discontinued the study as a pre-treatment 
failure (ie, participant has not been 
randomized/has not been treated). This statement was re-introduced in 
the protocol as it was inadvertently 
removed in Revi sed Protocol 02. 
Section 6.4.1, 
Retesting During 
Screening or Lead-In 
PeriodAdded criteria regarding SARS-CoV-2 
infection.Language was added to provide 
guidance for SARS-CoV-2 testing 
and for when pa rticipants develop 
suspected or confirmed SARS-CoV-2 
infection during the screening period.
Section 7.1.1, 
Administration and 
Table 7.1.1-2Added clarifying language regarding the 
duration of infusion and time between 
infusions within the section and in the 
footnote of the table. A statement was also 
added indicating that simultaneous infusions 
of nivolumab and ipilimumab will not be 
permitted.Language was added to clarify and 
emphasize study drug administration 
requirements and expectations.
Section 7.1.1.1, 
NivolumabAdded clarifying language regarding the 
duration of infusion.Language was added to clarify study 
drug administration requirements and 
expectations.
Section 7.1.1.2, 
IpilimumabAdded clarifying language regarding the 
duration of infusion.Language was added to clarify study 
drug administration requirements and 
expectations.
Section 7.2, Method 
of Treatment 
AssignmentAdded reference to Appendix 9.This update was made to better align 
the TNM staging for our study 
population.
Section 7.3.1 
Unblinding at the 
Time of Disease 
RecurrenceAdded guidance regarding the timing of the 
request for unblinding if a tumor biopsy 
collection at the time of suspected recurrence 
is planned.  This statement was added to provide 
additional guidance surrounding the 
unblinding process. 
Section 7.4.1, Dose 
Delay Criteria for 
Study TreatmentAdded Arm C to list of study arms.Update was made to align with study 
design.
Section 7.4.1, Dose 
Delay Criteria for 
Study TreatmentAdded a criterion for dose delay regarding 
SARS-CoV-2 infection.SARS-CoV-2 infection (either 
suspected or confirmed) will meet 
criteria for dose delay.
Section 7.4.2, 
Criteria to Resume 
TreatmentAdded criteria required to resume treatment 
following SARS-CoV-2 infection.All criteria indicated regarding the 
SARS-CoV-2 infection must be met 
to resume treatment.
Protocol Amendment No.: 06
Date: 08-Dec-2022 153
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 04
Section Number 
& TitleDescription of Change Brief Rationale
Section 7.7.1, 
Prohibited and/or 
Restricted 
TreatmentsRevised the statement regarding the use of 
botanical preparations.This language was revised to provide 
clarification regarding the 
complementary medications that are 
not permitted during the study.
Section 7.7.1, 
Prohibited and/or 
Restricted 
TreatmentsAdded a statement regarding live/attenuated 
vaccines and inactivated vaccines during the 
treatment period.This text was added to better clarify 
the prohibited and/or restricted 
treatments for participants enrolled in 
the study.
Section 9.1.3.2, 
Investigator 
Assessment of 
RecurrenceClarified that timing for scans should be based 
on date of first treatment, which is considered 
Week 1.Language was added to provide 
clarification regarding tumor 
assessment schedule calculations to 
ensure alignment with the study 
protocol criteria.
Section 9.1.3.3, 
BICR Assessment of 
RecurrenceUpdated language regarding the 
de-identification of relevant 
cytology/pathology results that support a 
diagnosis of recurrence.Language was added to provide 
guidance on the BICR recurrence 
assessment process.
Section 9.1.5, 
Outcomes Research 
AssessmentsAdded a statement to indicate that 
patient-reported outcome assessments should 
be completed prior t o study-related 
procedures. Clarification was provided regarding 
the timing of patient-reported 
outcome assessments in regards to 
other study-related procedures. 
Section 9.2.1, Time 
Period and Frequency 
for Collecting AE 
and SAE InformationOutlined the required time period for 
collection for AEs associated with 
SARS-CoV-2 and those non-serious AEs 
considered related to study therapy.Time period for collection of 
SARS-CoV-2 infection-related events 
has been added. The time period to 
collect information regarding AEs 
considered related to study therapy 
has been extended to better 
characterize and understand late-onset 
AEs considered related to study 
treatment. This will provide important 
safety data in the adjuvant setting and 
better understand the safety profile.
Section 9.2.3, 
Follow-up of AEs 
and SAEsOutlined the required time period for 
collection for AEs associated with 
SARS-CoV-2 and those non-serious AEs 
considered related to study therapy.Follow up expectations for 
SARS-CoV-2 infection-related events 
for those considered related to study 
therapy have been added.
Section 9.5, 
Pharmacokinetics; 
Table 9.5-1Revised the language regarding the timing for 
follow-up samples.This revision was made to ensure 
consistency and alignment across the 
protocol regarding the timing and 
permitted window for follow up 
visits.
Section 9.5, 
Pharmacokinetics; 
Table 9.5-1Updated the footnote regarding the end of 
infusion-PK sampling timing.This footnote was updated to better 
clarify the timing on e nd of 
infusionPK sampling.
Protocol Amendment No.: 06
Date: 08-Dec-2022 154
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 04
Section Number 
& TitleDescription of Change Brief Rationale
Section 9.8, 
BiomarkersAdded a description and Table 9.8.1 to 
summarize the biomarker sampling schedule 
and requirements for the study. Description and Table 9.8.1 were 
added to add clarification regarding 
the biomarker sampling schedule and 
requirements for the study.
Section 9.8.1, 
Additional Research 
CollectionAdded and updaed information about sample 
collection and storage.Updated information regarding 
sample collection and storage was 
provided. 
Section 9.8.1, 
Additional Research 
Collection, 
Table 9.8.1-1Revised the information in table regarding 
tumor biopsy sample.This revision was made to add 
clarification regarding the additional 
research sampling schedule the study.
Section 9.8.2, Tissue 
SpecimensAdded a statement indicating that tumor 
samples will be used for assessment of tumor 
recurrence score based on gene signature 
analysis.Gene signature analysis will be 
performed on tumor samples to 
predict the risk of recurrence of the 
tumor.
Section 9.8.7, Whole 
Blood for 
GenotypingAdded language to support whole exome 
sequencing assessment on whole blood 
samples.Statement was added to allow a 
whole exome sequencing assessment 
to be performed on whole blood 
samples.
Section 9.8.8 
Immunogenicity 
AssessmentsAdded reference to Table 9.5-1.This reference was added because the 
immunogenicity sampling schedule is 
provided in Table 9.5-1.
Section 9.8.9, Other 
AssessmentsAdded language on samples collected to 
assess SARS-CoV-2 serologic status.Serum will be collected for potential 
future measurements of anti-
SARSCoV-2 antibodies by serology 
(anti SARS CoV-2 total and 
immunoglobulin G [IgG]) to explore 
potential association with safety, 
efficacy, and/or immune biomarkers.
Section 10.1.1, 
Part A: Combination 
Comparison of DFSRemoved 1 interim analysis for DFS.
Updated Table 10.1.1-1.Interim Analysis 1 for the 
combination comparison of DFS was 
removed and the remaining interim 
analysis for DFS from Part A was 
delayed to allow for improved 
follow-up and data maturity for the 
DFS analyses and to align with the 
timing when enrollment is expected 
to be complete. OS hierarchical 
combination analyses aligned with 
DFS combination analyses. Table was 
updated to reflect the removal of 
Interim Analysis 1.
Section 10.1.2, Part 
B: Monotherapy 
Comparison of DFSRemoved 1 interim analysis for DFS.
Updated Table 10.1.2-1.Interim Analysis 1 for the 
monotherapy comparison of DFS was 
removed from Part B to allow for 
improved follow-up and data maturity 
Protocol Amendment No.: 06
Date: 08-Dec-2022 155
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 04
Section Number 
& TitleDescription of Change Brief Rationale
for the DFS analyses. OS hierarchical 
monotherapy analyses aligned with 
DFS monotherapy analyses. Table 
was updated to reflect the removal of 
Interim Analysis 1.
Section 10.3.4, 
Interim Analyses and 
Hierarchical TestingAdded details surrounding the hierarchical 
overall survival (OS) analysis, for both Part A 
and Part B, at the same time as the interim or 
final analysis for DFS in the same group of 
subjects.Details were added regarding the 
alignment of the OS hierarchical 
monotherapy analyses with DFS 
monotherapy analyses.
Appendix 2, Study 
Governance 
ConsiderationsUpdated appendix.This appendix was updated to align 
with the most recent Protocol Model 
Document.
Appendix 4, Women 
of Childbearing 
Potential Definitions 
and Methods of 
ContraceptionUpdated appendix.This appendix was updated to align 
with the most recent Protocol Model 
Document.
Appendix 9, 
Correlations of 
Classifications in 
Cancer Staging 
SystemsAdded appendix.This appendix was added to address 
correlations of classifications across 
cancer staging systems used in this 
study. 
Throughout 
DocumentUpdated â€œpatientâ€ terminology to 
â€œparticipantâ€ throughout the document, where 
applicable.This update was made to ensure 
alignment and consistency regarding 
terminology throughout the 
document. 
Overall Rationale for the Revised Protocol 03, 01-Nov-2019
As the treatment of RCC landscape continues to evolve, accumula tive evidence showed a single-
agent activity for anti-PD-1 or anti-PD-L1 monotherapy in the 1 L treatment of advanced RCC. 
Single-agent activity of anti-PD1 in the 1L metastatic setting supports the evaluation o f nivolumab 
as monotherapy. 
The original study design of the study will r emain unchanged and will be designated as Part A of 
the study. The additi on of a monot herapy arm in Part B of the study allows for assessment of the 
clinical benefit, as measured by  disease free survival (DFS) with OS as a key secondary endpoint, 
provided by nivolumab monotherapy and the contribution of ipili mumab to the benefit observed 
with combination therapy. If the safety profile is acceptable an d nivolumab monotherapy or 
nivolumab combined with ipilimumab is shown to improve DFS, this study would support the 
approval o f nivolumab or nivolumab combined with ip ilimumab in tr eatment-naive advanced RCC 
participants post-surgery.
Protocol Amendment No.: 06
Date: 08-Dec-2022 156
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 03
Section Number 
& TitleDescription of Change Brief Rationale
Section 2, Table 2-2 
On-Treatment 
Procedural OutlinectDNA collection addedTo explore utility as a biomarker 
associated with clinical efficacy (less invasive than tumor biopsy) 
Section 2, Table 2-3Clarified that anti-tumor therapies are to be 
collected in survival follow up. 
Clarification added on timing of PRO 
collection during follow-up and survivalTo clarify language
To clarify language and to collect 
long-term PRO assessments
Section 3, Table 3-1Updated with most recent listing, and data 
from clinical trialsUpdate was done to provide the most 
recent data and keep the protocol current
Section 3.1, Study RationaleUpdated to provide rationale for inclusion of the Part B treatment into the study design. To elucidate on the rationale for including a Part B into the study
Section 3.1.1 Research Hypothesis Updated to reflect in the addition of Part B into the study. Incorporation of Part B provides 
Section 3.2.1.1 Updated background information on nivolumab in RCC was added. Incorporate recent data on monotherapy in the RCC setting and also combination therapy with 
ipilimumab. 
Section 3.3 Benefit/Risk 
AssessmentUpdated to include discussion of nivolumab 
monotherapyTo elucidate on the benefit/risk assessment for including a Part B into 
the study
Section 4 ObjectivesRevised to include the objectives for Part B of 
the study. Primary and secondary objectives were updated to incorporation Part B 
of the study. 
Section 5.1 Overall 
Design Updated to reflect incorporation Part B in the 
study design: updated number of participants, 
randomization arms, and schemaUpdated with the details of Part B.  
Section 5.2, Number 
of ParticipantsUpdated the number of participants to account for Part A and Part B of the new study design.  The sample size was increased for incorporation of Part B.
Section 5.4.4, Rationale for 
Nivolumab MonotherapyRationale for the addition of the Part B study 
added. To elucidate on the rationale for the addition of the new monotherapy arm 
in Part B.
Section 5.5.2, Justification for Dose of Nivolumab Monotherapy Treatment Added.  Updated to incorporate justification for nivolumab 240 mg as monotherapy. To elucidate on the dosing justification on the new monotherapy arm
Section 6.2, 
Exclusion CriteriaAdded exclusion criteria for participants that have received a live vaccine within 30 days of 
first dose. Update was made to reflect the 
current program-level exclusion 
criteria
Protocol Amendment No.: 06
Date: 08-Dec-2022 157
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 03
Section Number 
& TitleDescription of Change Brief Rationale
Section 7.1.1, Table 
7.1.1-2 Dosing Schedule Added treatment for each cycle for Arm C in 
Part B. To provide dosing details on the new monotherapy arm, Arm C in Part B.
Section 7.7.3
Permitted therapyAdded a statement to indicate that 
concomitant medications are also to be recorded in the appropriate section of the CRF within 100 days of the last dose date of study 
drug To clarify when concomitant 
medications are to be recorded during the study
Section 9.1.5 
Outcomes Research 
Assessment Clarified descri ption of FKSI-19. To add more granularity on the 
FKSI-19 description
Section 9.2.9 Management 
AlgorithmsAdded myocarditis algorithmUpdate was made to reflect the 
current program-level myocarditis 
algorithm
Section 9.8.6 
Peripheral Blood 
DNA Mutation Research Added for collection of ctDNATo explore utility as a biomarker 
associated with clinical efficacy (less 
invasive than tumor biopsy)
Section 10.1 Sample Size Determination; Section 10.1.2 Monotherapy 
Comparison of DFSSample Size section was updated to reflect 
sample size determinations for Part A and B. Part A remains intact as the original design, Part B determinations were added (Section 10.1.2) to reflect determination of sample size for 
monotherapy comparison of DFS. 
Section 10.1.3 Contribution of 
Components Analysis of DFSCoC description added. CoC description and timing added to 
the protocol. 
Section 10.2, Populations for 
Analyses Populations for Part B analyses have been 
added. To reflect the additional populations for analyses in Part B. 
Section 10.3.3.3 Outcomes Research 
Analyses Updated to include clarification of analyses 
Updated to include nivolumab vs placebo 
comparisons. To clarify intended outcome research 
analyses
Section 10.3.4 Interim Analyses and 
Hierarchical TestingUpdated to include interim analyses for Part A 
and B, a nd to include description of 
hierarchical testing To clarify intended interim analyses, and hierarchal testing that will occur 
for the OS interim analysis. 
Overall Rationale for the Revised Protocol 02, 06-Apr-2018
The purpose of this revised protocol is to reduce frequency of patient questionnaires, update 
exclusion criteria 3f for serum creatinine, and provide additio nal information and/or clarif ication 
to sections indicated. Typographical and grammatical errors wer e also corrected.
Protocol Amendment No.: 06
Date: 08-Dec-2022 158
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
This applies to all sites and all patients. The changes in this amendment do not impact the safety 
of participants and should be implemented after Institutional R eview Board or Ethics Committee 
review.
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 02
Section Number & Title Description of Change Brief Rationale
Title Page Medical Monitor info updated. As per Administrative L etter
Synopsis Key Inclusion Criteria 
(Item a);
6.1 (Item 2a)Wording updated to indicate clean surgical 
margins are required for all patients and 
clarified timing of nephrectomy.Clarification of criteria
Synopsis Key Inclusion Criteria 
(Item d);
6.1 (Item 2d)â€œ(post-operative)â€ wa s added in NOTE:  
â€œ...on the bas eline (post-operative) tumor 
assessment...â€To clarify that this refers to the 
post-operative baseline 
assessment.
Synopsis Overall Design;
5.1 Overall DesignChanged wording regarding duration of 
time between nephrectomy and 
randomization (greater than 4 weeks and 
less than or equal to 12 weeks).Clarification
Figures 1-1 and 5.1-1 Updated study schema was inserted. Ease of viewing
Table 2-1 42-day screening window removed.Randomization must occur 
within 12 weeks of surgery 
which provides for an end of 
screening timepoint. 
Table 2-1  Lab test;
Appendix 7 Country-Specific 
RequirementsReplaced Germany with â€œcountry or local 
regulationsâ€ where HIV testing required.Appendix provides information 
regarding screening and 
exclusion criteria related to HIV 
testing.
Table 2.2 Patient Reported 
Outcomesâ€¢Decreased frequency of 
questionnaires.
â€¢Added footnote c indicating that 
Question GP5 on FSKI-19 can be left 
blank at baseline.â€¢Decrease need for patient to complete and will provide sufficient timepoints for evaluation.
â€¢Participant has not received treatment yet and question asks if patient is bothered by side effects of treatment.
Table 2.3 Tumor Assessments Updated allowable windows for scans.Provide more flexibility in 
scheduling Q6 month and yearly 
scans.
Table 2.3 Tumor Assessments;
9.1.3.2 Investigator Assessment 
of RecurrenceAdded bullet that tumor assessments can 
be discontinued when recurrence has been 
confirmed by BICR.Clarification to avoid confusion.
Table 2.3 Patient Reported 
Outcomesâ€¢Updated information for collection.
â€¢Added footnotes c and d to clarify that 
PROs can be performed via telephone and timing for recurred patients to obtain questionnaires.Clarify timing in survival 
follow-up.
Protocol Amendment No.: 06
Date: 08-Dec-2022 159
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 02
Section Number & Title Description of Change Brief Rationale
3 Introduction;
11 ReferencesSecond to last paragraph added 
information regarding sunitinib approval in 
adjuvant in US, including a reference to 
updated NCCN guidelines.Provide data regarding US 
approval.
Table 3-1, PROTECTUpdated outcome measure for PROTECT 
study.Provided update since study 
completed.
3.2.1.3 Nivolumab plus 
Ipilimumab in RCC;
Tables 3.2.1.3-1, 3.2.1.3-3, 
3.2.1.3-4Added information regarding results of 
CA209-214 - nivolumab plus ipilimumab 
in first line RCCProvide information regarding 
combination studies and results.
5.1 Overall Designâ€¢Changed wording regarding duration 
of time between nephrectomy and randomization (greater than 4 weeks and less than or equal to 12 weeks).
â€¢Removed info related to 42-day screening period and re-enrollment. 
â€¢Added clarifications on repeat labs during screening.Clarification
6.1 Inclusion Criteriaâ€¢Item 2a wording updated to indicate clean surgical margins are required for all patients and clarified timing of nephrectomy. 
â€¢Item 2c related to N1 status added further language indicating one or more regional lymph nodes having positive results. 
â€¢Item 2d (post-operative) was added in NOTE:   ....on the baseline (post-operative) tumor assessment ...â€¢Clarification of criteria
â€¢Clarification of criteria
â€¢To clarify that this refers to 
the post-operative baseline 
assessment
6.2 Exclusion Criteriaâ€¢Item 1a Germany removed and language updated to include all countries and locals where testing is mandated
â€¢Item 2c added regarding the exclusion of treatment with botanical preparations
â€¢Item 3f changed to exclude for serum creatinine of >1.5 x ULN unless creatinine clearance is â‰¥ 40 ml/minâ€¢Clarify exclusion of HIV positive participants in areas where testing is mandated. 
â€¢Nivolumab program language
â€¢Updated to reflect standard used in program allowing participants with adequate 
clearance to participate
6.4.1 Retesting During 
Screening Removed first paragraph regarding re-
enrollmentParagraph did not apply to 
retesting 
7 Treatment;
7.1.1 Administration;
7.1.1.2 IpilimumabAdded percentages to IMP injection 
solutionClarification and consistency
Protocol Amendment No.: 06
Date: 08-Dec-2022 160
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 02
Section Number & Title Description of Change Brief Rationale
7.1.1 AdministrationUpdated language in last two full 
paragraphsClarification
Table 7.1.1-1 Revised table title to better reflect contents Clarification
Table 7.1.1-2 Added note indicating approximately 30 
minutes between nivolumab and 
ipilimumab infusionsReminder/clarification
7.1.1.1 NivolumabReferred reader to IB for additional 
instructions on preparation.Additional instruction
7.1.1.2 IpilimumabAdded language regarding approximate 30 
minute between nivolumab and 
ipilimumab Reminder/clarification
7.2 Method of Treatment 
AssignmentAdded date of nephrectomy to bulleted list 
of information required for randomizationClarification
7.4.1 Dose Delay Criteria for 
Study TreatmentAdded Grade 3 asymptomatic amylase and 
lipase as not requiring dose delay.Nivolumab program language
7.4.2 Criteria to Resume 
TreatmentAdded information on allowable systemic 
corticosteroid doses Clarification
7.6 Treatment ComplianceAdded that source data will be verified by 
the BMS unblinded site monitor.Clarification
7.7.1 Prohibited and/or 
Restricted TreatmentsAdded bullet that any botanical 
preparations are prohibited.Nivolumab program language
7.7.3 Permitted TherapyChanged wording slightly from 
â€œPhysiologic replacement doses of 
systemic corticosteroids... for participants 
with adrenal insufficiencyâ€ to â€œAdrenal 
replacement steroid doses...â€Nivolumab program language
8.1.1 Study Treatment 
Discontinuation CriteriaRe-organized bulleted criteria into events 
that do require discontinuation and events 
that do not require discontinuation.Clarification to avoid confusion.
9.1.2 Methods of MeasurementRevised and expanded CT/MRI text, 
including details regarding 
contraindications.Clarification
9.1.2 Methods of Measurement Removed references to RECISTNo lesion measurements at 
baseline so criteria not 
applicable.
9.1.3.1 Assessment of Baseline 
Disease-free StatusChanged timing of imaging performed 
post-nephrectomy from â€œat leastâ€ to 
â€œgreater thanâ€ 4 weeks.Correction
9.1.3.2 Investigator Assessment 
of Recurrenceâ€¢Removed phrase â€œfor the duration of 
the disease-free follow-upâ€ from text regarding tumor assessments.
â€¢Updated General Considerations and 
replaced Table 9.1.3.2-1.â€¢Avoid confusion regarding 
follow-up assessments.
Protocol Amendment No.: 06
Date: 08-Dec-2022 161
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 02
Section Number & Title Description of Change Brief Rationale
â€¢Provide clarifications to 
criteria used to assess recurrence.
9.1.3.3 BICR Assessment of 
RecurrenceAdditional instruction added. Clarification
Table 9.1.4-1, Acceptable 
Imaging Assessment MethodsAdded a third alternative method for 
abdomen and pelvis.Consistency
9.2.2 Method of Detecting AEs 
and SAEsAdded text regarding collection and 
assessment of AEs.Nivolumab program language
Table 9.5-1 PK and 
Immunogenicity Sampling 
ScheduleAdded to footnote b regarding the timing 
of collecting predose samples.Clarification
Appendix 4 WOCBP and 
ContraceptionAcceptable contraception methods updated 
to include hormonal methods.Nivolumab program language
Appendix 7 Response Criteria 
(RECIST 1.1)Appendix removed.RECIST criteria not used in this 
study.
Protocol Amendment No.: 06
Date: 08-Dec-2022 162
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
APPENDIX 9 CORRELATIONS OF CLASSIFICATIONS IN CANCER STAGING 
SYSTEMS
The CA209-914 study stratification criteria is based on the 201 0, 7th edition American Joint 
Committee on Cancer (AJCC)/Union for International Cancer Contr ol (UICC) TNM classification 
and Fuhrman grading and therefore, only information on these cl assification systems should be 
entered into the database.
The AJCC/UICC TNM (tumor, node, and metastasis) classification on cancer staging systems are 
regularly updated. The AJCC/UICC 8th edition1was implemented in 2018 and it introduces some 
(minor) staging changes and re fines some definitions, but retai n s  m o s t  o f  t h e  7 t h  e d i t i o n  
parameters.2Thus, in the new edition, the wo rd â€œgrosslyâ€ to describe renal vein and segmental 
branch invasion has been removed from the T3a, because the 7th edition had over-reliance on the 
pathologist gross inspection of the hilar vessels. However, tumor involvement of renal vessels can 
be missed grossly. In additi on, for the T3a staging, the statem ent â€œMuscle containingâ€ was changed 
to â€œsegmental branchesâ€ and the â€œInvasion of pelvicalyceal syst emâ€ was added as this part of the 
collecting system is within the hilum.
For the purposes of our CA209-914 study conduct, we are maintai ning the Tumor staging 
equivalent between the 2010, 7th edition AJCC/UICC and the 2017 , 8th edition AJCC/UICC.3
2010, 7th edition AJCC TNM 
classification2017, 8th edition AJCC/ UICC 
TNM classification
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor â‰¤ 7 cm in greatest dimension, limite dto the kidney
T1a Tumor â‰¤ 4 cm in greatest dimension, limited to the kidney
T1b Tumor > 4 but â‰¤ 7 cm in greatest dimension, limited to the kidney
T2 Tumor > 7 cm in greatest dimension, limited to the kidney
T2a Tumor >7 cm but â‰¤ 10 cm in greatest dimension, limited to the 
kidney
T2b Tumor > 10 cm, limited to the kidney
T3 Tumor extends into major veins or perinephric tissues, but not into 
the ipsilateral adrenal gland and not beyond Gerotaâ€™s fascia
T3a Tumor grossly extends into the 
renal vein or its segmental 
(muscle containing) branches, or 
tumor invades perirenal and/or 
renal sinus fat but not beyond 
Gerotaâ€™s fasciaTumor extends into the renal 
vein or its segmental branches, 
or invades the pelvicalyc eal 
system, or invades perirenal 
and/or renal sinus fat but not 
beyond Gerotaâ€™s fascia
T3b Tumor grossly extends into the 
vena cava below the diaphragmTumor extends into the vena 
cava below the diaphragm
T3c Tumor grossly extends into vena 
cava above diaphragm or 
invades the wall of the vena 
cavaTumor extends into the vena 
cava above the diaphragm or 
invades the wall of the vena 
cava
T4 Tumor invades beyond Gerotaâ€™s fascia (includes contiguous 
extension into ipsilateral adrenal gland)
Protocol Amendment No.: 06
Date: 08-Dec-2022 163
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
Tumor grade â€” The AJCC 8th edition adopted the histologic grade (G1â€“G4) WHO/ISUP 
nucleolar grading, replacing the t raditional Fuhrman nuclear gr ade.
However, UICC 8E has retained the use of Fuhrman for clear cell  RCC and has not adopted the 
WHO/ISUP nucleolar grade-adopted 8E AJCC.
In the WHO/ISUP histologic grade, the nucleolar grade alone is sufficient to define grades 1 to 3 
for clear cell and papillary RCC.4Aggressive histologies such as sarcomatoid and rhabdoid 
differentiation are incorporated into WHO/ISUP grade 4.Therefore, for the purposes of our CA209-914 study conduct, we are maintaining the histologic-
grading equivalent between the Fuhrman and the WHO/ISUP systems .
Comparison of Conventional Four-Tiered Fuhrman Grading and WHO/ ISUP Grading System is 
below
5:
Grade Fuhrman Grade System WHO/ISUP Grading 
System
Nuclear Diameter 
(Î¼m)Nuclear 
ShapeNucleoli Nucleoli
1 Small (â‰ˆ10) Ro und/
uniformAbsent/
inconspicuousAbsent or inconspicuous 
and basophilic at Ã—400 
magnification
2 Large (â‰ˆ15) Irregular 
outlineVisible at Ã—400 
magnificationConspicuous and 
eosinophilic at Ã—400 
magnification and visible 
but not prominent at Ã—100 
magnification
3 Larger (â‰ˆ20) Obvious 
irregular 
outlineVisible and 
prominent at Ã—100 
magnificationConspicuous and 
eosinophilic at Ã—100 
magnification
4 Grade 3 plus bizarre 
multilobed nuclei Â± 
spindle cellsExtremely unclear 
pleomorphism, 
multinucleate giant cells, 
and/or rhabdoid and/or 
sarcomatoid differentiation
References
1American Joint Comittee on Cancer. Cancer Staging Manual, 8th Ed ition Updates and 
Corrections; 2018. Av ailable from URL: https://cancerstaging.or g/references-
tools/deskreferences/pages/8eupdates.aspx
2Paner GP, Stadler WM, Hansel DE, et al. Updates in the eighth e dition of the 
tumor-node-metastasis staging classification for urologic cancers. Eur Urol 2018;73(4):560-9. 
3Cornejo KM, Rice-Stitt T, Wu CL. Updates in staging and reporti ng of genitourinary 
malignancies. Arch Pathol Lab Med 2020;144(3):305-19.
Protocol Amendment No.: 06
Date: 08-Dec-2022 164
7.0 Approved 930108721 7.0v Approved 1.0 v
Clinical Protocol CA209914
BMS-936558 nivolumab
4Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Grading of cle ar cell renal cell carcinoma 
should be based on nucleolar prominence. Am J Surg Pathol 2011;3 5(8):1134-9.
5Samaratunga H, Gianduzzo T, Delahunt B. The ISUP sys tem of staging, grading and 
classification of renal cell neoplasia. J Kidney Cancer VHL 2014 ;1(3):26-39.
Protocol Amendment No.: 06
Date: 08-Dec-2022 165
7.0 Approved 930108721 7.0v Approved 1.0 v